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ABSTRACT
Glutathione peroxidase (GPX) is a selenoenzyme 
consisting of four identical subunits. Each subunit is 
approximately 21KD in size and contains selenium in the form 
of selenocysteine in the active site. Mammalian glutathione 
peroxidase activity is highest in erythrocytes with high 
levels also found in liver and kidney. The enzyme catalyses 
the reduction of hydrogen peroxide and organic 
hydroperoxides using glutathione as the reducing agent.
The enzyme plays a central role in antioxidative 
defence and hence has been implicated in a variety of 
clinical conditions where free radicals and hydroperoxides 
are thought to be involved, e.g. cancer, rheumatoid 
arthritis, and cardiovascular disease. It has also been 
implicated in selenium-deficiency diseases, and diseases 
where abnormalities in levels of selenium are seen, since 
severe nutritional selenium deficiency has been shown to 
cause a deficiency in glutathione peroxidase.
The functional GPX gene in humans is located on 
chromosome 3, and consists of two exons and one intron. 
Published sequences of human and animal GPX genes reveal 
that the selenocysteine residue is encoded by the 
"termination" codon UGA. Recent evidence suggests that 
selenocysteine is incorporated co-translationally, the UGA 
codon being suppressed by a selenocyteyl-tRNA and novel 
translation factors.
The aims of this investigation were to isolate and 
characterise the human GPX gene and related sequences. These 
sequences would then be used as hybridisation probes in the 
analysis of mRNA levels in patients with diseases where 
modulation of glutathione peroxidase levels is thought to be 
implicated.
In this thesis I present results to demonstrate:-
i) The isolation and characterisation of the human 
genomic sequence coding for the GPX gene and identification 
of this with the sequence of the human GPX gene recently 
published by other authors.
ii) The isolation of a cDNA apparently coding for 
a novel GPX-related selenopeptide, GPRP, and a comparison of 
this with the human GPX gene to determine the relationship 
between the two.
iii) The use of subcloned DNA fragments and 
synthetic oligonucleotides to distinguish between the two
sequences in hybridisation experiments with human genomic
DNA and mRNA.
iv) Analysis of mRNA levels for GPX and GPRP in 
white blood cells from patients with rheumatoid arthritis 
and hyper1ipidemia.
Results are discussed with particular reference to the 
relationship between the two genes. No significant 
differences in GPX or GPRP mRNA levels were seen in patients 
with rheumatoid arthritis or hyperlipidemia compared to 
controls. Therefore if GPX or GPRP levels are altered in
these conditions it is not as a result of changes in gene
expression at the transcriptional level.
After completion of this thesis, it was demonstrated 
that the GPRP sequence was identical to the 5' end of the 
mouse gene. The results concerning the relationship between 
the human GPX gene and GPRP will therefore have to be viewed 
in the light of this information. A full discussion of these 
results has been included in this thesis.
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Chapter 1 
Introduction 
1.1 Glutathione and Glutathione Peroxidase
1.1.1 Glutathione
Glutathione is a ubiquitous low molecular weight 
tripeptide found in aerobic biological species 
characterised by a reactive thiol group and a gamma-glutamyl 
bond which confers resistance to normal peptidase activity. 
The concentration of glutathione within mammalian cells is 
high, (in the millimolar range) and it is present mainly in 
the reduced form (GSH), although glutathione disulphide 
(GSSG), mixed disulphides (G-SS-protein) and thioethers also 
contribute to the total cellular pool. Intracellular 
glutathione is found mainly in the cytosol although some is 
found in mitochondria. Relatively small amounts of 
glutathione are found extracellularly, mainly in plasma, 
bile and glomerular filtrate.
The roles of glutathione in the cell are many and 
varied and are not reviewed in detail here (for extensive 
reviews see Meister and Anderson, 1983; Orrenius and 
Moldeus, 1984; Moldeus and Quanguan, 1987). They include:- 
maintenance of membrane integrity, modulation of protein 
conformation and enzyme activity, involvement in 
cytoskeletal organisation, protein and DNA synthesis, 
production of oestrogens, leukotrienes and prostaglandins, 
storage and transport of cysteine, promotion of 
neurotransmitter release, calcium homeostasis and 
detoxification of reactive intermediates formed
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intracellularly. The latter probably constitutes the most 
important function of glutathione in cellular defence, since 
it can detoxify compounds in two ways:- by acting as a 
nucleophile and forming excretable, inactive, conjugates or 
by acting as a reductant (where it is oxidised to GSSG). 
Conjugation reactions can take place either non- 
enzymatically, or can be catalysed by glutathione 
transferases. Similarly, reduction reactions can take place 
non-enzymatically, or can be catalysed by the glutathione 
peroxidases (Moldeus and Quanguan, 1987).
Since glutathione plays a key role within the cell, any 
reaction(s) which leads to an alteration of the levels of 
glutathione, or the balance of its various forms, are likely 
to have far-reaching consequences for cellular metabolism 
and integrity.
1.1.2 Glutathione Peroxidase
The glutathione peroxidase enzyme catalyses the 
reduction of potentially toxic hydroperoxides using GSH as 
the reducing agent. During this reaction GSH is oxidised to 
GSSG. This is reduced back to GSH by glutathione reductase, 
using NADPH as the reducing agent (figure 1.1). There are 
two forms of glutathione peroxidase activity; selenium 
independent and selenium dependent. The selenium independent 
activity is a function of the alpha class of glutathione 
transferases and will only catalyse the reduction of organic 
hydroperoxides, while the selenium dependent activity is a 
function of the selenium dependent glutathione peroxidase 
enzyme and will also catalyse the reduction of hydrogen 
peroxide.
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Figure 1.1: The Glutathione Redox Cycle
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1.1.3 Selenium Dependent Glutathione Peroxidase (GPX)
Selenium dependent GPX is a tetrameric protein of 
approximately 85KD molecular weight, and is the only 
eukaryotic selenium-containing enzyme characterised to date. 
The four identical subunits, each of approximately 21KD 
molecular weight (reported values can vary slightly), are 
arranged in a planar manner and each has a selenium atom in 
the form of selenocysteine in the active site. The active 
site forms a flat depression on the surface of the molecule 
and is derived from four protein loops rich in hydrophobic 
and aromatic amino acid residues. Inhibition experiments 
have shown that the selenocysteine residue plays a vital 
role in the catalytic process via a catalytic mechanism 
involving the oxidation/reduction of selenium by glutathione 
(Flohe, 1982). This is illustrated in figure 1.2. The enzyme 
is highly specific for GSH as the reductant, but will accept 
hydrogen peroxide or almost any organic hydroperoxide as the 
other substrate, possibly because the selenium residue is 
easily accessible and surrounded by aromatic and hydrophobic 
amino acid residues.
1.1.3.1 Distribution of Glutathione Peroxidase Activity
Human selenium dependent GPX levels are highest in 
erythrocytes with high levels also found in liver and 
kidney. However, the selenium dependent GPX activity in 
liver and kidney represents only a small proportion of total 
glutathione peroxidase activity in these organs (table 1.1). 
Selenium independent activity is predominant in liver, 
kidney cortex and skeletal muscle and is also present in 
kidney medulla, adrenal gland and platelets. Selenium 
dependent GPX activity is solely responsible for the 
glutathione peroxidase activity in all other tissues 
measured (Carmagnol et al, 1983) and therefore the heart, 
lung, brain, spleen and erythrocytes are of special
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ROOH GSH GSH
ROH HgO GSSG
Enzyme form >, T Jr T . 1
E-CysSe' E-CysSeOH E-CysSeSG E-CysSe"
1) E-CysSe" + H+ + ROOH -> E-CysSeOH + ROH
2) E-CysSeOH + GSH <-> E-CysSeSG + HgO
3) E-CysSeSG + GSH <-> E-CysSe" + H+ + GSSG
Figure 1.2: The “Ter-uni-ping-pong" Mechanism of Catalysis by Selenium-Dependent GPX
Table 1.1: Distribution of SeGPX Activity in the Human
SeGPX ACTIVITY OF TOTAL PEROXIDASE 
ACTIVITY
LIVER 579 12%
RENAL CORTEX 237 16%
ERYTHROCYTES 37.7* 100%
RENAL MEDULLA 16.3 43%
ADRENAL 33.5 78%
SKELETAL MUSCLE 7.8 15%
PLATELETS 31.6 91%
HEART 16.4 100%
LUNG 11.8 100%
BRAIN GREY MATTER 18.8 100%
CEREBELLUM 20.3 100%
SPLEEN 24.1 100%
* units are nmol NADPH transformed per minute per mg protein 
(From Carmagnol et al (1983). DBA v759 pp49-57)
$ units are nmol NADPH transformed per minute per mg Hb 
(from Rotilo et al (1986). Free Radicals and Arthritic Diseases 
pp 185-189. Eds A.J.G.Swaak & J.F.Koster. EURAGE.)
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interest since it is their only protection against cytosolic 
hydrogen peroxide and organic peroxides. The high level of 
GPX in erythrocytes is a reflection of it's importance in 
maintaining membrane integrity. The autoxidation of oxy- 
haemaglobin to met-haemaglobin causes the production of 
superoxide, and the action of superoxide dismutase results 
in the production of large amounts of hydrogen peroxide, 
hence GPX (and catalase) play an important role in the 
erythrocyte.
Throughout this thesis the glutathione peroxidase 
activity discussed will be that of the selenium dependent 
enzyme, unless otherwise stated. The activities of the two 
enzymes can be distinguished by the fact that only the 
selenium dependent GPX activity will use hydrogen peroxide 
as a substrate, whereas cumene hydroperoxide is used as a 
substrate by both peroxidases. In some cases tert-butyl 
hydroperoxide is used to measure the selenium-dependent GPX 
activity as the reduction of this compound by the non 
selenium-dependent glutathione peroxidase is negligible and 
experiments using hydrogen peroxide can be complicated by 
high backgrounds.
1.1.3.2 Other Forms of Selenium-Dependent GPX
Recently, two other forms of selenium dependent GPX 
have been discovered, a glycosylated form which constitutes 
over 90% of the GPX activity in human plasma (Takahashi et 
al, 1987; Avissar et al, 1989a) and a monomeric form whose 
substrate is phospholipid hydroperoxides in rat liver 
(Ursini et al, 1985; Duan et al, 1988). These proteins are 
not yet fully characterised or understood, they may be the 
first of many new selenoproteins to be identified in 
mammals.
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1.2 Selenoproteins and Selenium-binding Proteins
Many other selenium-containing proteins are present in 
mammalian systems apart from GPX. The function of these is 
not known, but there is evidence to suggest that metabolic 
perturbations due to selenium deficiency are not solely due 
to a decrease in GPX activity (Reiter and Wendel, 1985).
Work on selenium deficiency diseases, diseases where a 
decreased level of selenium is observed and conditions where 
selenium is considered to have some protective or 
therapeutic effect, has usually concentrated on finding a 
role for GPX, since it is the only well characterised 
selenium-dependent enzyme. However, it is important to 
consider other selenoproteins, as they may play a more 
important role in the aetiology of a particular disease.
1.2.1 Identification of Selenoproteins
It is important to distinguish between selenium-binding 
proteins and selenoproteins. There is only one clear report 
on a selenium-binding protein to date, discovered in rat 
tissue extracts by Sani et al, (1988). This protein showed 
highest affinity for those forms of selenium which have been 
previously shown to have greatest biological activity 
(Tarino, 1986) and is therefore probably a carrier protein, 
involved in selenium transport and metabolism. A selenium- 
binding protein would presumably be little affected by 
changes in selenium status compared to the effects expected 
on levels of selenoproteins, who depend on the presence of 
selenium for their translation (section 1.4). Hence the 
selenoproteins discussed are those which have been 
identified by electrophoresis on denaturing polyacrylamide 
gels after labeling with ^^ Se. Unfortunately, while this 
ensures that only proteins with selenium incorporated into 
the peptide chain are identified, it means that some of the
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selenoproteins discussed may represent subunits of a larger 
protein.
1.2.2 Functions of Selenoproteins
An example of a selenoprotein having a role where 
previously only GPX was thought to be involved, is in the 
inhibition of tumour formation by selenium in rodents 
(section 1.3.3.2). It had been postulated that this 
inhibition was mediated by glutathione peroxidase 
(Perchellet et al, 1986,1987), but several studies have 
indicated that aspects of selenium metabolism other than 
that in the enzyme GPX may be involved (Medina, 1986; Ip and 
Hayes, 1989). It is postulated that tumour prevention by 
selenium is effected by an inhibition of DNA synthesis, and 
a 58KD selenoprotein has been found whose levels correlate 
with the inhibition of DNA synthesis by selenium (Morrison 
et al, 1988a). Hence this selenoprotein may be more 
important in the prevention of tumour formation than GPX.
Other selenoproteins whose function has been 
tentatively identified include a 57KD plasma selenoprotein 
(selenoprotein P) with a proposed selenium transport 
function discovered by Yang et al, (1987), and a 19.7KD 
sperm tail mitochondrial capsule selenoprotein (Calvin et 
al, 1987). The latter has also been found in many other 
tissues in the rat and therefore may have a similar 
mitochondrial function in all cells (Behne et al, 1988).
1.2.3 Distribution of Selenoproteins
Many other selenoproteins whose function is not known, 
ranging in molecular weight from 10-75KD, have been 
identified in various tissues in rodents (Evenson and Sunde, 
1988; Behne et al, 1988; Morrison et al, 1988a; Bansal et 
al, 1989). Some are common to all tissues studied, whereas 
others are specific to certain tissues. A 22.2KD 
selenoprotein was found only in the brain, kidney, ovary.
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testes and thyroid, a 33.3KD selenoprotein only in testes 
and spermatozoa, a 70.1KD selenoprotein mainly in the testes 
(with some in brain, spleen and thyroid) and a 27.8KD 
selenoprotein was present in very large quantities in the 
thyroid, with small amounts in the liver and kidney (Behne 
et al, 1988). The tissue specificity of these particular 
selenoproteins implies that they have a specific role to 
play in the metabolic functions of these particular tissues, 
unlike GPX which (by virtue of it's central role in 
antioxidative defence) is found in many different tissues.
1.2.4 Priority for Selenium: An Indication of Importance?
The distribution of ^Se in rats after administration 
of [^^Se]-selenite has been examined in order to determine 
the relative importance of different selenoproteins (Behne 
et al, 1988). The assumption was made that selenoproteins 
with the most important role in metabolism would incorporate 
selenium preferentially and retain selenium longer than 
other, less important, selenoproteins. It was found that 
different tissues retained the ^^ Se for different lengths of 
time. Six weeks after the administration of [^Se]-selenite 
to selenium-deficient male rats, ^^Se could still be 
detected in large amounts in the brain, endocrine system and 
reproductive organs, while the heart, muscle, liver, 
erythrocytes and plasma had very little activity. This may 
indicate that selenoproteins in brain, endocrine and 
reproductive systems have a more important function than 
those in the other tissues, although the possibility that 
these organs serve as a storage facility for selenoproteins 
cannot be excluded. However, when the distribution of ^^Se 
was studied immediately after the administration of [^Se]- 
selenite to selenium-deficient rats, these selenoproteins 
were found to incorporate selenium preferentially to GPX.
The fact that they incorporate selenium first, and retain it 
for a longer period, might imply that they play a more 
important role in metabolism than GPX, and hence are
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unlikely to be merely carrier proteins. A diagram 
illustrating the hierarchy of supply of selenium is shown in 
figure 1.3 (Behne et al, 1988).
1.2.5 Distribution of Selenoproteins
The distribution of selenoproteins in selenium-adequate 
and selenium-deficient rats has been followed after 
administration of [^Se]-selenite by injection (Evenson and 
Sunde, 1988). Immediately after administration most ^^Se was 
found in a 55KD plasma selenoprotein, and may identify with 
the 57KD plasma selenium transport selenoprotein 
(selenoprotein P) discovered by Yang et al, (1987). The 
early increase and later decline in this experiment would 
support this protein's role as transport protein. In the 
selenium-deficient rat most of the ^^Se was initially 
present in liver. This had decreased by 72 hours post­
injection while the ^^ Se in kidney and in testis increased. 
Pretreatment of the rats with cycloheximide slowed the ^^Se 
decline in liver and blocked the increase in testis. It was 
therefore proposed that, in selenium-deficient rats, the 
liver served as a central deposit of selenium and the 
majority of selenoprotein synthesis occurred there. 
Subsequently, selenoproteins were exported to tissues with 
high priority for selenoproteins e.g. testes.
A recent report by Otter et al, (1989) has shown that, 
in the liver of selenium deficient mice, the rate of protein 
synthesis and secretion/degradation was significantly 
increased. This finding is supported by experiments to 
investigate the subcellular distribution of selenium in 
mouse liver (Reiter et al  ^ 1989). Analysis of liver 
fractions after injection of [^^Se]-selenite showed that 
accumulation of ^Be followed the order:
Golgi apparatus»Lysosomes>Cytosol=Microsomes>Peroxisomes, 
vesicles Nuclear & Plasma
Membrane
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other Selenoproteins
GPX
Brain, Endocr i ne, Reproducti ve
Other Selenoproteins
GPX
Heart, Muscle, Liver
Figure 1.3: The Hierarchy of Supply of Selenium in the Rat (from Behne etal. 1988)
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The high concentration of the cytosol was
attributed to a free selenium pool. The rapid increase in 
^^Se in the Golgi apparatus would be consistent with a role 
in the processing and export of selenoproteins from the 
liver.
1.2.6 Summary
The finding that many selenoproteins incorporate 
selenium preferentially to GPX in selenium deficiency 
implies that they also have an important role to play in 
metabolism. Hence further work on these selenoproteins may 
help elucidate the role of selenium in selenium-deficiency 
diseases. There are many selenoproteins which have been 
identified but whose function is unknown. A comparison of 
work from different sources in an attempt to determine the 
functions of these selenoproteins is difficult, as the only 
way by which these selenoproteins have been identified is by 
size and location. Sizing of proteins on polyacrylamide gels 
varies between laboratories and the ubiquitous nature of 
many selenoproteins precludes a positive identification by 
means of locational characteristics.
Current evidence on the synthesis and distribution of 
selenoproteins suggests that the selenoproteins are 
synthesised in the liver and then exported to those tissues 
with a high requirement for selenium and/or selenoproteins.
It has been shown that the predominant form of selenium 
in rat tissue, after dietary intake in the form of selenite, 
is selenocysteine (Hawkes et al, 1985). Therefore 
selenocysteine may be the predominant form of selenium in 
selenoproteins. It will be of interest to determine whether 
this proposal is correct using the techniques of molecular 
biology and gene cloning.
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1.3 Clinical Relevance of Selenium, Selenoproteins and 
Glutathione Peroxidase
It is well documented that GPX activity will decrease 
in response to severe nutritional selenium deficiency 
(Takahashi et al, 1986; Knight and Sunde, 1986). As a result 
of this, many other clinical conditions where selenium 
deficiency is observed are thought to involve a decrease in 
GPX in their aetiology. However, as has been shown in 
section 1.2, many other selenoproteins are found in mammals 
which may possibly be of equal or greater importance than 
GPX. Hence, even when a decrease in GPX activity is reported 
in selenium deficiency, there may also be decreases in other 
selenoproteins. Consequently any biological effects noted 
may not be due solely to a decrease in GPX activity.
1.3.1 Selenium-Deficiency Diseases
In many instances selenium deficiency, and hence a 
decrease in GPX, may be a result rather than a cause of a 
particular disorder. Examples of this include selenium 
deficiency in gastrointestinal disease, where capacity to 
absorb nutrients from the intestines is diminished (Loeschke 
et al, 1987), in phenylketonuria, where the special diet 
required may lack selenium (Zachara et al, 1987; Lloyd et 
al, 1989), and in long-term total parenteral nutrition 
(TPN), as reported by von Stockhausen et al, (1987) and 
Cohen et al, (1989). Short-term TPN can also cause selenium 
deficiency, a reduction in serum selenium of 50% after only 
3 weeks of treatment being observed (Korpela et al, 1988) . 
Thus patients receiving TPN have been known to suffer from 
cardiac myopathy, skeletal muscle dysfunction, macrocytosis 
and pseudoalbinosis as a result of selenium deficiency 
(reviewed in Nutrition Reviews, volume 47, 1989).
A disease where selenium deficiency is the causative 
factor would be expected to be cured by selenium
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supplementation. Hong and Chow, (1988) induced eosinophilic 
enteritis, eosinophilia and muscular dystrophy (as 
determined by electron microscopy of muscle tissue) in rats 
by feeding them on a vitamin E and selenium deficient diet, 
all these symptoms were later reversed by supplementation 
with vitamin E and selenium. However, when selenium 
supplementation of human patients with muscular dystrophy 
was tried, no significant change in muscle function or 
levels of lipid peroxides were seen (Backman et al, 1988; 
Jackson et al, 1989), implying that the muscular dystrophy 
seen in the rats was different from the human disease.
One well documented selenium deficiency disease which 
can be alleviated by selenium supplementation is Keshan 
disease, a cardiac myopathy common in young children and 
women of child-bearing age in the Keshan district of China. 
Kashin-Beck disease (a severe osteoarthropathy) also occurs 
in these regions of China and there has also been some 
success in treating this disease with selenium 
supplementation. However, the two diseases are never 
observed together in the same patient (Professor 
A.T.Diplock, personal communication) so selenium deficiency 
may not be the sole cause of these diseases. It is thought 
that Coxsackie virus infection is also involved in the 
aetiology of Keshan disease (Zumkley, 1987), while 
experiments by Zhang and Liu, (1989) lead to the suggestion 
that in Kashin-Beck disease water-born pathogens may be 
involved. Thus it has been suggested that selenium 
deficiency may lead to a reduction of resistance to the main 
causative factor, or to a reduced ability to repair 
subsequent cellular damage.
1.3.2 Cardiac Disease
Following the discovery of Keshan disease, and 
cardiomyopathies in patients receiving TPN, much work was 
concentrated on finding a role for selenium status in 
cardiovascular diseases. The evidence presented can be
— 16 —
confusing as there are many areas of metabolism where 
selenium and GPX could be involved. In an effort to clarify 
this I have drawn up a diagram which illustrates the main 
points and shows their interactions (figure 1.4). The 
interactions on this diagram have been given numbers, these 
are referred to in brackets in the text. The + and - signs 
alongside arrows in the diagram indicate whether the 
influence is promotional or inhibitory.
1.3.2.1 Epidemiological Studies
Epidemiological evidence for the involvement of 
selenium in cardiac disease is conflicting. Ischaemic heart 
death rate has been found to be inversely correlated with 
blood bank selenium levels in 25 cities of the USA (Jackson, 
(1987), and in a study of 1132 Eastern Finnish men aged 54 
years, men with ischaemic EGG responses to exercise had a 
lower mean serum selenium level than controls (Salonen et 
al, 1988). However, pre- and post-diagnostic serum selenium 
levels in samples from men who experienced heart attacks 
were found to be no different from those of control subjects 
(Ringstad et al, 1987; Kok et al, 1989).
Patients with diabetes, who are prone to platelet 
hyperaggregatibility and vascular disorders, have been shown 
to have abnormal levels of GPX, possibly as a cause of the 
diabetic state (Dohi et al, 1988; Fujiwara et al, 1989).
This may be an indication that GPX is involved in 
cardiovascular disease, or it may be merely a reflection of 
the selenium status of the subjects (no evidence is 
available at this time as to the selenium status of patients 
with diabetes).
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Figure 1.4: A Diagram Illustrating the Factors Involved in Cardiovascular Disease (see text for details)
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1.3.2.2 Experiments Using Animal Models
GPX is thought to be important in protection against
ischaemia-reperfusion damage, since free radicals are
thought to be generated during this process (Shlafer et
al, 1986). If this is the case then GPX may also be
important in aiding recovery from myocardial infarction. GPX 
levels have been shown to be increased in ischaemic and 
reperfused rat hearts (Arduini et al, 1987), but other 
studies on the glutathione redox status suggest that GPX is 
not involved (Chatham et al, 1988; Darley-Usmar et al,
1988).
A reduced protection against oxygen radicals in 
selenium-deficient rat hearts, and the finding that 
intravenous infusions of sodium selenite increase survival
times after ischaemia in pig hearts could suggest that
selenium has an antioxidative effect separate from that of 
GPX (Ytrehus et al, 1988; Koehler et al, 1988).
There is also evidence to suggest that selenium has a
direct pharmacological effect on the heart. Infusion of
sodium selenite in pigs caused an overall increase in 
cardiac output, due to an increased heart rate and a 
lowering of blood pressure. The low blood pressure being 
acheived as a result of coronary artery dilation and 
peripheral vasodilation (Koehler et al, 1988). The effect of 
selenium on blood pressure is interesting in the light of 
findings that patients suffering from hypertension have 
decreased levels of GPX activity in their polymorphonuclear 
leukocytes (Rahman and Nath, 1988). If the low GPX activity 
levels are indicative of low selenium levels this would 
imply an inverse correlation between selenium levels and 
blood pressure (1).
—  2_9 —
1.3.2.3 Atherosclerosis
Much evidence has accrued to suggest that selenium 
and/or GPX may be involved in the aetiology of 
atherosclerosis. A significant inverse correlation between 
plasma selenium and the severity of coronary atherosclerosis 
has been observed (Moore et al, 1984). Recently, Takahashi 
et al, (1987), discovered a glycosylated form of GPX in 
human plasma which is distinct from the cellular form of the 
enzyme and is probably synthesised in, and secreted from, 
the liver (Avissar et al, 1989b). The function of this new 
plasma GPX has not been determined, but it may be involved 
in the detoxification of lipid peroxides in the vascular 
system (2) which have been proposed as the primary agents 
for initiation of atherosclerosis (Yagi, (1986). Injury to 
the aortic intima by lipid peroxides may cause aggregation 
of platelets at the site (Yagi, 1987), which is the 
initiation step in atherogenesis (3,4). Prostacyclins will 
inhibit such aggregation (7), but lipid peroxides inhibit 
the biosynthesis of prostacyclin (8), (Moncada et al, 1976). 
Therefore they may also act as promoters of atherogenesis. 
Aggregated platelets produce chemoattractants such as 12- 
hydroxyeicosatetraenoic acid (12-HETE) which cause the 
migration of smooth muscle cells into the intima (9),
(Yagi,1986). These take up cholesterol and synthesise 
connective tissue eventually resulting in the formation of 
an atheromatous plaque. Thus it can be proposed that a 
decrease in GPX activity would result an increased level of 
lipid peroxides and increased risk of atherogenesis.
1.3.2.4 GPX and Selenium in Platelets
The involvement of GPX in platelet arachidonic acid 
metabolism further complicates issues surrounding it's 
involvement in cardiovascular diseases. A lipoxygenase 
enzyme catalyses the conversion of arachidonic acid to 12-
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hydroperoxyeicosatetraenoic acid (12-HPETE) and this 
hydroperoxide is reduced to the alcohol 12-HETE by a 
platelet peroxidase. As has already been mentioned, 12-HETE 
promotes the formation of atheromatous plaques, while 12- 
HPETE is an inhibitor of prostacyclin biosynthesis (Turk, 
1980) and therefore indirectly promotes platelet 
aggregation. The importance of the arachidonic acid pathway 
in heart disease was illustrated with the finding that 
patients with unstable angina have abnormalities of platelet 
arachidonic acid metabolism (Ghigo et al, 1988).
It has been reported that 12-HETE is formed from 12- 
HPETE by GPX (10), (van Rij et al, 1987; Bryant and Bailey, 
1982), while a more recent report (Hill et al, 1989) 
indicates that GPX functions to enhance lipoxygenase 
activity, and therefore production of 12-HPETE (11).
However, this latter report was contradicted by Hatzelmann 
et al, (1989). Thus GPX is apparently involved in the 
production of 12-HETE and/or 12-HPETE, so a decrease in 
platelet GPX activity may reduce the production of these 
metabolites and thereby reduce the risk of atherosclerosis 
via the effects on prostacyclin synthesis and plaque 
formation (9,12).
However, the relative magnitudes of the effects of GPX 
on reduction of lipid peroxides and production of 
arachidonic acid metabolites have to be considered when 
evaluating the role of GPX in cardiovascular disease. There 
is evidence that GPX activity levels were significantly 
reduced in platelets of 15 patients with acute myocardial 
infarction (Wang et al,1981). This suggests that the 
possible enhancement of platelet aggregability by GPX, via 
its involvement in the arachidonic acid cascade, is 
negligible compared to the beneficial effects of it's 
ability to detoxify lipid peroxides.
However, platelet GPX and/or selenium do appear to play 
some role in cardiovascular diseases. Experiments using 
radiolabelled selenium have determined that platelets have a
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higher concentration of selenium than any other cell or 
organelle and have the most stable selenium content (Kiem et 
al, 1987), hence it would appear that selenium has an 
important function in platelets. A decrease in platelet 
selenium of patients with myocardial infarction has also 
been observed (Kiem et al, 1987) and Salonen et al, (1988) 
report that in male subjects from Eastern Finland (a 
selenium deficient area) there was a strong inverse 
relationship between plasma selenium levels and extent of 
ADP-induced platelet aggregation.
1.3.2.5 Summary
Selenium and/or selenoproteins other than GPX may also 
play an important role in recovery from ischaemia. Selenium 
can have effects on other areas of metabolism implicated in 
heart disease, e.g. selenium supplementation can lead to an 
increased production of prostacyclin (13), which would 
inhibit platelet aggregation, and correlations between 
plasma selenium concentration and the level of antithrombin 
III (14) have been observed in patients with previous 
myocardial infarction (Schiavon et al, 1984; Aursnes et al, 
1988). However, GPX will still be of vital importance in the 
detoxification of lipid peroxides which are thought to be 
the cause of atherosclerosis.
1.3.3 Cancer
1.3.3.1 Epidemiological Evidence for the Involvement of 
Selenium in Cancer
Selenium deficiency has been correlated with an 
increased risk of cancer. Patients with cancer have been 
shown to have significantly decreased levels of selenium in 
pre-diagnostic serum samples (Willet et al, 1983), the 
association between low serum selenium and cancer being
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strongest in the cases of gastrointestinal and prostate 
cancers. Similar studies have shown significant correlations 
between pre-diagnostic serum selenium and cancer in fatal 
gastrointesinal, pulmonary and haematological cancers (Knekt 
et al, 1988; Ringstad et al, 1988a), and in thyroid cancer 
(Glattre et al, 1989). However, Virtamo et al, (1987) found 
that there was a difference in pre-diagnostic serum selenium 
in patients who developed cancer, but that this difference 
was not significant when serum samples taken up to one year 
before diagnosis were excluded from the study. They 
concluded that selenium deficiency was a result of the 
condition rather than a cause. It is worth noting that this 
latter study took place in Finland, where the control 
population has a low level of serum selenium.
A correlation between low (post-diagnostic) serum 
selenium levels and cancer has also been observed for the 
following examples:- gastrointestinal cancer (Kogata et al, 
1988; Pothier et al, 1987), malignant melanoma (Reinhold et 
al, 1989), pancreatic cancer (Burney et al, 1989) and breast 
cancer (Chaitchik et al, 1988). In the latter case it would 
appear that the low selenium level occured as a result of 
the disease, the level of selenium deficiency being found to 
increase with increasing progression of the disease. Also 
previous studies (van Noord et al, 1987) had determined that 
there was no difference in prediagnostic selenium levels 
between patients with breast cancer and controls. This would 
support the theory of Virtamo et al, (1987). In the case of 
gastrointestinal cancer however, there is clear evidence to 
suggest that selenium deficiency occurs well before the 
onset of the disease.
It should also be noted that selenium can affect the 
immune system (section 1.3.5), a stimulation of the immune 
system could be an efficient way of combating tumour 
promotion or tumour initiation by viral agents. A study of 
chemoprevention of human hepatitis in China showed that 
incidences of hepatitis infection were significantly lower
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in a population which had received selenium supplementation 
for 3 years (Yu et al, 1989).
Another point of interest is that cisplatin, a commonly 
used chemotherapeutic agent, can cause a decrease in plasma 
selenium (Vernie et al, 1988) and most of the studies on 
selenium deficiency in cancer do not adequately report the 
treatment which the patients were receiving. However, there 
have been many other epidemiological studies, and the 
majority find that there is a significant inverse 
correlation between serum selenium/dietary selenium intake 
and risk of cancer (Vernie, 1984).
1.3.3.2 Chemically Induced Tumours in Rodents
Experiments on chemically-induced tumourigenesis in 
rodents have shown that selenium supplementation can reduce 
or retard tumour development (Watson et al, 1987; Temple and 
Basu, 1987; Blakely, 1987; Reddy.B.S. et al, 1988). This 
inhibition appears to be stage-specific and figure 1.5 shows 
the specificity at various stages proposed by Medina, (1986) 
after an extensive review of the subject. In many of the 
animal model experiments the quantities of selenium used and 
the method by which they were administered varied so much 
that a conclusive view of the mechanism of action of 
selenium has not yet been reached. It is not even certain 
whether the inhibition of tumourigenesis by selenium in 
these experiments is a biologically-mediated effect related 
to the epidemiological findings of chemoprevention by 
selenium or some other, cytotoxic, effect caused by the 
massive doses of selenium used. It may be the case that the 
mechanism of chemoprevention is via the antioxidative action 
of GPX. Perchellet et al, (1987) proposed that the 
inhibition of tumour promotion by selenium was mediated by 
GPX antioxidant protection, having previously shown that GPX 
activity was significantly decreased in mouse epidermal
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Figure 1.5: Responsiveness of the Different Stages of Mammary Tumourigenesis to Selenium-mediated
Inhibition, (from Medina, 1986)
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cells treated with the tumour promoter 12-
tetradecanoylphorbolacetate, TPA, (Perchellet et al, 1986).
1.3.3.3 Evidence for the Involvement of GPX in Human Cancer
The free radical theory of carcinogenesis proposes that 
an increase in free radicals would cause an increase in DNA 
damage and therefore an increased risk of an initiation 
event in carcinogenesis. Therefore the
glutathione redox cycle is implicated by way of it's role in 
antioxidative defence. Evidence to support this comes from 
the discovery that glutathione biosynthesis is impaired in 
patients with Ataxia-Telangiectasia, a disease causing 
increased susceptibility to ionising radiation where 
patients are three times more susceptible to leukaemia, 
lymphoma and cancers of the stomach, ovary, breast and colon 
than normal subjects (Meredith and Dodson, 1987). There have 
also been some reports of decreased levels of GPX activity 
in various cancers, namely in malignant lymphoma (Bewick et 
al, 1987), cancer of the larynx (Drozdz et al, 1988) and 
hepatocellular carcinoma (Corrocher et al, 1986).
In the case of hepatocellular carcinoma there was a 
concomitant decrease in serum selenium concentration and it 
was shown that the decreased GPX activity was not likely to 
be caused by an increase in cell proliferation as GPX 
activity levels in hepatic hyperplasia remain normal (Rossi 
et al, 1987). Further evidence (Vo et al, 1988; Rossi et al, 
1988) has indicated that there is a definate impairment of 
the antioxidant defences in hepatoma.
An increase in GPX activity has been observed in 
various human lung tumours, in particular a 20-30 fold 
increase seen in two adenocarcinomas (Carmichael et al,
1988) . Increased GPX activity was also seen in chronic 
lymphocytic leukemia lymphocytes (Farber et al, 1989).
It may be the case that the decreases in GPX activity 
levels are merely a consequence of selenium deficiency
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(which itself may be a consequence of the disease and/or 
treatment) and that they have no direct relevance to the 
aetiology of the disease. Alternatively, the changes in GPX 
activity may be specific to certain types of tumours.
1.3.3.4 In vitro Evidence for the Involvement of Selenium, 
Selenium-binding Proteins and Selenoproteins
It is possible that selenium exerts it's anticancer 
activity by mechanisms other than via a contribution to GPX 
levels. It may act as an antioxidant in it's own right, or 
it may be involved through other, as yet uncharacterised, 
selenoproteins. Sani et al, (1988) discovered a 2S cellular 
binding protein in rat tissue extracts. The affinity of 
various forms of selenium for this protein showed direct 
correlation with their biological activity, hence the 
authors postulated that this was a carrier for selenium and 
could be involved in selenium transport and metabolism.
Studies on tumour cells in culture have shown that 
selenium in high doses can inhibit cell growth either by 
inhibiting DNA synthesis without affecting cell viability, 
or by cytotoxicity at higher doses (Nano et al, 1989). 
Inhibition of DNA synthesis blocks tumour promotion by TPA 
(Kinzel et al, 1984), hence this may be the mechanism by 
which selenium retards tumour development in rodents. 
Furthermore, addition of selenite to cell cultures can lead 
to an increase in cell adhesiveness, a decrease in confluent 
saturation density and induction of early contact inhibition 
(Yu et al, 1988). Comparitive studies with normal cells 
suggest that these effects of selenium are limited to tumour 
cells (Yu et al, 1988; Pung et al, 1987a; Pung et al,
1987b).
Studies on the distribution of radiolabelled selenite 
in conditions where selenite is inhibiting cell growth 
suggest that a cytoplasmic selenoprotein is responsible for 
the growth inhibitory effect of selenium (Morrison et al.
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1988b). This implies that inhibition of DNA synthesis and 
tumour promotion is mediated by selenoproteins. The later 
discovery of a 58KD selenoprotein whose levels correlate 
with inhibition of DNA synthesis by selenite support this 
theory (Morrison et al, 1988a).
1.3.3.5 Summary
It is clear from the above information that selenium 
appears to be involved in the aetiology of some types of 
cancers, yet it's involvement in others, and the mechanism 
by which it acts, remain to be clarified. The role of GPX is 
even less clear, epidemiological evidence suggests that 
selenium deficiency is involved in pulmonary cancers, yet 
there is a definate increase in GPX activity in some types 
of lung cancer. This would imply that levels of selenium and 
GPX activity are not always correlated, so any inference 
that GPX is involved in cancers on the basis that selenium 
is involved may not be correct.
1.3.4 Rheumatoid Arthritis
Selenium and GPX have also been implicated in the aetiology 
of rheumatoid arthritis. The epidemiological evidence for 
this is conflicting, as is the evidence to suggest that 
selenium supplementation can have beneficial effects in 
treatment. There are many theories that have arisen from 
observations of free radicals and lipid peroxides in this 
disease, and from experiments with inhibitors of GPX which 
suggest that selenium and GPX are involved, but even these 
are contradictory at times.
1.3.4.1 Epidemiological Evidence
There are reports that GPX activity levels are up to 
30% lower in blood samples taken from patients during active 
disease phases in rheumatoid arthritis. (Tarp, 1986; Aaseth
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et al, 1978). This may be due to a deficiency of selenium 
which has been noted in patients with rheumatoid arthritis 
(Mussalo-Rauhamaa et al, 1987; Tarp, 1986; Aaseth et al, 
1978), and significant correlations have been found between 
serum selenium concentration and the severity of the disease 
(Tarp et al, 1985). Selenium supplementation of patients 
with rheumatoid arthritis showed that, in spite of an 
increase in most haematological parameters, GPX activity 
levels in granulocytes remained significantly lower than 
controls (Tarp et al, 1987). In a disease such as arthritis, 
where phagocytizing cells are showing excessive activity, a 
deficiency in GPX is of significance since the protection 
against reactive species produced during the "respiratory 
burst" will be reduced. If GPX is involved in rheumatoid 
arthritis via consequences of an altered activity in 
granulocytes, then it is possible that the immune system as 
a whole is impaired. This would explain the increase in 
susceptibility to disease exhibited by patients with 
rheumatoid arthritis (Baum, 1971; Erhardt et al, 1989; 
Vandenbrouke et al, 1987).
There have, however, been cases where no abnormalities 
in blood GPX activity were seen (Abella et al, 1987; Peretz 
et al, 1987; Muscalo-Rauhamaa et al, 1987). The former two 
reports also investigated selenium levels in blood of 
patients and could find no difference from controls.
The evidence on both sides of this argument seems to be 
fairly well balanced. The diverse reports of whether 
differences in selenium are significant or not may be due to 
differing levels of selenium in the control populations 
used, as the soil selenium content in different countries 
varies and consequently the selenium content of blood 
samples in these populations will differ.
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1.3.4.2 Involvement of Glutathione Peroxidase
GPX has been implicated in rheumatoid arthritis as a 
result of the fact that free radicals and lipid peroxides 
are found in the synovial fluid of patients with rheumatoid 
arthritis (Lunec et al, 1981). Lipid peroxidation can cause 
a large increase in phospholipase A2 activity (Yasuda and 
Fujita, 1977) and it has been proposed that GPX and 
phospholipase A2 act in conjunction to detoxify lipid 
peroxides in membranes (van Kuijk et al, 1987). In the light 
of this, the recent discovery of high concentrations of 
phospholipase A2 in synovial fluid of patients with 
rheumatoid arthritis (Gonzalez-Buritica et al, 1989) would 
also indicate that GPX is involved here.
Interestingly, a synthetic compound, Ebselen, which 
exhibits GPX activity, has been shown to have anti­
inflammatory properties (Maiorino et al, 1988). As 
inflammation is a symptom in rheumatoid arthritis, this may 
be another possible area for the involvement of GPX.
Many of the slow acting drugs used in the treatment of 
rheumatoid arthritis are powerful inhibitors of GPX in vitro 
(Chaudiere et al, 1984). These include the mercaptans, 
mercaptosuccinate and a-mercaptopropionylglycine, 
penicillamine and gold-containing compounds such as 
auranofin, aurothiomalate and aurothioglucose. Inhibition of 
GPX by aurothioglucose in vivo has also been demonstrated 
(Hu et al, 1988a,1988b; Dillard and Tappel, 1986). An 
inhibition of GPX in vivo would explain some of the side 
effects of these anti-arthritic drugs, but the mechanism by 
which they relieve the symptoms of rheumatoid arthritis is 
still unknown.
One theory proposed by Chaudiere, (1986) is that an 
inhibition of GPX by anti-arthritic drugs would indirectly 
cause inhibition of leukocyte collagenase activity, via a 
reduction in the amount of oxidised glutathione (an 
essential activator of leukocyte collagenase).
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1.3.5 Diseases of the Immune System
1.3.5.1 Acquired Immune Deficiency Syndrome
Patients with Acquired Immune Deficiency Syndrome 
(AIDS) and AIDS -related complex have been shown to have a 
significantly reduced plasma, erythrocyte and whole blood 
selenium level compared to controls (Dworkin et al, 1988; 
Olmsted et al, 1989). Symptoms of selenium deficiency were 
also noted in these patients, including psoriasis which has 
been associated with selenium deficiency (Rowe and Keats, 
1989; Michaelsson et al, 1989). Erythrocyte GPX activity was 
also significantly reduced and there were significant 
correlations between total lymphocyte count and both plasma 
selenium and erythrocyte GPX activity (Dworkin et al, 1988). 
The reason for selenium deficiency in AIDS is unclear, it is 
not due to an inability to absorb selenium from the 
intestine (Olmsted et al, 1989), but the deficiency may 
contribute to the pathogenesis of the disease.
1.3.5.2 Selenium in Humoral and Cellular Immunity
Evidence to indicate that selenium can affect the 
immune system has come from observations that the survival 
rate of mice prone to autoimmune murine lupus can be 
improved by selenium supplementation (O'Dell et al, 1988), 
and that serum selenium levels are significantly depressed 
in acute stages of infection, regardless of the infective 
agent (Sammalkorpi et al, 1988). However, the exact 
involvement of selenium in these cases is uncertain.
Human lymphocyte proliferation in response to tumour 
cells in vitro can be inhibited in a specific manner by 
treatment with selenium at physiological concentrations 
(Petrie et al, 1989a), the generation of suppressor-cell 
activity was strongly inhibited by the presence of selenium, 
while cytotoxic T-lymphocyte activity was not affected. The
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inhibition of suppressor cell activity would allow 
expression of enhanced humoral and cellular immunity and may 
also account for the tumour preventative action of selenium 
(section 1.3.3). This is supported by evidence that selenium 
supplementation can enhance human antibody production and 
possibly selectively alter the immune response to cause 
switching from IgM to IgG production, and also increase 
activity of murine cytotoxic T-lymphocytes and natural 
killer cells (Reinhold et al, 1989; Petrie et al, 1989b). 
Poffenbarger et al, (1989), however, found no difference in 
natural killer cell function in selenium-deficient rats. 
Selenium supplementation can also increase phagocytosis in 
human PMN's (Greenman et al, 1988).
1.3.5.3 Glutathione Peroxidase
A deficiency of selenium has been shown to decrease the 
fungicidal activity of polymorphonuclear leukocytes (PMN's). 
Serfass and Ganther, 1975, who proposed that this was due to 
a reduced cellular capacity to cope with the oxidative burst 
required to kill the ingested organism. This is supported by 
the findings that PMN's low in GPX activity (from selenium 
deficient rats) have an increased susceptibility to 
exogenous hydrogen peroxide and an impaired system of 
microtubule assembly (Baker and Cohen, 1984; McCallister et 
al, 1980).
Further evidence that GPX may be involved in the immune 
response comes indirectly through observations of 
glutathione status in the cell. Inhibition of glutathione 
reductase in PMN's results in an inhibition of peptide 
induced shape changes and degranulation (Cohen et al, (1987) 
and enhancement of reduced glutathione status by /3- 
mercaptoethanol will cause an increase in the proliferative 
response of rat splenocytes to lectins (Lacombe et al,
1987; Fidelus et al, 1987). This evidence is supported by 
the findings that dietary glutathione supplementation
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enhances the T-cell mediated immune response in aging mice 
(Furukawa et al, 1987).
1.3.5.4 Summary
A number of reports suggest that selenium has a 
direct effect on the proliferative responses of lymphocytes, 
and indicate that selenium is vital to immune function.
Hence the selenium deficiency seen in patients with AIDS may 
be of detriment to the patient.
Whether this is indicative of an involvement of GPX depends 
upon whether other selenoproteins are involved and how much 
other glutathione metabolising enzymes contribute to the 
glutathione status of the cell.
1.3.6 Neurological Diseases
There have been numerous reports of altered selenium 
and/or GPX levels in a variety of neurological and 
neurodegenerative diseases including:- Multiple Sclerosis 
(Jensen and Clausen, 1986; Clausen et al, 1988; Zachara et 
al, 1986; Mazella et al, 1983), Batten's disease (Clausen et 
al, 1988; Santavouri et al, 1985), Schizophrenia (Buckman ^  
al, 1987), and Down's Syndrome. However, consistant data is 
only found in the case of Down's Syndrome (Trisomy 21).
1.3.6.1 Trisomy 21
Since the superoxide dismutase gene is located on human 
chromosome 21 it has been suggested by several authors that 
certain of the clinical symptoms observed may be due to the 
lack of a corresponding increase in GPX levels to nullify 
any peroxide overload created. Erythrocyte and platelet GPX 
activity levels have been observed to be increased by up to 
50% in patients with Down's Syndrome (Sinet et al, 1975; 
Gromadzinska et al, 1988; Crosti et al, 1989). Sinet et al 
proposed that this was either due to the gene for GPX being
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located on chromosome 21 and showing a gene dosage effect 
similar to that of superoxide dismutase, or the gene being 
regulated by levels of superoxide, hydrogen peroxide or 
superoxide dismutase. The subsequent location of the GPX 
gene on chromosome 3 precluded the first theory (Wijnen et 
al 1978), although the recent discovery of GPX-related 
sequences chromosome 21 may prompt a reassessment (McBride 
et al, 1988). Also, any gene dosage effect would be expected 
to cause an increase in GPX activity in all cells, and GPX 
activity in fetal brain cells and lymphocytes does not 
increase in trisomy 21 patients (Brooksbank and Balazs,
1984; Crosti et al, 1989). A decrease in GPX activity in 
plasma of patients has been observed (Gromadzinska et al,
1988), and in trisomy 21 foetal brain cells, where 
superoxide dismutase activity was increased by 60% and lipid 
peroxidation was increased by 36%, no increase in GPX 
activity was observed (Brooksbank and Balazs, 1984) . The 
failure of GPX to respond to increased oxidative stress in 
the brain may therefore be an important factor in this 
disease.
Interestingly, the findings of Gromadzinska et al,
(1988) suggest that the usually reliable correlation between 
selenium status and GPX activity do not apply in patients 
with trisomy 21. In spite of an observed increase in 
erythrocyte GPX activity of 30%, the selenium levels in 
whole blood, erythrocytes and plasma were decreased. When 
these selenium levels were compared with control subjects on 
similar diets they were found to be lower, implying that the 
decrease in selenium was a result of the disease and not of 
nutritional deficiency. This may indicate that the pathways 
involved in selenium transport and metabolism are disrupted, 
and again implies that other selenoproteins than GPX may be 
involved.
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1.4 Molecular Biology of Glutathione Peroxidase
1.4.1 The Human GPX Locus
By examination of GPX activity in human-chinese hamster 
somatic cell hybrids the human GPX gene was located to 
chromosome 3 (Wijnen et al, 1978) . The location was further 
mapped to position 3pl3-3ql2 using human-mouse somatic cell 
hybrids containing fragments of chromosome 3, (Johannsman et 
al, 1981). This result suggested that there was only one 
copy of the human GPX gene in the haploid genome. There is 
also good evidence that the locus is polymorphic (Beutler 
and Matsumoto, 1975; Meera Khan et al, 1986; Destro-Bisol 
and Spedini, 1989)), with high and low activity forms of the 
enzyme being present in certain individuals. However,
McBride et al, (1988) discovered that there were additional 
sequences which hybridised to the human GPX gene on 
chromosomes X and 21. As neither of the two new sequences 
appear to have an intron, and since the previous experiments 
by Wijnen et al had not detected GPX activity in hybrids 
other than those with chromosome 3, McBride et al postulated 
that the GPX-related sequences on chromosomes X and 21 were 
processed pseudogenes.
1.4.2 The GPX Gene
The precise structure and sequence of the mouse GPX 
gene was described by Chambers et al, (1986). It is 1.2Kb in 
size and consists of two exons and one intron coding for an
0.85Kb mRNA transcript. Figure 1.6 shows the position of the 
exons and the coding regions. Analysis of the DNA sequence 
showed that the selenocysteine residue is encoded in the 
mRNA by the "termination" codon, UGA. This was supported by 
sequencing the mRNA around the selenocysteine codon and was 
later confirmed by publication of the sequences of the 
human, rat and rabbit GPX cDNA's and genes (Ishida et al, 
1987; Sukenaga et al,
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Figure 1.6; The Structure of the Mouse GPX Gene
Table 1.2: The Percentage Amino Acid Homologies Between Glutathione Peroxidases of Different Species
HUMAN MOUSE RAT RABBIT
HUMAN 100 87 86 87
MOUSE 100 94 84
RAT 100 84
RABBIT 100
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1987; Mullenbach et al, 1987; Ho et al, 1988; Akasaka et al,
1989). The DNA sequences also show that GPX structure is 
highly conserved between species. The amino acid 
conservation between these sequences is shown in table 1.2 
and would indicate the importance of GPX as a protective 
enzyme.
1.4.3 The Selenocysteine Codon, UGA.
The fact that the amino acid selenocysteine is encoded 
by UGA has caused much discussion. It had originally been 
thought that selenium was incorporated into GPX by post- 
translational modification like many other unusual amino 
acids. The presence of the UGA codon raises the possibility 
that selenium is incorporated co-translationally. It also 
indicates that there are mechanisms which can suppress the 
termination codon, and the high expression of GPX in some 
tissues indicates that these mechanisms are very efficient. 
The formate dehydrogenase gene of E.coli was also found to 
have a selenocysteine residue encoded by UGA (Zinoni et al, 
1986). The understanding of the mechanism of incorporation 
of selenium into GPX has been helped by the work performed 
in E .coli.
1.4.4 Selenocysteine tRNA in Prokaryotes
An understanding of the mechanism of incorporation of 
selenium into proteins has come mainly from analysis of 
E.coli mutants. Leinfelder et al, (1988a) have identified 
four genes in E.coli which are responsible for 
selenocysteine incorporation into formate dehydrogenase, one 
of which, selC, encodes a functional tRNA species. This tRNA 
contains 95 nucleotides, has a number of "invariant" 
nucleotide positions which deviate from the norm, and has an 
amino acid acceptor stem of 8 bases instead of the 7 
normally found. The tRNA possesses an anticodon sequence 
directly matching the UGA codon but
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cannot be charged with selenocysteine, it can, however, 
accept serine (Leinfelder et al, 1988b). The tRNA is also 
present in 8 other enterobacteria. Sequence analysis of the 
tRNA gene in Proteus vulgaris shows that it varies in only 6 
nucleotides, and that it has the same unique properties as 
the E.coli SeCys-tRNA, i.e. it can be expressed and function 
in E.coli (Heider et al, 1989). This indicates that the 
mechanism of selenocysteine incorporation is not unique to 
E.coli. Further work on the structure of this tRNA by 
Burkard and Soil, (1988), has confirmed the length of the 
amino acid acceptor stem and determined that this results 
from abnormal cleavage of the tRNA precursor by RNAase P.
1.4.5 Selenocysteine tRNA in Eukaryotes.
Evidence is accumulating to suggest that the same 
mechanism as in formate dehydrogenase is used for the 
incorporation of selenium into GPX. The finding that the 
selenocysteine tRNÀ in prokaryotes will accept serine is 
supported by experiments in eukaryotes, where radioactive 
labelling techniques were employed to determine that the 
selenocysteine in GPX of rat liver is derived from serine 
(Sunde and Evenson, 1987). As this tRNA is clearly 
responsible for the insertion of selenocysteine, yet it 
cannot be directly charged with selenocysteine, a 
modification of serine to selenocysteine was postulated. 
Eukaryotic opal suppressor tRNA's which suppress the UGA 
termination codon had been isolated previously from bovine 
liver and found to be substrates in specific phosphorylation 
reactions in which phosphoseryl-tRNA is formed (Hatfield et 
al, 1982). A similar phosphoseryl-tRNA has also been found 
in chicken liver (Hatfield et al, 1983) and the gene for a 
human phosphoseryl-tRNA has been sequenced (O'Neil et al, 
1985). This phosphoseryl-tRNA could be an intermediate in 
the formation of selenocysteyl-tRNA. Alternatively the 
phosphoserine could be incorporated into the protein and the 
conversion of phosphoserine residues to selenocysteine
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residues could be a post-translational event. Both theories 
could explain the findings that selenium in the form of 
selenite or selenide is more readily incorporated into GPX 
than selenium in the form of selenocysteine (Sunde and 
Evenson, 1987).
1.4.6 A Co-translational or Post-translational Mechanism?
In the case of formate dehydrogenase of E.coli, Zinoni 
et al, (1987) performed localised mutagenesis at the UGA 
codon and concluded that the incorporation of selenium was a 
co-translational event. In this case, the pathway must be: 
seryl-tRNA -> phosphoseryl-tRNA -> selenocysteyl-tRNA -> 
selenocysteine residue in formate dehydrogenase.
In order to determine the mechanism of incorporation of 
selenium into GPX in eukaryotes, Mizutani and Hitaka,
(1988), compared the conversion of opal suppressor 
phosphoseryl-tRNA to selenocysteyl-tRNA with conversion of 
phosphoserine residues in a model protein (casein) to 
selenocysteine residues. No conclusive results could be 
obtained from this experiments, since phosphoserine was 
converted to selenocysteine in both the tRNA and the 
protein. Also, the conditions used in the experiments were 
artificial and unlikely to represent the in vivo situation.
More recently, Lee et al, (1989b) isolated a seryl- 
tRNA, phosphoseryl-tRNA and a selenocysteyl-tRNA from rat 
mammary tumour cells which all co-chromatographed on a 
reverse phase chromatography column. Hence it is assumed 
that these three tRNA's are the same molecule, acting as a 
carrier molecule for the conversion of serine to 
selenocysteine via phosphoserine, and as a direct 
selenocysteine donor to the growing polypeptide chain. This 
proves that the incorporation of selenocysteine into GPX in 
eukaryotes is also co-translational.
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1.4.7 Suppression of UGA Termination
The question of how selenocysteyl-tRNA suppresses the 
termination codon has been difficult to resolve. Specific 
suppression at high levels had been observed in eukaryotes, 
but this was only intramitochondrially (Heckman et al, 1980; 
Barren et al, 1980). This was probably facilitated by the 
expanded codon reading ability of mitochondria (Bonitz ^  
al, 1980). A search of the complete human and bovine 
mitochondrial genomes showed no sequences homologous to the 
GPX gene (Mullenbach et al, 1988), indicating that this 
particular suppression event takes place in the cytosol 
only.
1.4.7.1 Primary Structure Effects
Work on various suppressor tRNA's has shown that the 
degree of suppression can be affected by sequences within 
the mRNA close to the termination codons. In some cases this 
involves nucleotides immediately 3' to the termination codon 
(Bossi, 1983) while in others the 5' nucleotides are 
involved (Murgola et al, 1984) . As mutation of the UGA codon 
in E.coli to UGU or UGC does not completely stop 
selenocysteine incorporation into formate dehydrogenase 
(Zinoni et al, 1987), there must be some context effect in 
operation. Mullenbach et al, (1988), compared the 
nucleotides adjacent to UGA from the GPX genes of various 
species, and from the formate dehydrogenase gene, with those 
of 19 genes (both prokaryotic and eukaryotic) where the UGA 
codon is used as a termination signal. The nucleotide 
sequence around UGA in the GPX gene is highly conserved 
between species (figure 1.7), in spite of the fact that the 
amino acids for which the sequence codes have a high degree 
of degeneracy in their codons. This would suggest that the 
adjacent nucleotides are involved in the suppression event. 
However, the sequence around the UGA in the E.coli formate
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GPX rabbit 
GPX bovine 
GPX mouse 
GPX human 
GPX rat 
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Prokaryote 
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Figure 1.7: Comparison of the Nucleotide Sequence Immediately Surrounding the UGA Codon in Seven Species
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dehydrogenase gene is different from that in GPX. While it 
does have the same UC bases immediately 5' to the UGA codon, 
so do a number of the genes where UGA is used as a 
termination signal. Thus a simple, primary structure context 
effect is unlikely.
An alternative strategy for controlling codon usage 
could be in the utilisation of codon choice (Chada et al, 
1988). They observed that in human GPX mRNA there was a 
cluster of "rare codons" at the 5' end (rare meaning used at 
a frequency of less than 14% of expected) and suggest that 
clusters of rare codons could indicate regulation of 
translation by limiting the availability of the 
corresponding tRNA*s.
1.4.7.2 Secondary Structure Effects
It has been observed that in rat, human and mouse GPX, 
and in E.coli formate dehydrogenase, the bases immediately 
flanking the UGA codon are capable of forming a hairpin 
structure with the U as a "single base loop" (Chada et al, 
1988; Goldfarb, 1988). Chada et al examined 20 human and 
rodent mRNA's which used UGA as a termination signal and did 
not find any similar structures. They suggested that the 
hairpin, or structures bound to it, might influence the 
preferential use of selenocysteyl-tRNA over the release 
factor.
These observations, however, do not take into account 
the effect of the rest of the mRNA sequence on the secondary 
structure. Mullenbach et al, (1988), investigated the 
secondary structure of mRNA from mouse, bovine and human GPX 
and E.coli formate dehydrogenase by performing 100 random 
computer foldings of a 200bp segment of mRNA with UGA as the 
centre, using the RNA folding rules of Zuker and Steigler, 
(1981) and Martinez, (1984). After comparing the results 
with those obtained with mRNA from 19 genes which use UGA as 
a termination codon they proposed that the secondary
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structure of the mRNA was an important factor in regulating 
the use of the UGA codon. They found that termination UGA 
codons reside within a loop but adjacent to a stem structure 
(in some cases the A was paired in the stem) and suggested 
that the ribosome would stall at this point, thus causing 
chain termination. The UGA codons of selenocysteine were 
found to reside within a loop but not adjacent to a stem 
structure, hence permitting efficient readthrough.
1.4.7.3 Anti-termination Factors
It is possible that other cofactors are involved in the 
suppression mechanism. In E.coli, mutations in four genes 
(selA, selB, selC and selD) block selenocysteine 
incorporation into formate dehydrogenase (Leinfelder et al, 
1988a). While the selC gene codes for the selenocysteyl-tRNA 
(Leinfelder et al, 1988b), the selA, selB and sel D genes 
code for polypeptides of molecular mass 50KD, 70KD and 37KD 
respectively. Mutations in selA and selD block formation of 
selenocysteyl-tRNA, so these gene products could be involved 
in the regulation of the tRNA expression or the charging of 
the tRNA with selenocysteine. Mutation in the selB gene, 
however, results in the formation of selenocysteyl-tRNA but 
not incorporation of selenocysteine into formate 
dehydrogenase (Leinfelder et al, 1989). Later work by this 
group determined that the selB gene product, SELB, is a 
translation factor which binds specifically to 
selenocyteyl-tRNA, it does not bind to seryl-tRNA 
(Forchhammer et al, 1989). Therefore this protein is 
probably an elongation factor similar to the elongation 
factor Tu (with which it has extensive amino acid homology) 
which is specific to the insertion of selenocysteine into 
the polypeptide chain. It may also recognise mRNA context 
surrounding the UGA codon and/or compete for the binding of 
release factor in order to prevent termination at the UGA 
codon. In the light of this evidence, it is possible that a
— 43 —
similar mechanism is in operation for the suppression of UGA 
termination in eukaryotes.
1.4.7.4 Availability of the Selenocysteyl-tRNA
The availability of selenocysteyl-tRNA itself may also 
be a controlling factor in the suppression of the UGA codon. 
Recent work on the regulation of transcription of the 
Xenopus selenocysteyl tRNA (Lee et al, 1989a) has shown that 
it differs from the regulation of other eukaryotic tRNA's in 
a number of ways. Eukaryotic tRNA gene transcription is 
normally controlled by 2 internal control regions on the 5' 
and 3' sides of the gene (designated the A and B boxes 
respectively), with additional regulatory effects being 
exerted from the flanking regions of the gene. Lee et al 
showed that the A box does not regulate expression of 
selenocysteyl-tRNA. Furthermore, there are a series of 5' 
flanking regulatory regions including a GC-rich region, an 
AT-rich region and a TATA box, not previously observed in 
eukaryotic tRNA genes.
It is clear from this information, and from the 
structural abnormalities of the prokaryotic selenocysteyl- 
tRNA described earlier, that this molecule does not follow 
the pattern of eukaryote tRNA structure, function and 
regulation known to date. It may be structurally different 
in order to facilitate binding of enzymes involved in the 
formation of selenocysteine from serine via phosphoserine 
and/or to facilitate the binding of additional cofactors 
such as SELB which are involved in UGA codon recognition.
The regulatory differences may have evolved as a result of 
the complex controls required if selenocysteine 
incorporation is limited by the availability of the 
selenocysteyl-tRNA.
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1.4.7.5 Physiological Factors
Another possibility is that there are physiological 
factors which contribute to the regulation of suppression of 
the UGA codon. Engelberg-Kulka et al, (1988) observed that, 
while selenocysteine-containing proteins are generally rare, 
they are abundant in strictly anaerobic organisms such as 
Clostridia and in the anaerobic enzymes of facultative 
anaerobes such as E.coli and S .typhimurium. GPX itself is an 
important enzyme in the detoxification of harmful oxidants 
and it may be that it is synthesised in response to 
oxidative attack. It need not be anaerobiosis which 
regulates the codon usage, other changes in physiology may 
play a part. A sudden change in the intracellular 
environment may cause a change in conformation of the 
selenocysteyl-tRNA, or the region of mRNA around the UGA 
codon. This in turn may affect the ability of translational 
proteins to recognise the tRNA and mRNA and so enable 
efficient readthrough of the codon.
1.4.7.6 Summary
Much of the information on UGA suppression is compiled 
from different sources and assumptions that the same 
mechanisms are used in different organisms have been made. 
The suppression of the UGA codon may be affected by some or 
all of the factors mentioned. However, the consensus drawn 
from this information is that there are specific translation 
factors involved in the suppression of UGA which recognise 
selenocystyl tRNA and the secondary structure of the mRNA 
surrounding the codon. The unique nature of the regulation 
of transcription of selenocysteyl-tRNA could mean that the 
availability of selenocysteyl-tRNA is in itself a regulatory 
factor in this process.
1.4.8 Regulation of the GPX Gene.
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The regulation of expression of the GPX gene itself is 
complex. Sequences with homology to the Spl binding site 
consensus,sequence have been found in the 5' flanking region 
of the mouse GPX gene. These sequences were found upstream 
from a sequence which shows good homology with the "TATA" 
box consensus sequence, in the region -98 to -245 (where 
numbering starts at the transcription initiation site). 
Construction of plasmids containing fragments of the 5' 
region linked to the chloramphenicol acetyl transferase 
(CAT) gene, and use of these in expression studies in mouse 
L-cells confirmed that this region acted as a promoter 
(Chambers and Harrison, 1988).
GPX is possibly involved in developmentally-specific 
events (Frampton et al, 1987) and activation of the GPX 
gene, as measured by the presence of DNAse I sensitive 
sites, varies between different cell types (Chambers and 
Harrison, 1988). There is one DNAse I sensitive site around 
the promoter region of the gene common to all tissues 
measured, and others at between 0.5Kb and 3.5Kb downstream 
of the gene which are only present in specific tissues. One 
such region, at approximately 0.5Kb downstream of the gene, 
was found to contain sequences with homology to the 
consensus sequences for the transcriptional regulatory 
elements; octamer sequence, NFkB binding site and SV40 
enhancer sequence, although this region did not function as 
an enhancer in CAT assay experiments. Thus gene activation 
would appear to play a major role in the tissue specificity 
of GPX gene expression.
Another obvious regulatory factor in the expression of 
GPX is the availability of selenium. It has been shown that 
selenium deficiency results in a decrease in GPX activity 
and GPX protein levels (Takahashi et al, 1986; Knight and 
Sunde, 1986). However, evidence has recently emerged to 
suggest that selenium itself, or other selenoproteins, may 
be involved in regulation of GPX expression at the 
transcriptional level (Saedi et al, 1988). Using Northern
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blot analysis of mRNA from selenium-adequate and selenium- 
deficient rat liver they demonstrated that a decrease in GPX 
mRNA levels accompanied the decrease in GPX activity levels 
in selenium deficient rats. This was confirmed by Yoshimura 
et al, (1988), who also observed a decrease in GPX activity, 
accompanied by a decrease in GPX enzyme levels and a 
decrease in GPX mRNA in the selenium-deficient rat liver, 
and by Toyoda et al, (1989) who found that GPX mRNA levels 
in liver and kidneys of mice were decreased in response to 
selenium deficiency. This evidence is contradicted by 
Reddy.A.P. et al, (1988), who reported no change in GPX mRNA 
levels in selenium-deficient rat livers in spite of an 
observed decrease in GPX activity in the blood. The use of 
blood GPX activity as an index of selenium status in the 
liver does, however, leave this question open to doubt. It 
is well known that the expression of GPX varies greatly 
between different cell types and without measurement of GPX 
activity in the liver the results must be viewed with 
caution.
The fact that selenium deficiency results in decreased 
levels of GPX mRNA in rats implies that selenium exerts 
transcriptional control over this gene. Other evidence of 
transcriptional control by selenium itself, (or other 
selenoproteins) was found in studies on protein synthesis in 
perfused rat livers treated with selenium (Jia et al, 1989). 
Supplementation with selenium caused an overall increase in 
the rate of protein synthesis and the DNA/RNA ratio. An 
increase in RNA indicates that selenium has a role to play 
in transcriptional regulation and/or RNA stability, but 
whether this increase represents an increase in ribosomal, 
transfer, or messenger RNA remains to be determined. An 
increase in mRNA would indicate that selenium itself can 
also regulate expression of genes other than the GPX gene.
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1.5 Aims of this Investigation
There is a wealth of evidence implicating the 
glutathione redox cycle and selenium in numerous disease 
states. This is not surprising considering the importance, 
and central role, of the antioxidative defence systems in 
maintenance of cellular integrity. The involvement of 
selenium in some cases would appear to be unrelated to any 
clinical effect of glutathione peroxidase and, with the 
growing information concerning other selenoproteins, a 
deficiency of selenium associated with many diseases may not 
necessarily mean that glutathione peroxidase is directly 
involved. Similarly, in view of the multifunctionality of 
glutathione, the role of selenium and glutathione peroxidase 
in any disease may not be a direct one, but indirect via 
changes in metabolism associated with glutathione 
abnormalities.
It was expected that a study of the human glutathione 
peroxidase gene at the molecular level would help in the 
analysis of the role of glutathione peroxidase in various 
diseases. In the diseases where reports of alterations in 
GPX activity were controversial, a study of the levels of 
GPX mRNA in these conditions may help to resolve whether the 
expression of GPX is altered. An alteration in the 
expression of GPX may be an indication that altered levels 
of GPX activity are a causative factor in the disease, 
whereas if the levels of expression were unaltered the 
differences in GPX activity are more likely to be as a 
result of secondary effects or interference from outside 
agents which affect the functional ability of the enzyme.
The mouse GPX gene had been previously isolated 
(Chambers et al, 1986) and this was available for use as a 
hybridisation probe. When my studies started this was the 
only GPX gene to have been isolated and sequenced. The 
original aim was to isolate and sequence the human GPX gene 
from a genomic DNA library in lambda phage using the mouse
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GPX gene as a probe. The DNA sequence of the gene could then 
be compared with that of the mouse gene to determine whether 
the "termination" codon UGA was also used to specify 
selenocysteine in the human gene, and to determine the 
degree of conservation of gene sequence between species. It 
was also proposed to commence initial studies on the 
regulation of the GPX gene using DNAse hypersensitivity 
tests. The isolation of the human GPX cDNA was undertaken, 
as it was expected that this would make an ideal probe for 
investigating levels of GPX itiRNA in RNA from clinical 
samples.
The expression of GPX mRNA in disorders where selenium 
and/or GPX had been implicated was to be investigated by 
comparing the quantities of GPX mRNA with those of normal 
controls using human GPX sequences as a hybridisation probe 
in RNA dot blot and Northern blot experiments.
These aims were modified after the discovery of a novel 
cDNA (GPRP) with sequence homology to the human GPX gene, to 
include investigations into the precise sequence of this 
cDNA and it's relationship to glutathione peroxidase. As 
this cDNA appeared to code for a novel selenopeptide, and 
much evidence exists to suggest that selenoproteins other 
than GPX are involved in various diseases, it was considered 
important to include investigations into the expression of 
the mRNA of this novel selenopeptide in disease states. Much 
of the work on the human GPX gene was terminated (in favour 
of studies on the new cDNA) once it was certain that the 
human GPX gene had been isolated, as it would have been a 
repetition of work published during the course of the 
investigation by other laboratories.
Experiments to try and distinguish between the novel 
cDNA and the GPX gene in dot blots. Northern blots and 
Southern blots became necessary in order to determine the 
hybridisation conditions to be used in the expression 
studies. The expression studies were undertaken on white 
blood cells of patients with rheumatoid arthritis and
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Hyper1ipidaemia. Rheumatoid arthritis was chosen as the 
evidence for the involvement of selenium and GPX was most 
controversial in this case and it was hoped that a study of 
GPRP and GPX mRNA would help to clarify the matter. 
Similarly, patients with Hyperlipidaemia were chosen in 
order to try and clarify the involvement of GPX in 
cardiovascular disease. Patients with Hyperlipidaemia are 
judged to be at risk from cardiovascular disease and were 
used because patients who have established cardiovascular 
disease or have suffered from myocardial infarction may be 
taking medication which could interfere with the study.
— 50 —
Chapter 2 
Experimental Procedures
2.1 Introduction
In this chapter the experimental procedures used throughout 
this investigation are described in detail. Where a 
procedure is common to one or more protocol, it is 
described in section 2.3. Recipes for the buffers, media 
and solutions used in the procedures are detailed in 
alphabetical order in Appendix A. Most procedures used are 
modifications of previously reported methods, original 
references are given where appropriate. Details of 
procedures are given, along with brief discussion of the 
major principles involved in the method.
2.2 Materials
The suppliers of enzymes and kits are given in the 
appropriate methods sections, as are the suppliers of 
equipment and any other reagents specific to a relevant 
section.
2.2.1 Chemicals
All chemicals were obtained from BDH, Analar grade, with 
the exception of the following:
Sigma Chemical Company; Citric acid (trisodium salt), 
sodium chloride, MOPS, EDTA, Ethidium bromide. Polyvinyl 
pyrrolidone, Bromophenol blue. Xylene cyanol. Spermidine 
Trihydrochloride.
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Biorad; Acrylamide, NN'-methylenebisacrylainide, TEMED, 
Ammonium persulphate.
ERL Ultra Pure Reagents; Agarose, Low melting point 
agarose. Guanidine Hydrochloride, Guanidinium thiocyanate. 
Urea.
DIFCO; Bacto-tryptone, Bacto-agar.
Beta Labs; Yeast extract 
Whatman; DE52.
Pharmacia; Ficoll 400.
ICN Biomedicals Ltd; Nusieve™ agarose.
2.2.2 Radiochemicals
All procedures involving radiochemicals were carried out in 
accordance with the guide-lines set out in "Local Rules for 
Protection against Ionising Radiation", published by the 
University of Surrey Safety Office. The radiochemicals were 
obtained from Amersham International and were used within 
two weeks ( for ^^ P ) or four weeks ( for ^^ S ) of the 
release date. The following radiochemicals were used:
1. Deoxycytidine 5'-[a-^^P] Triphosphate, Triethylammonium 
salt. Specific activity approximately 3,000 Ci/mmol.
lOmCi/ml. (Abbreviated to a-^^P dCTP )
2. Adenosine 5'-[gamma-^^P] Triphosphate, Triethylammonium 
salt. Specific activity approximately 3,000 Ci/mmol.
lOmCi/ml. (Abbreviated to gamma-^^P ATP )
3. Deoxyadenosine 5'-[a-^^S] Thiotriphosphate, 
Triethylammonium salt (Sp isomer). Specific activity 
approximately 1,200 Ci/mmol. lOmCi/ml. (Abbreviated to 
a-^^S dATP ) .
2.2.3 Bacterial Strains
The strains of E.coli used, along with their genotypes and 
preferred culture media, are shown in table 2.1.
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2.2.4 Cloning Vectors
The restriction maps of the plasmid and phage vectors used, 
along with information on antibiotic selection etc are 
shown in figures 2.1,2.2,2.3,2.4.
2.3 General Procedures
The following methods were routinely used in a number of 
different experiments. They are set out here and will not 
be described in the individual procedures.
2.3.1 Phenol Extraction
Where no details of phenol extraction are given the 
procedure was as follows: An equal volume of room 
temperature TE-saturated phenol was added to the aqueous 
solution and mixed thoroughly. The emulsion was centrifuged 
at 9,000rpm, 4 °C for 10 minutes in the JA20.1 rotor,
Beckman J2-21 centrifuge (or maximum speed in the microfuge 
if small volumes were used) to separate the phases.
Protein, SDS and agarose were extracted into the lower 
(phenol) phase, while the nucleic acids remained in the 
upper (aqueous) phase. Often a white interface was also 
present. The top, aqueous phase is then removed and can be 
further extracted with phenol until the interface is clear 
and then with phenol/chloroform (a 1:1 mixture of TE- 
saturated phenol and chloroform/isoamyl alcohol), followed 
by chloroform in order to remove the phenol.
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%^ able 2.1: E.coli Strains and their Genotypes
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MULTIPLE 
v  CLONING /
PvuJI R s q I
Hael
IqgZ
TaqI
Amp" PÜC18/19 
2686 bpHae:
Rsal
MULTIPLE CLONING SITES
pUC19 AAGCTTGCATGCCTGCAGGTCGACTCTAGAGGATCCCCGGGTACCGAGCTCGAATTC 
Hind III Pst I Xba I BamH I EcoR I
pUClS GAATTCGAGCTCGGTACCCGGGGATCCTCTAGAGTCGACCTGCAGGCATGCAAGCTT 
EcoR I BamH IXba I Pst I HindiI
UP = Universal Primer
RP = Universal Reverse Primer
Figure 2.1: Restriction map of the pUC plasmids showing the multiple cloning site of pUC18 and 19. (Norran
et al. 1983)
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Figure 2.3: Restriction Map of Phage ACh28 (Rimm et al. 1980).
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Figure 2.4: Restriction Map of Phage Xgtll (Young and Davis, 1983). See Appendix B for 
explanations of the genotype abbreviations.
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2.3.2 Ethanol Precipitation of DNA
Where no details of the precipitation method are given, the 
DNA was precipitated by the addition of a 0.5 volume of 
7.5M ammonium acetate and 2 volumes of 100% ethanol. The 
mixture was left at -70“C for 20 minutes, or -20°C 
overnight, to precipitate the DNA. The DNA was pelleted by 
centrifugation at maximum speed in the Eppendorf 
microcentrifuge for 10 minutes at approximately 8°C. The 
supernatant was removed immediately, the pellet washed with 
70% ethanol and vacuum dried in a Univap for 15 to 20 
minutes.
2.3.3 Use of the Univap
The Univap (Uniscience Ltd) is a centrifugal evaporator 
which dries samples by heating them while centrifuging at 
low speed under vacuum. There are two rotors which take 
either microcentrifuge tubes or 14ml Falcon test tubes. The 
sample to be dried is placed in the Univap, which is set at 
a temperature of 45°C and the vacuum applied from the 
vacuum pump (Aquavac, Uniscience) once the centrifuge has 
reached l,000rpm. The rotor spins at approximately 2,000rpm 
and samples of approximately 50/il are usually dry after 
15-20 minutes.
2.3.4 Agarose Gel Electrophoresis
Agarose gel electrophoresis of DNA was carried out by the 
standard method described in Maniatis et al, 1982. In this 
procedure the DNA molecules migrate according to their 
size. Appropriate DNA markers are run at the same time so 
that the length of the DNA molecules can be estimated. X  
DNA, Hind III fragments (Amersham) were used for sizing DNA 
molecules between 0.5 and 9Kb in length, while 0X174 DNA, 
Hae III fragments (Amersham) were used for sizing DNA 
molecules between 0.2 and 1.4Kb in length. The buffer used 
was E buffer in all cases except for the isolation of small
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fragments from the 3' non coding region of the GPX and C P U  
genes, where borate buffer was used. The agarose was used 
at concentrations of between 0.6% and 3%, depending on the 
size of molecules involved (i.e. to separate a 9.3Kb from 
an 8.9Kb fragment 0.6% agarose was used whereas for the 
isolation of lOObp fragments 3% agarose was used), for most 
purposes, 0.8% or 1% concentrations were used. For the 
small scale mini gels the Pharmacia GNA-100 submarine 
apparatus was used, most work was performed with this 
apparatus. For Southern blots of genomic DNA, or 
restriction enzyme mapping the BRL Model H5 Submarine Gel 
Apparatus was used.
The gels were stained with ethidium bromide (Maniatis et 
al, 1982) and visualised under UV light using a UV 
transilluminator. Model TM20 (Genetic Research 
Instrumentation Ltd).
2.3.5 Photography
Gels were photographed through an orange filter using a 
Polaroid Land Speed MP-4 camera and Polaroid type 55 
positive/negative film (single sheets). Photographs were 
taken with the aperture wide open for 12 seconds and left 
to develop for 25 seconds. If the negative was to be kept 
it was soaked in water for 3-16 hours then rinsed in water 
and air dried.
2.3.6 Recovery of DNA from Agarose Gels
The method used to extract fragments of the mouse GPX gene, 
the human GPX gene and the human C P U  cDNA for use as 
hybridisation probes was adapted from that reported by 
Maniatis et al, (1982). After electrophoresis in a low 
melting point agarose gel the fragments were visualised by 
staining and UV illumination and then cut out in the 
smallest possible volume of agarose. An equal weight of 
water was added, the agarose melted at 70“C and then the 
mixture cooled to 37°C (for gels of a concentration of
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agarose greater than 1%, enough water was added to bring 
the final concentration of agarose to 0.5%). After 20 
minutes an equal volume of ice cold TE-saturated phenol was 
added, mixed thoroughly and left on ice for a few moments 
to precipitate the agarose. The mixture was centrifuged for 
10 minutes at 2,000rpm in the bench centrifuge (MSE Minor 
•S') and the top, aqueous, layer removed to another tube. 
The agarose interface was re-extracted with an equal volume 
of water and the top layer pooled with that from the first 
extraction. This was extracted a further three times with 
room temperature phenol (or until the interface was clear) 
and then extracted with sequential equal volumes of 
butan-2-ol to remove the residual phenol and simultaneously 
reduce the volume. When the volume had been reduced to 
400/il or less it was transferred to a microcentrifuge tube 
and the DNA precipitated using ethanol (see section 2.3.2). 
The DNA pellet was dissolved in TE to a final concentration 
of approximately lOOng/^1.
2.3.7 Geneclean™ Procedures
Geneclean™ procedures remove unwanted RNA and salt 
contamination from small quantities of plasmid DNA. They 
can also be used to extract small fragments of DNA from 
agarose gels. The range of DNA fragments for which this 
method is effective is between lOObp and lOKbp. The 
reagents are supplied in a kit, available from Stratech 
Scientific Ltd.
2.5 volumes of sodium iodide solution was added to the DNA 
sample, either in solution or in agarose. If the DNA was in 
agarose the mixture was then heated at 55°C until the 
agarose melted. Glassmilk™ solution was added 
(approximately 1/xl glassmilk to each lug of DNA, with a 
minimum volume of 5/xl) . The solution was mixed and left at 
room temperature for 5 minutes. During this time the DNA 
was adsorbed onto the silica matrix in the glassmilk
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solution. The glassmilk was pelleted by centrifugation at 
14,000 rpm in the Eppendorf microfuge for 5 seconds. The 
supernatant was removed and the glassmilk washed by 
resuspending in 500/xl of ice cold NEW^" solution (a sodium 
chloride/ethanol wash) and recentrifuging for 5 seconds.
The washing procedure was repeated twice more, then the 
pellet was resuspended in sterile, distilled water (the 
amount of water depending on the initial volume of 
glassmilk added, i.e. as many fj.1 of water were added as 
there were /xl of glassmilk) . The mixture was incubated at 
50“C for three minutes to release the DNA from the matrix 
and then centrifuged in the microfuge at 14,000 rpm for 30 
seconds. The resulting supernatant contained the purified 
DNA.
2.3.8 Autoradiography
In all cases Kodak X-Omat AR high speed X-ray film was used 
(unless this was temporarily unavailable, in which case 
Fuji type RX high speed was substituted). For 
autoradiography of the gels or filters were wrapped in 
cling film or thin plastic and placed, with the film, in a 
film cassette (X-ray Accessories Ltd.) containing Croner 
lightning plus enhancing screens. Exposure was at -70°C for 
the required amount of time. Typical exposures were 1-3 
days for DNA dot blots and Southern blot mapping of 
subclones, 3-7 days for RNA dot blots, and 1 week for 
screening of phage libraries, genomic Southern blots and 
Onblots. For autoradiography of ^^ S (used in DNA 
sequencing), the film was placed directly onto the dry 
sequencing gel in the cassette and exposed at room 
temperature overnight.
For developing, the films were allowed to return to room 
temperature (if they had been exposed at -70°C) and put 
through a Fuji Medical Film Processor RGII. This developed, 
fixed, washed and dried the film automatically. The
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Chemicals used in the processor were RG developer and RG 
fixer from Wardray Products Ltd.
2.4 Restriction Enzyme Digests
Where no specific details of restriction enzyme digests are 
given these were carried out as follows: 1/xl of enzyme was 
used to digest each 1/xg DNA in a total volume not less than 
5x the volume of enzyme used, usually 20/xl or 30/xl except 
in the case of genomic digests. An appropriate amount of 
lOx enzyme reaction buffer was included in order to provide 
optimum salt concentrations for the enzyme. (A list of 
enzymes with their reaction buffers, recognition sites and 
the supplier is given in table 2.2). The reaction mixture 
was incubated at 37°C (except Sma I and Apa I, 30°C and Tag 
I, 65°C) for a minimum of 90 minutes (usually overnight). 
Genomic DNA was digested in a total volume of 120/xl. 
Typically 10fig DNA (in a volume of 15/xl) was digested with 
5/xl of enzyme. Spermidine (4mM) and DTT (O.lmM) were also 
incorporated in the reaction. In mapping experiments 1/xl of 
RNAse A was included in each digest to remove any RNA 
contamination which occasionally obscured the smaller DNA 
fragments. All restriction enzymes were stored at -20°C and 
kept on ice during use.
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Table 2.2: Restriction Enzymes
Enzyme Recognition Site 
(5* - 3')
Supplier Reaction Buffer
EcoR I G'AATTC Amersham E8
BRL React^" 3
BamH I G'GATC Amersham E6
BRL React^” 3
Hind III A'AGCTT Amersham E8
BRL React^" 2
Xba I T * CTAG Amersham E4
BRL React^" 2
Pst I CTGCA'G BRL React^M 2
Pvu II CAG'CTG BRL React^" 6
Taq I T'CGA BRL React^" 2
Apa I GGGCC'C BRL React^" 4
Xho I C 'TCGA BRL React^" 2
Sst I GAGCT'C BRL React^ *^  2
Rsa I GT'AC BRL React^^ 1
Nar I GG'CGCC BRL React 1
Bgl I GCCNNNN'NGGC BRL React^" 2
Bgl II A 'GATCT Amersham E4
Sma I CGC'GGG Amersham E19
Hpa I GTT'AAC Amersham E18
Msp I C ' GGG Amersham E9
Hae III GG'GG Amersham E8
Kpn I GGTAG'G Amersham E13
Sau 3AI 'GATG Amersham E4
Nco I G 'GATGG Amersham E6
Hae II PuGGGG'Py Amersham E8
Ava II G'G(A/T)GG Amersham E9
Acc I GT' (A/G) (G/T)AG Amersham E8
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2.5 I s o l a t i o n  of P l a s m i d  D N A
Three different principles of plasmid DNA isolation are used 
in the following methods. For large scale preparations the 
classical cesium chloride method was used (originally 
described by Radloff et al, 1967) as it yielded greater 
quantities of DNA, while maintaining the purity. This method 
relies on the principle that covalently closed circular 
plasmid DNA cannot bind as much ethidium bromide as can the 
linear fragments of chromosomal DNA. As the density of the 
DNA decreases with the amount of ethidium bromide bound, and 
chromosomal DNA binds more than plasmid DNA, then the two 
can be separated by isopycnic centrifugation in cesium 
chloride. The disadvantages of this method are that it is 
expensive, time consuming and a slight mistake in removing 
the plasmid band can ruin the whole preparation by 
contamination with chromosomal DNA. A quicker method of 
preparing plasmid DNA was developed by Birnboim and Doly 
(1979.) , using the principle that there is a narrow range of 
pH (12-12.5) where dénaturation of chromosomal, but not 
plasmid, DNA occurs. Upon neutralisation the denatured DNA 
forms an insoluble network and can be removed by 
centrifugation, leaving the plasmid DNA in solution. This 
method enabled up to 30 small scale preparations to be done 
in a day and so was useful in screening recombinants, 
although the quality of the DNA was not usually as good as 
that produced by the cesium chloride method. Another quick 
method of preparing plasmid DNA is the STET/boiling method 
(adapted from that of Holmes and Quigley, 1981), this was 
used most often in screening recombinants as the whole 
procedure only takes one hour to perform. The method lyses 
the cells using a detergent solution (STET), lysozyme and 
boiling, two variations of the procedure are described.
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2 . 5 . 1  L a r g e  S c a l e  P l a s m i d  P r e p a r a t i o n
This method was adapted from that reported by Maniatis et al 
(1982) and used for all large scale preparations of 
plasmids. 500ml of the appropriate culture media containing 
the appropriate antibiotic (see section 2.2.3 and 2.2.4) was 
inoculated with 1ml of a fresh overnight culture of the 
cells containing the plasmid required. The culture was 
incubated, shaking, overnight at 37“C and the cells 
harvested by centrifugation for 10 minutes at 3,000rpm, 4 °C 
(JS4.2 rotor, Beckman J6 centrifuge ). The supernatant was 
discarded and the cells resuspended in 17ml of Tris-Sucrose 
solution. This suspension was transferred to two 50ml 
centrifuge tubes and 1.3ml of freshly prepared lysozyme 
solution (20mg/ml in 0.25M EDTA pH8) was added to each. The 
tubes were kept on ice and the solution swirled 
intermittently for 5 minutes, followed by the addition of 
8.6ml of 0.25M EDTA to each and a further 5 minutes of 
swirling on ice. 13ml of Brij/DOC solution was added rapidly 
from a 10ml pipette and the mixture drawn up and expelled 
six times to ensure even mixing. After a further 30 minutes 
of incubation on ice the cell debris and most of the 
chromosomal DNA was pelleted by centrifugation for 45 
minutes at 15,000rpm, 4°C. The supernatant was decanted off, 
taking care not to disturb the pellet, and 0.2ml of 2Omg/ml 
ethidium bromide solution added. Cesium chloride was then 
added to 0.95g/ml and the concentration confirmed by 
measurement of the refractive index (1.38-1.39). The 
solution was transferred to Beckman polyallomer quickseal 
tubes, the tubes balanced to within 0.05g and sealed. The 
tubes were centrifuged for 60 hours at 40,000rpm, 18°C (60ti 
rotor for 35ml tubes, 70ti rotor for 14ml tubes, Beckman 
L7-65 ultracentrifuge). The upper plasmid band was extracted 
by side puncture and the ethidium bromide removed by 
extraction with water-saturated butan-l-ol until the top 
(organic) layer was clear. The aqueous phase was then
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dialysed against TES, two changes, and TE, two changes, and 
the plasmid DNA precipitated using ethanol (section 2.3.2). 
The final pellet was resuspended in 300/xl water, the OD260 
determined and the concentration of DNA calculated from the 
equation OD26ol=50/xg/ml.
The above method was used initially for the preparation of 
the plasmids containing the mouse GPX gene. It was later 
modified as follows: The plasmid band was extracted and the 
ethidium bromide removed by extracting with equal volumes of 
cesium chloride-saturated isopropanol (1:1 mixture of 
isopropanol and 0.95g/ml CsCl in TE) until the top layer was 
clear. The DNA was then precipitated by the addition of 0.25 
volume of 3M sodium acetate, 1.25 volumes of water and 2.5 
volumes of isopropanol. This mixture was left at room 
temperature for 30 minutes to precipitate the DNA which was 
pelleted by centrifugation at 14,000 rpm in the microfuge 
for 15 minutes. The pellet was dried in the Univap, 
resuspended in 300/xl water, and the concentration measured 
as above.
2.5.2 Plasmid Mini Preparations
These methods were used whenever large numbers of 
recombinant subclones were to be screened. The first 
described is modified from that of Birnboim and Doly (1979), 
this particular method is not suitable for preparation of 
plasmid DNA for long term storage, unless a phenol 
extraction is included. The second method described is 
modified from that of Holmes and Quigley, (1981) and is a 
much faster method, however the plasmid DNA obtained by this 
method was often contaminated with large amounts of RNA. To 
overcome this a further modification of the method, 
incorporating the Geneclean procedure, was used. This 
improved the quality of the plasmid DNA but decreased the 
overall yield.
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Method 1.
1ml of a fresh overnight culture of cells containing the 
plasmid were pelleted in a large microcentrifuge tube by 
centrifugation at 14,000 rpm in the microfuge. These were 
resuspended in 100/xl of freshly prepared lysis solution 
(1Omg/ml lysozyme in Tris/Glucose/EDTA) and left on ice for 
30 minutes. 200/xl of NaOH/SDS solution were added, left on 
ice for 5 minutes, then 150/xl of 3M sodium acetate pH5.2 
added and left on ice for a further 60 minutes. The debris 
was pelleted by centrifugation at 14,000 rpm in the 
microfuge for 5 minutes. 400/xl of the supernatant was 
removed, 1ml of 100% ethanol added, and the plasmid left to 
precipitate at -70°C for 20 minutes. The plasmid was 
pelleted by centrifugation as before, and resuspended in 
100/xl of O.IM ammonium acetate. A further precipitation, 
using 300/xl of 100% ethanol, was performed in the same way 
and the final pellet dried for 20 minutes in the Univap. The 
plasmid was resuspended in 100/xl of sterile water, 10/xl of 
this preparation could easily be visualised on a stained 
agarose gel.
Method 2•
Cells were harvested from 5ml of a fresh overnight culture 
by centrifugation at 8,000 rpm for 10 minutes at 4 “C (JA20.1 
rotor, Beckman J2-21 centrifuge). The cells were resuspended 
in 1ml of STET solution, transferred to eppendorf 
microcentrifuge tubes and 0.2ml of STET/lysozyme solution 
added. The mixture was vortexed, incubated at room 
temperature for 60 seconds, placed in a boiling water bath 
for 90 seconds and then immediately centrifuged at 14,000 
rpm in the eppendorf microcentrifuge for 15 minutes. The 
pellet containing the E.coli chromosomal DNA and cell debris 
was removed, leaving a clear supernatant containing soluble 
proteins and plasmid DNA. Phenol extraction was performed 
(section 2.3.1) and the plasmid DNA recovered by ethanol 
precipitation (section 2.3.2).
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In the alternative method, the plasmid DNA was recovered 
from the clear supernatant using the Geneclean procedure 
(section 2.3.7).
2.6 Growth of Lambda Phage
There are two distinct life cycles of lambda phage; lytic 
and lysogenic. In the lysogenic cycle the phage DNA is 
integrated into the host's chromosomal DNA due to expression 
of the lambda Cj gene product which binds to the and Or of
lambda DNA preventing transcription of the replicative
genes. In the absence of this repression the phage enters 
the lytic cycle in which it reproduces until approximately 
100 progeny are formed and the host cell is lysed. Under 
normal conditions not all infecting phage will enter the
lytic cycle of growth due to the expression of the Cj gene
product, plaques produced will be turbid due to the unlysed 
cells. Lysogenic lambda phage such as /gtll have an altered 
Cj gene (0^857) and the gene product is heat labile, thus 
the repressor can be inactivated by heat shock at 42“C for 
30 minutes. Hence growth of Xutll is carried out at 42°C to 
prevent any phage entering lysogeny. ^Ch28 has its cloning 
sites within the Cj gene and therefore recombinant phages do 
not have a repressor and are unable to enter lysogeny (due 
to insertional inactivation of the gene). Hence ^Ch28 
recombinants can be grown at the more normal temperature of 
37°C.
2.6.1 Titration of Lambda Phage
Magnesium-containing growth media and buffers were used to 
produce conditions optimal for phage adsorbtion. 100/xl of 
the appropriate host cell stock (see section 2.2.3) was used 
to innoculate 10ml of LBMg-broth and grown until late log 
phase (OD65o=0.5, approximately 6 hours) and the cells 
harvested by centrifugation for 10 minutes at 2 ,000rpm in
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the bench centrifuge. The cells were resuspended in 1/lOth 
volume of lOmM MgSO^ and lOOjLtl of the suspension mixed with 
100jL6l of diluted phage. Serial dilutions of phage had been 
prepared in phage buffer and aliquots of the 10 ,^ 10 ,^ and 
10® dilutions were usually titred. The phage were adsorbed 
to the cells at 37°C for 15 minutes and then 3ml of top 
LBMg-agar (at 48°C) were added with immediate mixing. The 
mixture was then poured onto pre-warmed (37°C), 9cm diameter 
LBMg-agar plates. When the top agar had set the plates were 
incubated, inverted, overnight at 37“C (42“C for XU^ll). The 
titre was calculated by counting the plaques and expressed 
as plaque forming units per ml of original phage suspension 
(pfu/ml).
2.6.2 Preparation of High Titre Phage Stocks
Phage were grown on agar plates as in section 2.6.1 using a 
high enough innoculum so that confluent lysis was seen. The 
top agar was scraped off the plate, mixed with 1.5ml of 
phage buffer plus lOO/xl chloroform and left at 4 °C 
overnight. The agar was pelleted by centrifugation for 20 
minutes at 9,000rpm, 4 “C (JA20.1 rotor, Beckman J2-21 
centrifuge) and the supernatant removed. After a further 
centrifugation as before to remove residual traces of agar 
the supernatant was stored over a drop of chloroform at 4°C. 
This supernatant was titred and was usually in the range of 
1q8_io10 pfu/ml.
2.7 Screening of Phage Libraries
XCh28 Library
The human genomic library (human fibroblast DNA) in XCh28 
was obtained from Dr. G. Brownlee (University of Cambridge). 
Screening for recombinant clones of interest was carried out 
according to a method modified from that of Benton and 
Davis, (1977). 7.5ml of concentrated E.coli LE392 cells in
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MgS04 were infected with 100/xl of phage (at a concentration 
of 5x10® pfu/ml) by allowing the phage to adsorb at 37"C for 
30 minutes. 5 aliquots of 1.5 ml were distributed into 
sterile 50ml Falcon tubes. 50 ml of warm top LBMg-agarose 
was added to each and the mixture poured onto 245mm x 245mm 
bottom LBMg-agar plates (Nunc). This resulted in five plates 
of 10^ pfu per plate. The plates were then incubated at 37“C 
overnight so that semi-confluent lysis could be observed.
The plates were then placed at 4°C for a minimum of 15 
minutes to harden the agarose so that it would not stick to 
the nitrocellulose filters. A nitrocellulose filter 
(Schleicher & Schull) was carefully placed on each plate and 
left in contact with the agarose for 5 minutes. The position 
of the filter was marked by making pin-holes into the 
agarose with a syringe needle dipped in bromophenol blue 
solution. The filter was carefully removed and the attached 
phage lysed by placing on a pad of Whatman 3MM filter paper 
soaked in O.IM NaOH for 1 minute. The released phage DNA was 
denatured by transferring the filter to a fresh pad soaked 
in 1.5M NaCl for 1 minute. Filters were neutralised by 
treatment with 0.2M Tris.HCl for 5 minutes and 2x SSCP for 5 
minutes as before. The filters were blotted dry and the DNA 
fixed by baking them at 80“C for 3 hours. For convenience 
they were then cut in half with a sharp scalpel prior to 
hybridisation. A duplicate set of filters were made from the 
plates at the same time and treated as above. Hybridisation 
screening with radiolabelled DNA probes was carried out as 
described in section 2.16 (the stringent washing step being 
at 48°C in IxSSC,0.1%SDS for 2 x 45 minutes) and positive 
plaques detected by autoradiography. These were picked out 
in an area of agarose approximately 0.5cm^. The agarose was 
left in 1ml of phage buffer overnight at 4°C to elute the 
phage and the supernatant used for further rounds of plaque 
purification and screening on small petri dishes (90mm 
diameter).
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At each further round of screening dilutions of phage were 
made such that the numbers of plaques on the plates 
gradually decreased resulting in final round plates with 
about 20 positive plaques. These pure plaques were picked 
and high titre stocks were made.
Xgtll Library
This human liver cDNA library was obtained from 
Dr.A.G.DiLella (University of Texas) and was screened in the 
same way as above using E.coli Y1090 as the host cell and 
growth at 42°C. The method was scaled down such that only 
10^ phage were screened, requiring only one 245mm x 245mm 
LBMg-agar plate.
2.8 Large Scale Preparation of Recombinant Phage DNA
2.8.1 XCh28 Recombinant
This method was adapted from that of Kaslow, (1986), and 
used in the preparation of DNA from the XCh28 recombinant 
clone. A cleared lysate of phage was prepared by mixing 10ml 
of an overnight culture of E.coli LE392, grown in LB-broth 
with magnesium, with 100/xl of high titre (10®pfu/ml) phage 
stock at 37“C for 10 minutes and adding this to 450ml of 
LB-broth. The culture was incubated, shaking, at 37°C until 
lysis occurred (4-7 hours). 0.5ml chloroform was added to 
lyse any remaining bacteria, the culture cooled on ice for 5 
minutes and the debris removed by centrifugation for 10 
minutes at 8,000rpm, 4 °C (JA14 rotor, Beckman J2-21 
centrifuge). To the supernatant was added 500/xl of DNAse I, 
10 mg/ml (BRL) and the mixture incubated at 37“C for 30 
minutes to degrade the E.coli chromosomal DNA. 100ml of 0.3M 
Tris.HCl pH 9, 0.15M EDTA, 1.5% SDS was added and heated at 
70“C to dissociate the phage particles and inactivate the 
DNAse I. The E.coli and phage proteins and the E.coli DNA 
fragments were precipitated by the addition of 60ml 8M
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potassium acetate pH 4.8, and cooling on ice for 20 minutes. 
The precipitate was pelleted by centrifugation for 10 
minutes at 4,000rpm, 4 “C (JS4.2 rotor, Beckman J6 
centrifuge) and the supernatant retained. Phage DNA was 
precipitated from this by the addition of 0.5 volume of 
isopropanol at room temperature. After standing for 15 
minutes the DNA was pelleted by centrifugation as above. The 
pellet was resuspended in 5ml of water, 250/xl of 10 mg/ml
RNAse A (BRL) added and the mixture incubated at 37“C for 15
minutes to degrade any bacterial RNA present. Then 250/xl of 
1Omg/ml Proteinase K were added and incubation continued for 
a further 15 minutes at 37“C to degrade any residual 
bacterial or phage protein and the RNAse A. Phenol 
extractions were then performed ( as in section 2.3.1) until 
the interface was clear and DNA precipitated from the final 
aqueous phase using ethanol (see section 2.3.2). The final 
DNA pellet was resuspended in 250/xl of water and the
concentration estimated as in 2.5.1.
2.8.2 Recombinant
The recombinant clone isolated from the cDNA library in 
Xgtll was slow growing and as a consequence the usual method 
could not be used. It was found that the yield of phage was 
small in comparison to the amount of protein, PEG and SDS 
present in the final stages of the preparation. Thus by the 
time enough phenol extractions had been performed to remove 
these impurities there was very little DNA left. Therefore 
the following method was devised to overcome these problems, 
using a DE52 ion exchange column to remove E.coli debris and 
contaminants from the growth media (Helms et al, 1985).
500/xl of high titre phage (approximately 10^ pfu/ml) were 
added to 500/xl of lOx E.coli Y1090 and incubated at 37 °C for 
30 minutes. This mixture was inoculated into 50ml of LBMg- 
broth and incubated, shaking, overnight at 42°C. To the 
lysed cells was added 1ml of chloroform and the flask shaken 
for a further 15 minutes. After cooling on ice the debris
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was removed by centrifugation for 10 minutes at 8 ,000rpm,
4 ”C (JA17 rotor, Beckman J2-21 centrifuge). 25ml of the 
supernatant was passed through a DE52 column equilibrated 
with phage buffer ( column volume 60cm^) by gravity feed.
The void volume was allowed to pass through and the eluant 
collected in a sterile 50ml centrifuge tube. To this was 
added 0.5 volume of PEG/NaCl solution and the mixture left 
on ice for 60 minutes. The phage precipitate was collected 
by centrifugation for 10 minutes at 10,000rpm, 4 “C (JA20.1 
rotor, Beckman J2-21 centrifuge) and resuspended in 6 ml of 
phage buffer. 120/xl of 0.5M EDTA pH8 and 120/xl of 10% SDS 
were added and the mixture heated at 6 8 “C for 15 minutes to 
break open the phage particles. This was then extracted with 
phenol until the interface was clear ( see section 2.3.1 ) 
and the DNA precipitated from the aqueous phase with 
ethanol. The DNA was dissolved in 50/xl water and the 
concentration estimated by visualisation on stained agarose 
gels (usually about Ifig/fil) .
2.9 Small Scale Phage DNA Preparation
This method (adapted from Maniatis et al, 1982) was used 
after a recombinant clone had first been isolated as a quick 
method to check the genomic DNA or cDNA insert size. A phage 
lysate was prepared from an agar plate as for the 
preparation of high titre stock. To 600jL6l of lysate was 
added 65/xl each of 10/xg/ml DNAse I and 10/xg/ml RNAse A, the 
mixture was incubated at 37“C for 30 minutes. Then 600/xl of 
PEG/NaCl solution was added and incubation continued for 60 
minutes on ice. The precipitated phage was collected by 
centrifugation for 20 minutes in the microfuge at 14,000 
rpm. The supernatant was discarded and the phage pellet 
dissolved in 500jLtl of phage buffer, this was centrifuged for 
10 minutes as before to remove any insoluble material and 
the phage-containing supernatant transferred to a clean
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tube. To this was added 5/xl each of 10% SDS and 0.5M EDTA 
pH8 and the mixture incubated at 6 8 °C for 15 minutes to 
release the phage DNA. Proteins in the sample were extracted 
with phenol until the interface was clear (see section 
2.3.1) and phage DNA in the aqueous phase precipitated by 
the addition of an equal volume of isopropanol and 
incubation overnight at 4°C. The DNA was pelleted by 
centrifugation in the microfuge for 15 minutes, washed with 
70% ethanol and resuspended in 10/zl water. This method 
usually yielded approximately lO^g DNA from a single plate.
2.10 Sub-cloning of DNA Fragments into pUC Vectors
The plasmid cloning vectors pUC18 and pUC19 were chosen for 
subcloning because they contain a large number of 
restriction enzyme sites in the multiple cloning region and 
transformants are selectable by ampicillin resistance. An 
additional advantage is that the cloning site is situated 
within the plasmid jS-galactosidase gene. Thus ^-gal" E.coli 
transformed with native plasmid give blue, ^-gal*, colonies 
on X-gal plates, whereas recombinant plasmids give white, 
0-gal", colonies. Also, DNA sequencing can be performed 
directly on the vector from both ends of the DNA insert as 
the universal primer and reverse primer ( S e q u e n a s e ™  
catalogue, 1988, Boehringer Mannheim catalogue, 1988) 
binding regions are present at either side of the multiple 
cloning site. Restriction enzyme maps of these vectors are 
shown in section 2.2.4.
2.10.1 Subcloning of Recombinant Bacteriophage 1211
For the subcloning of the human genomic DNA fragment in 
recombinant lambda phage 1211 the vector pUC19 was digested 
with BamH I, and lOOng of this electrophoresed on a 1% 
agarose gel to check that it had been linearised. The enzyme 
was removed from the remainder of the digest by phenol
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extraction (section 2.3.1) and the linear plasmid recovered 
by precipitation using ethanol (section 2.3.2). This was 
resuspended in 40/xl of distilled water to give an 
approximate final concentration of lOng BamH I-cut pUC19 per 
111 of water. In preparation of alkaline phosphatase-treated 
pUC19, the plasmid was prepared as before but, prior to 
phenol extraction, 10 units of alkaline phosphatase (calf 
intestine, Boerhinger) were added to the digest and 
incubation continued for a further 60 minutes at 37°C. 
Recombinant lambda phage 1211 was also digested with BamH I, 
and the digest electrophoresed on a 0 .6% low melting point 
gel. The human genomic DNA insert was extracted from the gel 
using Geneclean (section 2.3.7), phenol extraction was not 
used in this case as it was felt that Geneclean gave more 
efficient recovery of small quantities of DNA. lOng of cut 
plasmid DNA was mixed with the cut recombinant phage or the 
human DNA fragment to give a 1:1 and 1:3 molar ratio 
according to size (i.e. for a plasmid of 2.7Kb and an insert 
of 0.9Kb the quantities used would be lOng plasmid and 3.3ng 
insert for a 1:1 ratio) and incubated at 65“C for 2 minutes 
before cooling on ice. This step was included in all 
ligation reactions in order to ensure that all self annealed 
"sticky ends" were available for the formation of 
recombinant molecules. 2/xl of 5x ligase buffer, l/xl of T4 
DNA ligase (Bethesda Research Laboratories) and sterile 
water were added to a final volume of 10/il and the reaction 
allowed to proceed at 14°C overnight. The ligation buffer 
was provided with the enzyme and gave reaction conditions of 
66mM Tris.HCL pH7.6, 6 .6mM MgCl2, lOmM DTT, and 0.1-lmM ATP. 
The ligation mixes were kept at 0“C until required (not 
longer than 24 hours) when 5jul was used for transformation 
of competent E.coli cells. Controls of lOng uncut plasmid 
(to check competency of cells), of no plasmid (to check 
selection of cells) and of lOng cut plasmid without insert 
(to check efficiency of ligation) were included in each 
experiment.
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As the above cloning procedure did not work, a smaller 
fragment of the recombinant phage 1211 which still contained 
the whole of the GPX gene was found (see section 3.3). This 
was subcloned in the same way as above except the enzymes 
used to cut the phage 1211 and plasmid pUC19 were BamH I and 
Xba I instead of only BamH I.
2.10.2 Subcloning of Recombinant Bacteriophage 1312
The cDNA fragment of recombinant phage 1312 was subcloned by 
a shotgun procedure as the cDNA was too small to isolate in 
large quantities. Plasmid vector pUC18 was prepared in the 
same way as for pUC19, using EcoR I as the restriction 
enzyme. The phage 1312 was cut with EcoR I and a small 
quantity run on an agarose gel to check it had cut. The 
remainder of the digested DNA was precipitated with ethanol 
and redissolved in water. The ligation procedure was carried 
out as above, without prior separation of the cDNA insert. 
The left and right arms of the recombinant phage would not 
have been able to circularise in the plasmid as they each 
had only one EcoR I cut sticky end. Recombinants therefore 
would only contain the cDNA insert. Again, 5/xl of the 
ligation mixture was used in each transformation of 
competent cells.
2.10.3 Preparation of Competent Cells
Competent cells were prepared by the a modification of the 
magnesium chloride/calcium chloride method originally 
described by Lederburg and Cohen, (1974). 2ml of a fresh 
overnight culture of E.coli TBl cells were inoculated into 
100ml of TYN broth. The culture was incubated at 37°C with 
shaking until the OD^ qo was 0.35 (about 2 hours). The culture 
was cooled on ice for 30 minutes and the cells harvested by 
centrifugation for 10 minutes at 5,000rpm, 4 “C (JA17 rotor, 
Beckman J2-21 centrifuge). The supernatant was decanted and 
the cells gently resuspended in 20ml MgClg lOOmM using a 
pasteur pipette. After leaving on ice for 5 minutes the
— 76 —
cells were pelleted as before, the supernatant discarded and 
the cells gently resuspended in 10ml 75mM CaCl2 in lOmM 
Tris.HCl. After a further 35 minutes on ice the cells were 
again harvested and resuspended in a fresh 4ml of 
CaCl2/Tris.HCl. These cells were kept on ice until needed 
(no longer than 20 hours).
2.10.4 Transformation of Competent Cells
The DNA to be used was made up to lOO/il with CaCl2/Tris.HCl 
in a 14ml Falcon tube and 200/il of competent cells added, 
this mixture was left on ice for 30 minutes. The cells were 
then heat shocked by incubating at 42°C, with agitation, for 
2 minutes and left on ice for a further 15 minutes. 1.2ml of 
warm TYN broth were added and the cells incubated at 37“C 
for 20 minutes unshaken, followed by 40 minutes shaking at 
low speed in the rotary shaker. 200/xl of transformed cells 
were then plated onto selection plates and incubated 
inverted overnight at 37°C.
2.10.5 Selection of Transformed Cells
The pUC plasmid vectors contain the lac Z (a-complementing) 
gene for expression of the 0-galactosidase gene. Insertion 
of a DNA fragment into the multiple cloning site of the 
plasmid causes inactivation of the lac Z gene. The 
chromogenic substrate X-gal is cleaved by 0-galactosidase 
releasing a blue indolyl derivative and is hence a good 
marker for the presence of the 0 -galactosidase gene product. 
TBl cells are constitutive for 0-galactosidase induction but 
express a mutant 0 -galactosidase and so would not normally 
show blue on plates containing X-gal. If they are 
transformed by a plasmid containing an active lac Z a gene 
(i.e. non-recombinant) this will complement the defective 
0 -galactosidase gene and so they will grow as blue colonies 
on X-gal plates. Hence the selection plates used are TYN 
agar containing 150jLtg/ml ampicillin and 40jLig/ml X-gal. The 
ampicillin selects for the small proportion of cells which
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have received and retained the transforming plasmid DNA and 
the X-gal indicates which of these plasmids are recombinant. 
White, 0-gal', colonies are picked and mini plasmid 
preparations carried out in order to determine the size and 
characteristics of the subcloned DNA fragment.
2.11 Isolation of RNA from Mammalian Samples
2.11.1 Isolation of RNA from Blood
RNA was prepared from 10ml blood samples (taken into 
heparinised tubes) by a method modified from that of 
Chemzynski and Sacchi, (1986). Blood samples were kept at 
-20°C until use (not longer than two weeks) and thawed 
quickly by shaking at 37°C. As soon as the samples were 
thawed 40ml of ice cold Sucrose Lysis Buffer was added to 
each sample in 50ml Falcon tubes, with thorough mixing, to 
lyse the erythrocytes. The total white cells were pelleted 
by centrifugation for 10 minutes at 2,000 rpm, 4 °C (JS4.2 
rotor, Beckman J6 centrifuge). The supernatant was decanted 
off and the pellet washed by gently resuspending in a 
further 40ml sucrose lysis buffer and pelleting as before. 
The white cell pellet was resuspended in 1ml of Solution D, 
this lyses the cells and ensures that the RNAses present are 
inactivated. 0.1ml of 2M sodium acetate pH4, 1ml of water- 
saturated phenol and 0 .2ml of chloroform:isoamyl alcohol 
(49:1) were added sequentially with thorough mixing. The 
final mixture was vortexed for 10 seconds, transferred to 
14ml Falcon tubes and left to cool on ice for 15 minutes.
The tubes were centrifuged for 20 minutes at 9,000 rpm, 4 °C 
(JA20.1 rotor, Beckman J2-21 centrifuge). The top aqueous 
phase containing RNA was transferred into two 
microcentrifuge tubes, care being taken not to disturb the 
phenol interface which contains DNA. RNA was precipitated by 
addition of an equal volume of isopropanol and leaving at
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-20“C for 90 minutes. The RNA was pelleted by centrifugation 
at 14,000 rpm in the microfuge for 15 minutes. The pellet 
was resuspended in 150^1 of Solution D and the precipitation 
step repeated. The final pellet was washed by gentle 
resuspension in 70% ethanol and recentrifugation for 5 
minutes. The RNA pellet was dried in the Univap for 20 
minutes and resuspended in 50/il DEPC-treated water. After 
measurement of the OD260 the samples were stored at -80°C.
The concentration of RNA in the samples was determined from 
the equation OD26ol=40/xg/ml.
2.11.2 Isolation of RNA from Liver
RNA was extracted from liver by a modification of the 
guanidinium thiocyanate method originally described by 
Chirgwin et al, (1979). Ig of liver was homogenised in 16ml 
of guanidinium thiocyanate solution using a Polytron 
(Kinematica GmbH, Switzerland). The cell debris was removed 
by centrifugation for 10 minutes at 9,000rpm, 10“C (JA20.1 
rotor, Beckman J2-21 centrifuge). 8-9 ml of the supernatant 
was layered onto 3.5ml cushions of 5.7M CsCl solution in 14 
ml quickseal tubes and centrifuged in the Beckman L7-65 
ultracentrifuge overnight at 36,000rpm, 20“C using the 70ti 
rotor. The supernatant was removed with a syringe inserted 
through the tube wall. The top of the tube was cut off and 
the inside side wiped clean of liquid using sterile cotton 
buds. The pellet was resuspended in 5ml of 7M guanidine 
hydrochloride solution by vigorous shaking and heating to 
65“C. To this was added 250^1 of 0.5M EDTA, 250/zl of 2M 
potassium acetate pH 4.8 and 2.5ml of cold 100% ethanol. The 
mixture was left at -70°C for 20 minutes to allow 
precipitation of the RNA and the tubes centrifuged for 10 
minutes at 9,000rpm as above. The supernatant was removed 
and the pellet resuspended in 2.5ml of sterile, DEPC-treated 
water by vortexing and heating to 65°C. The suspension was 
centrifuged again, the supernatant saved and the pellet 
resuspended in 2.5ml of water. After a further spin the
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aqueous phases were combined, 0.5ml of 3M sodium acetate pH
4.8 and 10 ml of 100% ethanol added and the mixture left at 
-70“C for 20 minutes or at -20°C overnight. The RNA was 
pelleted by centrifuging for 20 minutes at 10,000rpm as 
above. The supernatant was removed and the pellet 
resuspended in 250^1 of water. The concentration of RNA was 
determined by reading the OD260 and using the equation 
OD26ol=40/xg/ml. Usual yields from this method are 500/xl of 
RNA at a concentration of 4-5jLtg/ml.
2.12 Isolation of DNA from Blood
Genomic DNA was prepared from 10ml blood samples (taken into 
EDTA tubes) by a method modified from that of Blin and 
Stafford, (1976). Blood samples were kept at -20°C until use 
and thawed quickly by shaking at 37°C. Total white cells 
were isolated as in the method for RNA preparation from 
blood (section 2.11.1). The white cell pellet was 
resuspended in 5ml of Proteinase K buffer and 50jLtl of Triton 
XlOO and 50/xl of 20mg/ml Proteinase K were added. This 
mixture was incubated at 37“C for 16 hours and then 4ml of 
TE-saturated phenol added. The phenol was gently mixed into 
the solution and the sample incubated in a shaking water 
bath at 55°C for 60 minutes. The two phases were separated 
by centrifugation for 10 minutes at 2,000rpm, 4°C (JS4.2 
Rotor, Beckman J6 centrifuge) and the upper phase containing 
the DNA carefully removed to a clean tube (using a wide bore 
pipette tip). This was re-extracted with 3ml TE-saturated 
phenol, then with 2ml Te-saturated phenol until the 
interface was clear. 1ml of 3M sodium acetate pH 4.8 was 
added to the aqueous phase and mixed, then 2 volumes of 100% 
ethanol was carefully layered on the surface and the DNA 
spooled out using a glass pasteur pipette. The DNA was 
redissolved in 200^1 sterile water.
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2.13 P r e p a r a t i o n  of  O l i g o n u c l e o t i d e s
Oligonucleotides for DNA sequencing were prepared and 
provided by Mr Tim Warren of Milligen Ltd. They were 
synthesised on the Milligen/Biosearch 7500 DNA Synthesiser 
and arrived attached to the solid phase columns used in 
synthesis. Oligonucleotides used for hybridisation 
experiments were synthesised in the Microbiology department. 
University of Surrey, using an Applied Biosystems Model 381A 
DNA Synthesiser. Before use the oligonucleotides were 
cleaved from the columns, the base protecting groups removed 
and the dimethoxytrityl protecting group at the 5' end 
removed, the diagram in figure 2.5 shows the position of 
these groups on the synthesised oligonucleotide. The 
sequences of the oligonucleotides used are shown below:
For DNA Sequencing:-
PjiM 5» GGTAGAGGCCGGATAAG 3 '
RPjim 5' GAGGCGCCGCCGTGTCA 3 '
Pi 5' ACTGTGCCGCCGCGGAG 3'
Pg 5' CTTATCCGGCCTCTACC 3'
For Hybridisations :-
C P U  5' ACACCGCTTACTTTCTCCTCTGGTA 3'
GPX 5' GTTTTCATCTATGAGGGTGTTTCCT 3'
2.13.1 Cleavage from the Column Support
A disposable 3ml syringe was inserted into one end of the 
column and ammonium hydroxide solution (29.5% NH3 in water) 
was drawn up through the column until 1ml had entered the 
syringe. A second syringe was inserted into the other end of 
the column and the solution forced backwards and forwards 
through the column slowly five times. The column/syringe 
assembly was left at room temperature for 45 minutes with 
the solution in contact with the column support, after which 
time the solution was again pumped back and forth five
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times and left at room temperature for a further 90 minutes. 
The solution was pumped back and forth again before all the 
solution was drawn into one syringe and transferred to a 
screw cap tube. The oligonucleotide is in the ammonium 
hydroxide solution and the cyanoethyl group protecting the 
phosphate has been removed.
2.13.2 Base De-protection
The ammonium hydroxide solution containing the 
oligonucleotide was sealed tightly in the screw cap tube and 
incubated at 55°C overnight. (This removed the benzoyl and 
isobutyryl groups which were present on the exocyclic amines 
of A , C (benzoyl) and G (isobutyryl) during synthesis in 
order to prevent side reactions taking place). The solution 
was cooled to room temperature and transferred to a 
microcentrifuge tube. The tube was placed in the Univap and 
the rotor and heat switched on without the vacuum. After 3 0 
minutes the vacuum was switched on and drying allowed to 
continue until the sample was completely dry (2 hours)
2.13.3 Removal of the Dimethoxytrityl Group
The Dimethoxytrityl (DMT) group protects the 5' end of the 
oligonucleotide during synthesis. The dried oligonucleotide 
was resuspended in 400jLtl of glacial acetic acid and left at 
room temperature for 60 minutes. 400jLtl of distilled water 
were added and the solution evaporated to 1/2 its original 
volume in the Univap (15 minutes) . 200/xl of diethyl ether 
were added, mixed and centrifuged briefly in the microfuge 
to separate the phases. The upper organic phase, containing 
DMT, acetic acid and other organic by-products, was removed 
and the extraction of the aqueous phase, containing the 
oligonucleotide, was repeated. The final aqueous phase was 
evaporated to dryness in the Univap, and the oligonucleotide 
resuspended in 1ml of sterile, distilled water. The ODg^ o was 
measured and the concentration of the oligonucleotide 
calculated from the equation OD26ol=20/xg/ml.
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2.14 L a b e l l i n g  of  D N A  w i t h  32-P
2.14.1 Nick Translation
This method was used for labelling large (greater than 
500bp) fragments of DNA with Nick translation was
performed according to the method originally described by 
Rigby et al, (1977), using a kit supplied by Bethesda 
Research Laboratories. Solution A2 contains dATP, dGTP, 
dTTP, and the enzyme reaction buffer, the enzyme solution 
contains a mixture of DNAse I and DNA polymerase I. DNAse I 
introduces nicks in double stranded DNA at widely separated 
sites, this exposes a free 3 '-OH group to which DNA 
polymerase I can add free nucleotides (of which dCTP is 
labelled with ^^ P) . At the same time the exonuclease 
activity of polymerase I is removing 5' mononucleotides, 
hence the enzyme travels along the DNA synthesising 
fragments which contain ^^ P.
The DNA to be labelled was diluted to a concentration of 
approximately lOOng/^1, 1/xl was used in the reaction. 5/xl of 
solution A2 was added to the DNA, along with 10/xl (100/xCi) 
of a-^^P dCTP, and the volume made up to 50/xl with sterile 
water. This was mixed and then 5/xl of the enzyme solution 
added. After a further mixing the reaction was allowed to 
continue for two hours at 15°C. The reaction was stopped by 
the addition of 5/xl solution D (0.5M EDTA), unincorporated 
nucleotides are removed using a NAGS column as described in 
section 2.14.3. Before use the labelled DNA probe was boiled 
for 5 minutes to ensure that the DNA was denatured to single 
strands.
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2.14.2 5' End Labelling
5 * end labelling is the method originally described by Maxam 
and Gilbert, (1980), whereby free 5* hydroxyl groups in DNA 
are phosphorylated with by T4 polynucleotide kinase 
(Boehringer Mannheim), using gamma-^^P ATP. It is suitable 
for small lengths of DNA, especially oligonucleotides as 
they already have a free 5' hydroxyl group. Where DNA 
fragments obtained by restriction digests of recombinant DNA 
were to be used it was necessary to remove the 5' phosphate 
group using alkaline phosphatase. This was done by adding 
alkaline phosphatase (0.5U per lOOng DNA) to the completed 
restriction digest (before electrophoresis of the digest) 
and leaving the reaction to continue at 37°C for 60 minutes. 
In this way a phenol extraction step to remove alkaline 
phosphatase was avoided and consequently the yield of 
prepared DNA fragments was increased. For the labelling 
reaction 300ng of DNA was mixed with 2.5jLtl lOx Kinase 
buffer, 5/xl (50/xCi) gamma-^^P ATP, and 2/xl T4 polynucleotide 
kinase in a total reaction volume of 25/xl. The reaction was 
allowed to proceed for 30 minutes at 37°C and then stopped 
by the addition of 2/xl of 0.5M EDTA. Double stranded DNA 
fragments to be phosphorylated were denatured to single 
strands by heating in water to 70“C for 1 minute before 
cooling on ice and adding the reagents. Unincorporated ^^ P 
ATP was removed by the NAGS column procedure described in 
section 2.14.3. In the case of labelled double stranded DNA 
fragments, these were boiled before use to ensure that the 
DNA is single stranded.
2.14.3 NAGS Purification of Labelled DNA
NAGS is an ion exchange resin that can bind nucleic acids at 
low salt concentrations and release them at higher salt 
concentrations. Pre-packed NAGS mini columns (Bethesda 
Research Laboratories) were used to remove unincorporated 
nucleotides from preparations of radio-labelled DNA probes.
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The column was hydrated by slowly pushing 10ml of 2M NaCl in 
TE through using a 10 ml syringe. The column was then 
equilibrated with 25ml of the appropriate loading buffer 
(0.5M NaCl in TE for double stranded DNA 1,000 bp or 
greater, 0.2M NaCl in TE for dsDNA less than l,000bp, and 
O.IM NaCl in TE for oligonucleotides). 1ml of the loading 
buffer was added to the labelled probe mixture and this was 
slowly pushed through the column, the eluant was collected 
and again pushed through the column. At this point the DNA 
was firmly bound to the column support. The unincorporated 
nucleotides were washed through with 15ml of loading buffer. 
The labelled DNA was eluted with 500/xl of the appropriate 
elution buffer (2M NaCl in TE for dsDNA greater than 
l,000bp, IM NaCl in TE for dsDNA less than l,000bp and 
oligonucleotides) and was ready for use in hybridisation 
experiments.
2.14.4 Measurement of Incorporation of 32-P
Where a value for percentage incorporation of radioactivity 
into a probe is given, it was determined as follows. 1/xl of 
the labelling mixture was taken after the addition of the 
NACS loading buffer and diluted into 1ml of water. From this 
10/xl were spotted onto a Whatman glass fibre disk to measure 
total radioactivity. A further 800/xl sample was mixed with 
100/xl of lOmg/ml salmon sperm DNA in a 14ml Falcon tube, 
cooled on ice and 5ml of cold 5% TCA added. The DNA was left 
on ice to precipitate for 15 minutes. The solution was 
filtered through a glass fibre disk which was then washed 
with 3x 5ml cold 5% TCA followed by 5ml 75% ethanol. This 
filter retains the incorporated radioactivity. The filters 
were placed in scintillation vials and counted on an LKB 
Rackbeta liquid scintillation counter with all channels open 
for 2 minutes. The % incorporation was then calculated.
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2.15 P r e p a r a t i o n  of F i l t e r s  for H y b r i d i s a t i o n
The following methods were used to prepare filters for 
hybridisation. Southern blotting was used both for the 
analysis of genes of interest in mammalian genomic DNA and 
for restriction site-mapping of recombinant plasmid clones. 
Northern blotting was performed in order to determine the 
size of mRNAs of interest and to gain an estimate of their 
abundance in the total cellular RNA. RNA Dot blots were used 
as a rapid test for the presence of a particular mRNA in 
different tissues or species, and also to quantitate mRNA 
abundance more precisely. RNA dot blots can be performed 
with only 1/xg of RNA per assay whereas Northern blotting 
requires 20/xg, thus they are the method of choice in 
situations where low yields of RNA are obtained (e.g. in 
preparations from blood samples). DNA dot blots were used 
in screening recombinant plasmids for the presence of 
genomic or cDNA inserts with homology to the glutathione 
peroxidase gene probes and in experiments to optimise 
washing conditions. DNA dots were also used on RNA dot blots 
to provide positive controls for the glutathione peroxidase 
and C P U  probes. To detect genes in genomic DNA using 
oligonucleotides as probes, Onblots were performed. These 
are described in a separate section (2.17)
2.15.1 Southern Blotting
The method was adapted from that reported by Maniatis et al, 
(1982), after the original technique described by Southern 
et al, (1975). Following electrophoresis of DNA the agarose 
gel was stained and photographed. At least 10/xg of genomic 
DNA was loaded on the gel if single copy genomic fragments 
were to be detected by hybridisation to ^P-labelled DNA 
probes. The gel was immersed in 5 volumes of 0.25M HCl and 
shaken slowly at room temperature for 15 minutes. This 
treatment partially depurinates the DNA, breaking it down 
into smaller pieces so that the large fragments of DNA can
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transfer more efficiently. The HCl solution was replaced by 
5 volumes of Southern Blot Denaturing Solution and shaken 
slowly at room temperature for 45 minutes, followed by the 
same treatment using Southern Blot Neutralising Solution.
The DNA fragments were then transferred from the gel to a 
filter membrane by capillary action as in the original 
procedure using 2Ox SSC. Initially the filter membranes used 
were of nitrocellulose (Schleicher & Schull), these were 
later replaced by the more robust Hybond N nylon transfer 
membrane (Amersham). After transfer overnight the filter was 
rinsed briefly in 4x SSC and the DNA fixed in situ as 
detailed in section 2.15.5.
2.15.2 Northern Blotting
20/xg RNA samples were electrophoresed on formaldehyde 
denaturing gels as described in Maniatis et al, (1982).
After staining with ethidium bromide and photographing, the 
gel was soaked in lOx SSC for 5 minutes before being taken 
for capillary transfer to Hybond N nylon membrane 
(Amersham). The blot was set up in the same way as for a 
Southern Blot with the exception that lOx SSC was used to 
soak the filter papers and hybridisation membrane, and for 
the capillary transfer. After transfer the RNA was fixed to 
the membrane (see section 2.15.5) which was then stored at 
4 “C wrapped in cling film until use.
2.15.3 RNA Dot Blots
RNA was denatured for binding to filters by the formaldehyde 
method of Lehrach et al, (1977). Dilutions of total RNA were
made and the total volume made up to 100/xl with DEPC-treated 
water. The RNA was denatured by the addition of 300/xl of 
18.5% formaldehyde in lOx SSC (made by mixing equal volumes 
of 37% formaldehyde and 2Ox SSC) and heating to 65°C for 15 
minutes. A nylon filter (Hybond N, Amersham) was soaked in 
lOx SSC and the dot blot apparatus was assembled (Hybri 
Dot^" 96-well Filtration Manifold, Bethesda Research
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Laboratories) . Vacuum was applied slowly (such that a 400/xl 
sample took 5 minutes to pass through the membrane) and the 
samples loaded into the wells. The samples were washed 
through with 400/tl of lOx SSC and the RNA fixed to the 
filter for hybridisation as in section 2.15.5.
2.15.4 DNA Dot Blots
A nylon or nitrocellulose filter was soaked in 2Ox SSC and 
the DNA spotted directly on to it using a micropipette. The 
filter was left to air dry and then the DNA fixed to it for 
hybridisation (section 2.15.5). For the mini plasmid 
preparations of recombinant plasmids 5/xl of each DNA was 
spotted. For the later experiments to determine optimal 
washing conditions the appropriate amount of DNA in a volume 
of 100/xl of 2Ox SSC was applied using the dot blot 
apparatus. Where DNA dots were included on RNA filters as 
positive hybridisation controls they were also applied in a 
total volume of 100/xl 2Ox SSC. (The filter had been soaked 
in lOx SSC as described for the RNA dots).
2.15.5 Use of Membrane Filters
Where nitrocellulose filters were used the DNA or RNA was 
fixed to them by baking at 80“C for 3 hours. Hybond N nylon 
filters were used later as they were more resilient than 
nitrocellulose and hence could be reused more times without 
damage. The DNA or RNA is fixed to the nylon membranes by UV 
cross-linking (UV transilluminator Model TM20) and an 
experiment was set up to determine the optimum time of 
exposure to UV for our particular instrument. 1/xg dots of 
RNA and DNA were applied to the nylon filters in rows of 
four dots each and the filters placed face down on the 
transilluminator. The UV light was switched on and every 30 
seconds (for 6 minutes) a row of DNA and RNA dots were 
removed, thus producing a set of filters with exposure times 
from 30 seconds to 6 minutes. The filters were hybridised 
against a DNA probe labelled with by nick translation
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(section 2.14.1) as in the standard methods (section 2.16) 
and autoradiographed for three days. The optimum time of 
exposure to the UV light was found to be 3 minutes for both 
DNA and RNA. Both nylon and nitrocellulose filters are 
stored wrapped in cling film at 4°C.
Where a filter was to be reused it was necessary to remove 
all the hybridised radioactive probe from the previous 
experiment. Nitrocellulose filters were stripped by three 
sequential washes in distilled water at 70°C for 30 minutes. 
Nylon filters were washed by adding boiling 0.1% SDS and 
shaking at room temperature until it had cooled, this was 
repeated twice more. Filters were checked using the Geiger 
counter and, whenever possible, by autoradiography If probe 
was still present additional washes were performed. Washed 
filters were rinsed in 2x SSC and stored wrapped in cling 
film at 4°C.
2.16 Hybridisation Procedures
In the majority of hybridisation experiments involving 
radioactive DNA probes the formamide method was used. For 
oligoprobe hybridisations the exact procedure depended on 
the type of filter being probed. The various methods are 
described in detail in the following sections, along with 
the general methods used for washing the radioactive probes 
off the filters.
2.16.1 Formamide Method
This method was adapted from that reported by Anderson and 
Young, (1985) and was employed in all experiments where 
double stranded probes were used. The presence of the 
formamide reduces the Tm of nucleic acid hybrids and enables 
hybridisations to be performed at a lower temperature, this 
is advantageous because at lower temperatures the probe is 
more stable and nitrocellulose filters are less likely to
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disintegrate. Filters were pre-wetted in 5x SSC and then 
prehybridised for 7-16 hours at 42“C in approximately 1ml of 
Prehybridisation solution per square cm of filter. This 
ensured that all the non-specific binding sites were 
blocked. The Prehybridisation solution was removed, the 
(boiled) probe added to the appropriate volume of 
Hybridisation solution, mixed and the filter incubated in 
this solution at 42“C overnight with shaking. Approximately
0.1ml of Hybridisation solution per square cm of filter was 
used and the filter was sealed in a plastic bag where 
practicable. Where there were a large number of filters to 
be hybridised the hybridisation was carried out in plastic 
Tupperware boxes. In this case the volume of hybridisation 
solution used was increased. The double stranded DNA probes 
used were specific fragments of the mouse GPX gene, a 
fragment of the human GPX gene and a fragment of the human 
GPX-related cDNA clone CPU. These are detailed in sections
3.1.1 and 5.1.1.
2.16.2 Oligoprobe Hybridisations
These were carried out according to the methods published in 
the 1988 Clonetech Products and Protocols Catalogue. Where 
hybridisations to DNA were attempted the method for 
hybridisation of oligoprobes to dried gels was used. Two 
different oligoprobes were used, one a 25 base 
oligonucleotide corresponding to nucleotides 979-1004 of the 
3* non-coding region of the human GPX gene (Sukenaga, et al, 
1987) and the other a 25-mer corresponding to nucleotides 
113-137 of the 3' non-coding region of C P U  (section 5.3.1) 
For details of the sequence of these oligonucleotides see 
section 2.13.
2.16.3 Washing of Filters
The washing conditions used are described for each separate 
experiment in the results sections as they vary according to 
the type of experiment performed and the type of probe used.
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Where a weak signal was expected (e.g. for probes with less 
than 100% homology with the target DNA or RNA, oligoprobes, 
and/or filters with small amounts of DNA/RNA) low stringency 
washing conditions were used (i.e. high salt concentrations 
and low temperatures). Conversely, where a strong signal was 
expected (for probes with 100% homology and for filters with 
large quantities of DNA/RNA), high stringency washing 
conditions were employed (i.e. low salt concentrations and 
high temperatures). The preliminary washes, however, were 
the same for most experiments and were as follows;
1. Ix 10 minutes at room temperature in 2xSSC,0.1%SDS
2. 2x 15 minutes at room temperature in 0.5xSSC,0.1%SDS
3. Stringent wash, variable
4. Ix 15 minutes at room temperature in 5xSSC
2.17 Onblots
The Onblot procedure is a method where an agarose gel 
containing size separated DNA fragments is dried down and 
used directly (without Southern Blotting) in hybridisation 
experiments. The procedure used for drying the gels was 
modified from that of Tsao et al, (1983), and the 
hybridisation procedure was based on the method of Miyada et 
al, (1985). After staining and photographing, the gel was 
placed in 5 volumes of Denaturing solution and gently shaken 
at room temperature for 30 minutes to dissociate the double 
stranded DNA. The solution was replaced by Neutralising 
solution and then left at 4°C with occasional shaking for 30 
minutes. The gel was placed in the gel drier (model 483 slab 
drier. Biorad) on Whatman 3MM filter paper, covered in Saran 
wrap and the vacuum applied for 30 minutes or until the gel 
appeared flat. The vacuum was left on and heat applied 
(60°C) for a further 60 minutes to complete the drying 
procedure. The gel was stored on the paper at room 
temperature until required. Prior to hybridisation the gel
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was floated off the paper in water. Excess water was blotted 
off and the gel placed in a plastic hybridisation bag. The 
labelled probe was added to Hybridisation solution 
(approximately 0.5ml per square cm of gel) and the mixture 
added to the bag. The gel was left to hybridise for 16 hours 
at 60“C and then washed twice in 6x SSC at room temperature 
for 15 minutes followed by a further wash in 6x SSC at 35“C 
for 3 minutes. The gel was wrapped in cling film and 
autoradiography performed as in section 2.3.8. In order to 
remove the probe so that the gels could be rehybridised, the 
denaturing/neutralising step was repeated.
2.18 Sequencing of DNA
Sequencing of part of the Gp71 genomic DNA clone and of the
C P U  cDNA clone was carried out by a modification of the
dideoxy method first described by Sanger et al, (1977), as
detailed in the Sequenase^" booklet and using the Sequenase^" 
kit (US Biochemicals). This kit contained all the reaction
components except for the M13 reverse primer (Amersham
International), the oligonucleotide primers (kind gift from
Mr Tim Warren, Milligen Ltd) , and the a-^^S dATP (Amersham
International). Double stranded DNA sequencing was performed
on the plasmids, rather than first subcloning into the
bacteriophage M13 as first described by Chen and Seeburg,
(1985). The method uses a genetically modified form of
bacteriophage T7 DNA polymerase (Sequenase^", United
Biochemicals Ltd), rather than the Klenow fragment of E.coli
DNA polymerase I (pol I). T7 polymerase is a more
progressive, replicative enzyme than pol I which is
essentially a repair enzyme. Thus T7 polymerase (and
particularly Sequenase^” ) is better able to copy template
DNA strands in that it polymerises the nucleotides more
rapidly and is less impeded by secondary structure e.g. GC-
rich regions. It is thus particularly useful for sequencing
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double stranded DNA templates. The sequencing reaction 
conditions are described below, along with details of the 
gel electrophoresis apparatus and the gel preparation.
2.18.1 Sequencing Gel Electrophoresis Apparatus
The apparatus used was made in University workshops and is 
shown in figure 2.6. It proved to give better results than 
various commercial apparatus tested.
2.18.2 Preparation of Glass Plates
The sequencing plate dimensions were 58 x 20 x 0.5cm, the 
front plate being notched as shown in figure 2.6. The plates
were scrubbed with Decon and hot water, then rinsed and
dried. 10ml of the siliconising agent dimethyldichlorosilane 
was spread over the inside surfaces of the plates and left 
to dry in the fume cupboard (approx. 5 minutes). The plates 
were then wiped with ethanol, followed by acetone. The gel 
spacers and combs (0.4mm thick) were cleaned using ethanol 
and the plates assembled as in figure 2.6. Bulldog clips 
were used to clamp the plates together and they were sealed 
using Sylglas™ waterproof tape (The Sylglas Company,
London). Re-siliconisation was performed after every 5th or 
6th use of the plates.
2.18.3 Preparation of DNA Sequencing Gels
6% polyacrylamide gels were prepared according to the method 
of Sanger and Coulson, (1978). 11.25ml of 40% acrylamide 
stock solution and 7.5ml of lOx Tris-borate buffer were 
added to 31.5g of urea. Distilled water was added to 75ml 
and the urea dissolved by heating at 37°C. The mixture was 
degassed and cooled on ice for 20 minutes.
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Figure 2.6; Sequencing Electrophoresis Apparatus
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The plates were inclined for gel pouring at an angle of 
approx. 30° from the horizontal, and supported with one 
corner lower than the other. This prevented large bubbles 
forming between the plates as the gel was poured. 420jLtl of 
freshly prepared 10% ammonium persulphate and 75jLtl of TEMED 
were added to the acrylamide-urea solution, mixed quickly 
and drawn into a 50ml syringe. The gel ejected gently from 
the syringe so that it flowed evenly between the plates.
When the space between the plates was full, the flat side of 
the comb was inserted and the top of the plates clamped 
firmly with bulldog clips. The gel was left to polymerise 
and then stored in the cold room wrapped in cling film until 
required (not less than two hours and not longer than three 
days). Prior to use the gel was positioned in the apparatus 
and allowed to warm to room temperature.
2.18.4 Preparation of Single Stranded Template DNA
Double stranded plasmid DNA was denatured to provide a 
single stranded template for the T7 DNA polymerase to copy. 
This was achieved by the addition of 2/xl of 2M NaOH to 4/xg 
of plasmid DNA (in a volume of 18/xl water) and incubation at 
room temperature for 5 minutes. The denatured plasmid was 
precipitated by the addition of 8/xl 5M ammonium acetate 
pH7.5, followed by 100/xl of 100% ethanol. After standing at 
-70°C for 15 minutes, the sample was centrifuged at 14,000 
rpm in the microfuge for 15 minutes and the supernatant 
decanted. The pellet was resuspended gently in 70% ethanol 
and recentrifuged. The pellet was then dried in the Univap 
and stored at -20°C until use (usually overnight).
2.18.5 Annealing of Primers
The denatured plasmid DNA was reconstituted in 7/xl water and 
2/xl of sequencing buffer was added to this. The appropriate 
primer oligonucleotide was added in a volume of 1/xl. For the 
M13 universal primer and reverse primers this contained
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O.Spmol of oligonucleotide, whereas for the CPU-specific 
oligonucleotide primers a range of concentrations was tried 
in order to obtain the best results. A 1/10 dilution of the 
resuspended oligonucleotides from section 2.13.3 was found 
to be optimum, resulting in concentrations of approximately 
100ng//tl. The mixture was heated at 65 “C for 4 minutes and 
then transferred to the 37°C waterbath for 30 minutes before 
cooling to room temperature. This slow cooling of the 
mixture ensured that homologous base pairing and annaeling 
took place. Figure 2.7 shows the sequencing strategy 
employed for C P U  and illustrates where the various primers 
annealed to the DNA. The sequences of the oligonucleotide
primers are given in section 2.13.
2.18.6 Labelling Reaction
In this reaction the primer was extended in the presence of 
limiting concentrations of deoxyribonucleoside triphosphates 
and CK-^ S^ dATP. This ensured that initiation of 
polymerisation by the T7 DNA polymerase predominates over 
chain elongation -so that each newly synthesised strand 
contained similar amounts of incorporated radioactivity, 
regardless of the final length of the extension, and thus 
enabled the smallest fragments to be detected. 1/xl of O.IM 
DTT, 2/xl of labelling mix (containing dTTP, dCTP and dGTP) ,
0.5/xl of dATP (5/xCi) , and 2/xl of Sequenase^" were added
to the DNA-primer mixture. The labelling reaction was then 
allowed to proceed at room temperature for 5 minutes.
2.18.7 Extension/Termination Reaction
3.5/xl of the labelling reaction was added to each of four 
tubes containing the termination mixes (A, C, T, G) which 
have been pre-warmed to 37°C. The termination mixes contain 
80/xM of each of the deoxynucleoside triphosphates and 8/xM of 
the appropriate dideoxyribonucleoside triphosphate to cause 
random chain termination.
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Figure 2.7: Sequencing Strategy of CP11
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In some reactions extension mix was added to the termination 
mix. This contained a higher concentration of 
deoxynucleoside triphosphates thus decreasing the relative 
proportion of dideoxyribonucleosides. This resulted in an 
increase in the amount of long DNA strands synthesised and 
enabled the sequence to be read for a greater distance from 
the primer. The reaction was allowed to proceed for 5 
minutes at 37 °C and then stopped by the addition of 4/21 of 
loading buffer from the kit. The loading buffer also 
contained the marker dyes bromophenol blue and xylene 
cyanol.
2.18.8 Electrophoresis of Samples
The samples in loading buffer were heated to 75“C for 2 
minutes before loading onto the gel. The comb was removed 
from the gel, inverted, and the teeth positioned so that 
they just entered the flat top surface of the gel. The wells 
so formed were rinsed thoroughly to remove all traces of 
urea and 3/xl of each sample were loaded using a Drummond 
sequencing pipette (Drummond Scientific Co.). The apparatus 
was run at SOW constant power to ensure constant temperature 
conditions. Electrophoresis was performed either until the 
bromophenol blue had travelled 45cm ("short gel") or until 
the slower migrating xylene cyanol band had travelled 45cm 
("long gel").
2.18.9 Preparation of the Gel for Autoradiography
The clamps and sealing tape were removed and the plates 
gently prised apart so that the gel remained attached to one 
of the plates. The gel and plate were then placed carefully 
into 10% methanol/10% acetic acid for 20 minutes in order to 
fix the gel. This was then rinsed with water and placed in 
water for 20 minutes to leach out the urea which would have 
otherwise have interfered with autoradiography. (The water 
wash was omitted if the gel had already started to detach
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from the glass plate. In fact a substantial amount of urea 
leaches out into the methanol/acetic acid). A sheet of 
Whatman 3MM paper was wetted and placed onto the gel, two 
further (dry) sheets were added and the gel peeled off the 
plate onto the paper. This was dried in a gel drier (Model 
483 Slab Drier, Biorad) at 80“C for 60 minutes and then 
autoradiography was performed as described in section 2.3.8
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Chapter 3
Isolation and Characterisation of the Human 6PX gene
The following results detail the experiments performed in 
order to isolate a human genomic fragment with sequence 
homology to the mouse GPX gene from the recombinant phage 
library in /\Ch28 (see section 2.7). Experiments were then 
undertaken to establish whether the isolated human genomic 
fragment contained the human GPX gene.
3.1 Isolation of a Recombinant Phage with Sequence Homology 
to the Mouse GPX Gene
This section details the experiments performed in the 
isolation of a recombinant phage containing human genomic 
DNA with sequence homology to the mouse GPX gene and 
determination of the size of the human DNA fragment 
isolated.
3.1.1 Preparation of DNA for Use as Hybridisation Probes
The DNA probe used for screening the human recombinant phage 
library in /s,Ch28 for the human GPX gene was the 2D6 fragment 
of the mouse GPX gene. This comprises the 3' half of the 
mouse gene (see figure 3.1) which contains exon 2, the 
intron and a small part of exon 1 .
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The 2D6 fragment had been previously cloned into plasmid 
pAT153 (Dr Peter Goldfarb, The Beatson Institute for Cancer 
Research, Glasgow) and the resulting plasmid, p2D6, was 
grown in the host cell E.coli MC1061. A large scale 
preparation of plasmid DNA was performed according to the 
method in section 2.5.1 and the 2D6 insert was excised using 
the restriction enzyme EcoR I , this is shown in figure 3.2, 
along with a restriction enzyme map of p2D6. A large scale 
digest of the plasmid was carried out and the preparation 
run on a 1% low melting point agarose gel. The 0.7Kb 2D6 
fragment was excised from the gel and the DNA purified by 
the cold phenol method described in section 2.3.6.
In order to later determine whether fragments of the whole 
human GPX gene had been isolated, the mouse AlO fragment was 
also prepared for use as a probe. This comprises the 5' half 
of the mouse gene (figure 3.1) and contains the whole of 
exon 1. This fragment had been cloned into pUC12 to give 
plasmid pAlO (Ian Chambers, The Beatson Institute for Cancer 
Research, Glasgow), which was grown in the host cell E.coli 
JM83. The 0.8Kb AlO insert was excised using the restriction 
enzymes EcoR I and Hind III, as shown in figure 3.3, and 
prepared in the same way as for the 2D6 fragment.
3.1.2 Isolation of Recombinant Clones Hybridising to the 
Mouse GPX Gene
The human genomic library in XCh28 was screened using the 
method detailed in section 2.7. 500ng of the mouse 2D6 
fragment was labelled with 150/xCi of a-^^P dCTP by nick 
translation (section 2.14.1). The labelled probe was added 
to 250ml of Hybridisation buffer and hybridisation was 
carried out in a large (24 x 24 x 10 cm) Tupperware box. The 
first attempt at screening did not result in the isolation 
of any recombinant clones hybridising to the probe. The few 
plaques which had appeared to hybridise at the first round 
of screening did not do so in further rounds so it was 
assumed that they were false positives
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Figure 3.2: Restriction enzyme map of plasmid p2D6 and a gel showing the excised mouse DNA fragment 2D6
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Figure 3.3: Restriction enzyme map of plasmid pAlO and a gel showing the excised mouse DNA fragment AlO
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due to non-specific binding of the probe. The screening was 
repeated using a further 10^ phage. One positive clone was 
identified in the first round of screening (figure 3.4) and 
this was isolated by three further rounds of screening. 
Typical results from the further rounds of screening are 
shown in figure 3.5. A stock of recombinant phage clones 
which hybridised to the mouse gene was prepared (section 
2.6) and stored at 4°C. As all these plaques had originated 
from the same plaque in the primary round of screening, only 
one of them (recombinant phage 1211) was studied further.
3.1.3 Determination of the Size of the Genomic DNA Insert 
in the Recombinant Phage
DNA was made from the recombinant lambda phage 1211 using 
the small scale method (section 2.9.0). From the map of 
^Ch28 (figure 2.4) it can be seen that the recombinant DNA 
inserts can be excised using the restriction enzyme BamH 1. 
This enzyme was used to digest approximately 2jitg of the 1211 
DNA and the resulting fragments were electrophoresed on a 1% 
agarose gel. After staining with ethidium bromide the 
results showed that the DNA had been cut by the restriction 
enzyme (as the 23Kb and 9.3Kb arms of the phage could be 
seen) but the genomic DNA insert was not apparent. It was 
suspected that the genomic insert was of a similar size to 
the 9.3Kb arm of the lambda phage and so could not be 
separated from this on a 1% agarose gel. Hence the 
experiment was repeated and the digest electrophoresed on a 
0.6% agarose gel. This revealed that the genomic insert was 
approximately 8 .6Kb in size (as estimated by comparison with 
the DNA, Hind 111 size markers). This gel is shown in 
figure 3.6, along with a restriction enzyme map of 
recombinant 1211 showing the genomic DNA insert.
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Figure 3.4: Autoradiograph of a Filter from First Round Screening of the ACh28 Human Genomic Library 
Showing the Positive Hybridisation Signal produced by Recombinant Phage 1
Further Screening to Isolate Recombinant 1211
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Figure 3.5: Autoradiograph of Filters from the Second and Fourth Rounds of Screening of the ACh28 Human 
Genomic Library Showing Positive Hybridisation Signals Produced by recombinant Phage 12, 1211 and 1212
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3.2 Subcloning of the 8 .6Kb human genomic DNA fragment from 
Recombinant Phage 1211
The 8 .6Kb genomic fragment from recombinant clone 1211 was 
excised using the restriction enzyme BamH I and subcloned 
into pUC19 at the BamH I cloning site (for a restriction map 
of pUC19 see section 2.2.4). Two different approaches to 
subcloning were tried. In the first shotgun cloning was 
used, where the whole preparation of BamH I digested 1211 
was included in the ligations. In this approach only the 
8 .6Kb fragment could be incorporated into the circular 
plasmid, as the two arms of the phage have only one "sticky 
end" each. Alternatively, the 8 .6Kb fragment was isolated 
from a gel for direct cloning into pUC19. This approach was 
tried in order to maximise the chances of obtaining 
subclones, as the number of pUC19 molecules available for 
the formation of circular recombinants will be greater if 
the phage arms are not present.
3.2.1 Preparation of the Plasmid pUC19 for Use in 
Subcloning
A large scale preparation of pUC19 plasmid DNA was 
undertaken (section 2.5.1). SOOng of pUC19 DNA was digested 
with the restriction enzyme BamH I and lOOng of this 
electrophoresed on a 1% agarose gel to check that it had 
been linearised, this is shown in figure 3.7. The enzyme was 
removed from the remainder of the digest by phenol 
extraction (section 2.3.1) and the linear plasmid recovered 
by precipitation using ethanol (section 2.3.2). This was 
resuspended in 40/il of distilled water to give an 
approximate final concentration of lOng BamH I-cut pUC19 per 
jLtl of water.
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(The sizes
A = X DNA, Hind III fragments 
B = Uncut pUC19 
C = pUC19, BamH I cut 
D = pUC19, EcoR I cut 
of the X  DNA, Hind III fragments are as in fig 3.2
Figure 3.7: A gel showing pUC19 linearised with the restriction enzyme BamH I.
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3.2.2 Preparation of DNA from the Recombinant Phage 1211 
for Subcloning
Recombinant 1211 DNA was prepared by the large scale method 
(section 2.8.1). To prepare DNA for the shotgun cloning 
approach, 10/xg of 1211 DNA were digested with the 
restriction enzyme BamH I and 1/lOth of the digest 
electrophoresed on a 0 .6% agarose gel in order to check that 
the DNA had been cut. The enzyme was removed from the 
remaining digest by extraction using phenol as before. After 
precipitation using ethanol, the DNA was dissolved in 
sterile distilled water to a concentration of lOOng/^1.
The 8 .6Kb insert was prepared by cutting the DNA as above, 
electrophoresing the whole of the digest on a 0 .6% low 
melting point agarose gel and extracting the insert from the 
gel by the Geneclean procedure (section 2.3.7). The final 
concentration of the DNA was approximately 30ng/^l.
3.2.3 Subcloning Results
Ligations were carried out as detailed in section 2.10.1 and 
transformation of competent cells performed as described in 
sections 2.10.3-2.10.5. Initial attempts at shotgun 
subcloning were unsuccessful, as were all attempts using the 
direct insert subcloning approach. Table 3.1 shows the 
results obtained from the first successful experiment using 
the shotgun cloning approach.
All the white colonies (except the one growing on the "no 
DNA" control) were picked into 10ml of TYN-broth with 
ampicillin and grown overnight, a blue colony was also 
picked for use as a control. Only 8 out of the 15 cultures 
grew and 5ml of each of these was used for mini plasmid DNA 
preparations by the STET method (section 2.5.2). The final 
DNA preparations were dissolved in 30/xl of distilled water 
and 5/il of each electrophoresed on a 0.8% agarose
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Table 3.1: Cloning Strategy and Results from Subcloning Experiment 1.
DNA ENZYME RATIO NO OF 
WHITE
NO OF 
BLUE
EFFICIENCY OF 
TRANSFORMATION
*no DNA 1 — —
*pUC19,10ng - 258 3.9x10^
*pUC19,lOng BamH I - 59 8.9x10^
pUC19,10ng BamH I ND ND ND
pUC19,20ng+1211 BamH I 3:1 2 100 7.7x10^
pUC19,10ng+1211 BamH I 1:1 3 39 6.4x10^
pUC19,10ng+1211 BamH I 1:3 1 49 7.6x10^
*pUC19,10ng BamH I 5 24 4.4x10^
pUC19,10ng BamH I - 200 3. OxloS
pUC19,20ng+1211 BamH I 3:1 4 150 1 .2x10^
pUC19,10ng+1211 BamH I 1:1 - 120 1 .8x10^
pUC19,10ng+1211 BamH I 1:3 - 120 1 .8x10^
* = no ligase included in these controls 
= units in cells per jug of DNA
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gel to check the sizes of the plasmid DNA. Figure 3.8 shows 
the gel after staining with ethidium bromide, the highly 
stained areas at the bottom of the gel represent the RNA 
contamination which is common with this particular quick 
plasmid preparation method.
It can be seen from these results that four of the clones 
(4,5,6 and 8 ) were the same size as that of the blue, j8- 
gal+, colony picked as a control (pUC19, no insert). One 
clone (3) was smaller than pUC19 and three (1,2 and 7) did 
appear to have an insert but they were only approximately 
4Kb in size so couldn't have the expected insert of 8 .6Kb. 
The number of blue colonies seen for the unligated cut pUC19 
control was large, representing l/5th of the number seen on 
the plates with uncut pUC19 (table 3.1). This implies that 
the pUC19 DNA was not completely cut by the restriction 
enzyme. More worrying was the appearance of white colonies 
on this control, normally indicating that a plasmid has been 
religated containing an insert. In this case the plates 
where competent cells have been plated out without being 
transformed by any plasmid also had a white colony. This 
would indicate that the competent cells were contaminated by 
an organism resistant to ampicillin and appearing white on 
X-gal plates, therefore these white colonies have nothing to 
do with the subcloning procedure. In the light of this it is 
not surprising that this particular subcloning experiment 
did not yield any useful results.
The experiment was therefore repeated, this time using pUC19 
which had been treated with alkaline phosphatase in order to 
prevent recircularisation of the plasmid upon ligation. The 
plasmid was prepared in the same way as before but, prior to 
the phenol extraction procedure, 10 units of alkaline 
phosphatase (calf intestine, Boehringer) were added to the 
restriction enzyme digest and incubation continued at 37“C 
for a further 60 minutes. A further 7 ampicillin resistant 
white colonies were obtained from this experiment, the 
results of the cloning are given in table 3.2.
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KEY:
(The sizes
M = X DNA, Hind III fragments 
1-8 = Plasmid DNA from ^-gal" subclones 
9 = Plasmid DNA from ^-gal* colony 
of the X DNA, Hind III fragments are as in fig. .2]
Figure 3.8: A gel showing plasmid DNA prepared from the subclones obtained from subcloning experiment 1.
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Table 3.2: Cloning Strategy and Results from Subcloning Experiment 2.
DNA ENZYME RATIO NO OF NO OF . EFFICIENCY OF 
WHITE BLUE TRANSFORMATION*
*no DNA - — -
*pUC19,10ng - 500 7.6x10
*pUC19,10ng BamH I — 2 3.0x10
*pUC19y^, lOng BamH I — 3 4.5x10
pUC19,lOng BamH I 1 7 1 .2x10'
pUC19A, lOng BamH I — 1 1.5x10-
pUC19A,10ng+1211 BamH I 1:1 2 — 3. 0x10-
pUC19A,20ng+1211 BamH I 3:1 1 — 7.5x10'
pUC19A,20ng+1211 BamH I 1:2 4 2 9.1x10-
* = no ligase included in these controls.
pUClS* = cut pUC19 treated with alkaline phosphatase.
* = units in cells per fig DNA
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The /3-gal', Amp'^  colonies were grown in TYN-broth with 
ampicillin and mini plasmid DNA preparations were performed 
as before. The DNA was electrophoresed on a 0.8% agarose gel 
to check the sizes of the subclones. The gel, after staining 
with ethidium bromide, showed that six of these subclones 
(Gpl-5, plus Gp7) were again approximately 4Kb in size, 
while the seventh (Gp6) looked large enough to contain an 
8 .6Kb insert (figure 3.9). An incomplete restriction digest 
of Gp6 with BamH I linearised the plasmid, this is shown in 
figure 3.10. No band smaller than the uncut, closed 
circular, form of the plasmid could be seen, indicating that 
one BamH I site had been lost during the cloning procedure. 
The size of the linear plasmid was found to be approximately 
9Kb.
3.2.4 Characterisation of Subclones
One representative of the 4Kb subclones (Gpl) was used for 
further investigation, along with the 9Kb subclone, Gp6 . DNA 
Dot Blots of Gpl and Gp6 DNA were performed in duplicate, 
using nitrocellulose filters. 5/xl of each sample were 
applied to the filter using a micropipette and samples of 
pAlO, p2D6 (as positive hybridisation controls), pUC19, and 
X phage DNA (as negative hybridisation controls) were 
included. The two duplicate filters were hybridised with one 
of the mouse GPX probes (AlO or 2D6) in a volume of 15ml of 
Hybridisation buffer using the standard procedures (section 
2.16).
The mouse probes had been prepared by labelling lOOng of 
each with lOO/xCi dCTP by nick translation, as detailed 
in section 2.14.1. The stringent washing step used for the 
filters was 2 x 45 minutes at 55“C in 0.2x SSC. The results 
(figure 3.11) showed that the AlO probe (representing the 5' 
half of the mouse gene) hybridised to both clones Gpl and 
Gp6 , yet the 2D6 probe (representing the 3' half of the 
mouse gene) did not hybridise to either of the clones.
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KEY:
M = X DNA, Hind III fragments 
Gpl-7 = Plasmid DNA from (3-gal~ subclones 
B = Plasmid DNA from )0-gal* colony 
(The sizes of the XDNA, Hind III fragments are 
as in figure 3.2)
Figure 3.9: A gel showing plasmid DNA from the subclones obtained from subcloning experiment 2.
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KEY:
M = X DNA, Hind III fragments 
A = Gp6 DNA, BamH I cut 
(The sizes of the \DNA, Hind III fragments are 
as in figure 3.2)
Figure 3.10: A gel showing subclone Gp6 cut with the restriction enzyme BamH I
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DNA Dot Blots of 1211 Subclones
Hy br id i se d w i t h : -  2 D 6  a  10
p A I O  p 2 D 6  p U C 1 9  X D N A  p A l O  p 2 D 6  p U C 1 9  X D N A
#  #
a  $  e
GP1 G P 6 Blue GP1 G P 6  Blue
Figure 3.11: DNA Dot Blots of lambda phage 1211 subclones, Gpl and Gp6
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As the 2D6 probe had not been labelled to a satisfactory 
level of incorporated radioactivity in this experiment 
(estimated by Geiger counter readings), the 
presence of the 3' half of the gene was not completely 
discounted at this stage.
As the clone Gpl did not have a large insert, it was decided 
not to continue investigation of this. A large scale plasmid 
DNA preparation of the Gp6 subclone was carried out as in 
section 2.5.1 and a restriction digest with the enzyme BamH 
I carried out in order to better determine the size of this 
plasmid. The enzyme did not cut the DNA so 50/xg of the Gp6 
preparation was cleaned by the Geneclean method (section 
2.3.7) using 25/zl glassmilk solution in order to obtain DNA 
clean enough for restriction mapping. Gp6 DNA was then cut 
with a variety of restriction enzymes and the digests run on 
an 0.8% gel, this is shown in figure 3.12. The enzyme Hind 
III should have resulted in a linear plasmid of 
approximately 9Kb, as there is one recognition site in
pUC19. It can be seen from the gel that there is one band of
approximately 4Kb for the Hind III digest. Similarly, the
Pst I and Pvu II digests resulted in smaller fragments than 
would have been expected for a 9Kb plasmid. From this 
information it was postulated that the clone was, in fact, 
two plasmid molecules containing a 1.69Kb insert joined 
together, rather than one plasmid with a large fragment 
inserted. The postulated map is also shown in figure 3.12.
3.3 Restriction Enzyme Mapping of the Phage Recombinant 
1211 and Subcloning of a 3.3Kb Human Genomic Fragment
It was apparent, from the preceding section, that the 
subcloning of the 8 .6Kb insert fragment from phage clone 
1211 into pUC19 was not succeeding. As this may have been
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s T U V W  X Y Z M
KEY:
M = X DNA, Hind III fragments
W = Gp6 , Sma I eut
X = Gp6 , Kpn I eut
Y = Gp6 , Sst I eut
Z = Gp6 , Pvu II eut
S = Gp6 , EcoR I eut 
T = Gp6 , Xba I eut 
U = Gp6 , Pst I eut 
V = Gp6 , Hind III eut 
= 1.69Kb insert 
(The sizes of the XDNA, Hind III fragments are 
as in figure 3.2)
? PstI
Pvul
Pvun
Pvu I  
PstI 
Hindi
PstI B
A,B = Possible reeognition sites for Pvu II
Figure 3.12: A restriction enzyme map of the subclone Gp6, and the gel from which the mapping information
obtained.
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due to the large size of the fragment in question, it was 
decided to map phage clone 1211 in order to find a smaller 
fragment which could be subcloned more easily (yet still 
contained the whole of the sequence homologous to the mouse 
GPX gene).
3.3.1 Restriction Enzyme Mapping of the Recombinant Phage 
1211
1211 DNA was digested with EcoR I, BamH I, Xba I and 
combinations of the three. EcoR I and Xba I were chosen 
because XCh28 does not have recognition sites for these 
enzymes, BamH I was chosen as it was the enzyme used to 
excise the whole of the genomic insert. The digests were run 
on a 0 .8% gel and the gel stained with ethidium bromide and 
photographed (figure 3.13).
A Southern blot of the gel was performed (section 2.15.1) 
and the resulting filter hybridised with the 2D6 mouse probe 
(prepared by labelling lOOng of 2D6 DNA with lOOjLtCi ^^ P dCTP 
by nick translation) in a volume of 15ml Hybridisation 
solution (sections 2.16 and 2.14.1). The stringent washing 
step used for the filters was 3x 45 minutes at 55“C in O.lx 
SSC. After autoradiography the filter was washed to remove 
the probe (section 2.15.5) and re-probed with the AlO mouse 
probe in the same way. Figure 3.14 shows the results 
obtained. It can be seen that there is a 3.3Kb BamH I - Xba 
I fragment which contains a DNA sequence with homology to 
both halves of the mouse GPX gene. The restriction map of 
the recombinant 1211 insert obtained from this experiment is 
shown in figure 3.15.
3.3.2 Preparation of DNA for Subcloning
Linear pUC19 with Xba I and BamH I "sticky ends" was 
prepared by digesting approximately 2jig of pUC19 DNA with 
Xba I and BamH I and electrophoresing the whole digest on a 
0.8% low melting point agarose gel (figure 3.16). The
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mKEY:
M = X DNA, Hind III fragments 
m = 0X174 DNA, Hae III fragments
1 = Uncut 1211
2 = 1211 DNA, EcoR I eut
3 = 1211 DNA, Xba I eut
4 = 1211 DNA, BamH I eut
5 = 1211 DNA, EcoR I & BamH I eut
6 = 1211 DNA, EcoR I & Xba I eut
7 = 1211 DNA, Xba I & BamH I eut
8 = 1211 DNA, EcoR I & Xba I & BamH I eut
(Sizes of the XDNA, Hind III and 0X174 DNA, Hae III marker
fragments are as in figures 3.2 and 4.12 respectively)
Figure 3.13: Restriction Mapping Gel of the Recombinant Phage 1211
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Southern Blots of Recombinant 1211
Hybridised With:- 2D6 AlO
X « X
B X X B  B x X B
U E X B E E B E  U E X B E E B E
SIZE OF DNA
9 . 4  -  
6 . 7  -
4 . 4  _
2 . 3  _  
2.0 _
1.4 _  
1. 1 -  
0 . 9  -  
0.6 -
\
K E Y -
U-Uncut 1211 
B-BamHI  
E-EcoRI  
X -X b a l
Figure 3.14: Southern Blots of Recombinant 1211 Mapping Gel
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Map of the Recombinant 1211 Insert
X X E E Bj— _______________ I
A10 206
________1Kb
KEY:-
B-BamHI
E-EcoRI
X-Xbal
Figure 3.15; Restriction Enzyme Map of the Recombinant 1211 Insert (The sequence showing homology to the
mouse gene is indicated by shading)
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#  W  î'?
W  W
KEY:
M = X DNA, Hind III fragments 
A = pUC19 DNA, Xba I & BamH I cut 
(The sizes of the X^NA, Hind III fragments are 
as in figure 3.2)
Figure 3.16: A gel showing pUC19 linearised by Xba I and BamH I
— 1 2  6 —
linear band was excised from the gel and the DNA purified by 
the cold phenol procedure, as detailed in section 
2.3.6. The purified DNA was dissolved in distilled water to 
a concentration of approximately lOng/jLtl.
The 3.3Kb fragment of 1211 was prepared by cutting 
approximately 10/xg DNA with BamH I and Xba I and 
electrophoresing the mixture on a preparative 0 .8% low 
melting point agarose gel, this is shown in figure 3.17. The 
3.3Kb band was excised from the gel and purified by the cold 
phenol method (section 2.3.6), the DNA was dissolved in 
distilled water to a concentration of approximately lOng/jLtl.
3.3.3 Subcloning Results
Ligations were performed as in section 2.10.1, with linear 
pUC19 (EcoR I cut) included as a control for the ligase. 
Linear pUC19 (Xba 1 and BamH 1 cut) was incubated with 
ligase in order to check that both enzymes had cut the 
plasmid. Preparation of competent cells and transformation 
procedures were carried out as described in sections 
2.10.3-2.10.5. The results are shown in table 3.3.
The 9 0-gal", Amp** colonies obtained were grown overnight in 
TYN-broth with ampicillin. Mini plasmid DNA preparations 
were performed by the Geneclean method (section 2.3.7) and 
2jLtl of each preparation digested with Xba 1 and BamH 1. The 
digests were electrophoresed on a 0 .8% agarose gel in order 
to determine the sizes of the inserts in the subclones. The 
gel, after staining with ethidium bromide, is shown in 
figure 3.18. The Geneclean method of plasmid DNA preparation 
did not give good yields of DNA, but it can be seen that 
digests of subclones Gp71 and Gp72 gave the expected bands 
at 2.7Kb (plasmid) and 3.3Kb (insert).
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KEY:
M = X DNA, Hind III fragments 
F = 3.3Kb fragment
U = -13Kb Fragment due to partial digest by 
BamH I
(The sizes of the XDNA, Hind III fragments are 
as in figure 3.2)
Figure 3.17: Preparitive gel of Recombinant 1211 DNA cut with Xba I and BamH I
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Table 3.3: Cloning Strategy and Results from Subcloning of the 3.3Kb Human Genomic DNA Fragment
DNA ENZYMES RATIO NO OF NO OF EFFICIENCY OF
WHITE BLUE TRANSFORMATION*
*no DNA - - —
*pUC19,10ng - 800 1 .2x10^
*pUC19,10ng EcoR I - 1 1.5x10^
pUC19,10ng EcoR I - 13 2 .0x10^
pUC19,lOng BamH I, Xba I - 5 7.6x10^
pUC19,10ng+1211 BamH I, Xba I 1:1 1 43 6.7x10^
pUC19,10ng+1211 BamH I,Xba I 1:3 3 48 7.7x10^
pUC19,30ng+1211 BamH I,Xba I 3:1 3 55 2.9x10*
pUC19,20ng+1211 BamH I,Xba I 1:1 3 31 2 . 6x10*
* = no ligase included in these controls
* = units in cells per /xg of DNA
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KEY
m = X DNA, Hind III fragments 
Gp61-93 = Plasmid DNA from 0-gal" subclones, cut 
B = Plasmid DNA from 0-gaI* colony, cut 
(The sizes of the XDNA, Hind III fragments are 
as in figure 3.2)
Figure 3.18: Mini Plasmid DNA preparations of the subclones, cut with the restriction enzymes Xba I and
BamH I
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3.3.4 Characterisation of Subclones
Dot blots of the DNA from the subclones were performed, in 
duplicate, by the application of 2^1 of each miniprep onto 
nitrocellulose using the dot blot apparatus. Positive 
controls of plasmid 2D6, plasmid AlO and phage 1211 were 
included, as were negative controls of pUC19 and \ DNA.
The filters were hybridised against the AlO and 2D6 halves 
of the mouse gene as in section 3.2.4, the resulting 
autoradiographs are shown in figure 3.19. Subclones Gp71,
72, 81, 91, and 92 showed homology with both halves of the 
mouse gene. As Gp71 and 72 had also shown the presence of a 
3.3Kb insert, one of these (Gp71) was chosen for further 
study. Large scale plasmid DNA preparations of Gp71 and Gp72 
were performed and 2/xl of the DNA was cut with Xba I and 
BamH I. The digests were electrophoresed on a 0.8% agarose 
gel to confirm that the 3.3Kb insert was present, this is 
shown in figure 3.20.
3.4 Restriction Enzyme Mapping, and Southern Blot Analysis, 
of Subclone Gp71
The sequence of the human GPX gene had recently been 
published by Ishida et al, (1987), and a restriction map of 
the gene could therefore be produced from this sequence 
using the Microgenie^” software on the Olivetti M24 PC. The 
following section details the restriction mapping 
experiments performed on the subclone Gp71 and comparison of 
the results obtained with the deduced restriction map of the 
human GPX gene.
3.4.1 Restriction Enzyme Mapping of Subclone Gp71
Using the restriction map of the human GPX gene, and a
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DNA Dot Blots of 1211 Subclones
H yb r id ised  w ith ; - 2D6 A10
O  CD <o z
<  CM Ûa a X
T— ^ CO<D K K N.
CM T- CM 5200 0) 0) O) 3
m
CM T- CM CO 0)00 cm cm o) 3
CO
Figure 3.19: DNA Dot Blots of the 1211 Subclones
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KEY:
m = X DNA, Hind III fragments 
(The sizes of the XDNA, Hind III fragments are 
as in figure 3.2)
Figure 3.20: Gel showing subclones Gp71 and Gp72 cut with restriction enzymes Xba I and BamH I
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restriction map of pUC19, restriction enzymes were chosen 
which had recognition sites within the GPX gene yet few 
sites within pUC19. Restriction enzyme digests were set up 
in duplicate, as shown in table 3.4.
After incubation overnight at 37“C, 20jLtl of each reaction 
mixture was loaded onto a 2% agarose gel, resulting in two 
identical gels. The gels were electrophoresed in series for 
3 hours at 100mA using the BRL model H5 apparatus. The gel 
was stained with ethidium bromide and photographed. The 
distance of the marker fragments from the origin was 
measured and a semi-log plot of distance from origin vs size 
of marker fragments was drawn. The gel and the graph are 
shown in figure 3.21.
The sizes of the unknown fragments were estimated by 
measuring the distance travelled from the origin and 
deducing their size using the graph. Table 3.5 shows the 
sizes of the fragments.
In order to clarify the positions of recognition sites for 
Apa I, Xho I, Pvu II and Rsa I within Gp71, further digests 
were set up as in tables 3.6 and 3.7.
Electrophoresis of the gels and sizing of the fragments was 
carried out as above. Figures 3.22 and 3.23 show the gels 
with the graphs used in the determination of fragment sizes. 
Table 3 .8 gives a summary of all the mapping information 
obtained.
3.4.2 Southern Blotting of Gp71 Restriction Mapping Gels
In order to determine the position of the sequence of 
interest within the 3.3Kb insert it was decided that the 
mapping gels should be probed with the mouse GPX gene, so 
that fragments containing sequences with homology to the GPX 
gene could be identified. Two filters were obtained from the 
duplicates of mapping gel A (figure 3.21) by Southern 
blotting. These were hybridised with one of the two halves 
of the mouse gene, either AlO or 2D6, in a
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Table 3.4: Components of restriction enzyme digestions in mapping experiment A
COMPONENT
Ml
M2
Gp71,l/xg//il
React'" 2 
React^" 6
TM
React 1
React^” 4 
RNAse A
HgO
Xba I 
BamH I 
Hind III 
Bgl I 
Pvu II 
EcoR I 
Pst I 
Xho I 
Apa I 
Rsa I
RESTRICTION ENZYME DIGESTS 
Ml U 1 2 3 4 5 6 7 8 90 10 11 M2
— 4 4 4 4 4 4 4 4 4 4 4 4 -
— — 4 4 4 4  — — 4 4 4  — — —
- - - - - - - - - - - - 4 -
- 1 1 1 1 1 1 1 1 1 1 1 1 -  
36 35 27 27 27 29 27 29 29 29 29 29 29 36
—  —  —  2 2  —  —  —  —  —  —  —  —  —
— _ — — — 2 2  — — — — — — —
- - - - - - 2 2 - - -  - - -
- - - - - - - - - - - - 2 -
KEY: 
Ml = X DNA cut with Hind III M2 — 0X174 cut with Hae III
u = Uncut Gp71 6 = Pvu II
1 = BamH I, Xba I 7 = EcoR I
2 = Hind III, Xba I 8 = Pst I
3 = Hind III, BamH I 9 = Xho I
4 = Bgl I 10 = Apa I
5 = Bgl I, Pvu II 11 = Rsa I
The numbers in the table represent the quantity of components
added in jLxl.
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Table 3.5: Sizes of DNA fragments obtained in restriction mapping experiment A
ENZYMES FRAGMENT SIZES
Xba I,BamH I 4.2/2.7
Xba I,Hind III 5.0
Hind III,BamH I 4.2/2.7
Bgl I 3.3/1.8/1.2
EcoR I 4.4/0.59/0.44
Pst I 2.7/1.45/1.35/0.59
Apa I 4.4/1.15
Xho I 4.4/1.4
Pvu II 2.3/1.35/0.83/0.54/0.52/0.275/0.14
Pvu II,Bgl I 1.25/1.2/0.86/0.83/0.54/0.52/0.44/0.28/0.14
Rsa I 1.9/0.83/0.78/0.67/0.44/0.4/0.22/0.22
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1 ,, 2 4 6 8 10
1 3 5 7 9 11M2
(See table 3.4 for key. Sizes of the \DNA, Hindlll and 
0X174 DNA, Hae III marker fragments are as in figures 3.2
and 4 .12 respectively)
S
G
CJ
uZ
<zQ
i/1
0
4020 50 603010
Distance Travelled (mm)
Figure 3.21: Restriction mapping gel A and the graph of distance from origin vs size of fragment used in
determination of fragment sizes (semi-log plot)
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Table 3.6: Components of Restriction enzyme digests in mapping experiment B
RESTRICTION ENZYME DIGESTS
COMPONENT Ml 1 2 3 4 5 6 7 8 9 10 11 12 M2
Ml 2
M2 2
Gp71,lAtg//xl - 2 2 2 2 2 2 2 2 2 2 2 2 -
React^” 2 - 2 2 2 2 2 2 2 2 2 2 2 2 —
RNAse A - 1 1 1 1 1 1 1 1 1 1 1 1 -
HgO 18 14 13 13 13 13 13 14 13 13 13 13 13 18
Xho I - 1 1 1 1 1 1 - - - - - - -
BamH I - - 1 - - - - - 1 - - - - -
Xba I - - - 1 - - - - - 1 - - - -
EcoR I - - - - 1 - - - - - 1 - 1 -
Bgl I - - - - - 1 - - - - - 1 - -
Pst I - - - - - - 1 - - - - - 1 -
Apa I 1 1 1 1 1 - -
KEY:
Ml = X DNA cut with Hind III M2 = 0X174 cut with Hae III
1 = Xho I 7 = Apa I
2 = Xho I,BamH I 8 = Apa I,BamH I
3 = Xho I, Xba I 9 = Apa I,Xba I
4 = Xho I,EcoR I 10 = Apa I,EcoR I
5 = Xho I,Bgl I 11 = Apa I,Bgl I
6 = Xho I,Pst I 12 = Pst I, EcoR I
The numbers in the table represent the quantity of components
added in /xl.
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7 9 11,2 '
6 à g. 18 _
(See table 3.6 for key. Sizes of the XDNA, Hind III and 
0X174 DNA, Hae III marker fragments are as in figures 3.2
and 4.12 respectively)
30
20
10
<za
0 5
01
10 20 30 40 50 60 70 80
Distance from Origin (mm)
Figure 3.22: Restriction mapping gel B and the graph of distance from origin vs size of fragment used in
determination of fragment sizes (semi-log plot)
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Table 3.7: Components of restriction enzyme digests in mapping experiment C
COMPONENT
RESTRICTION ENZYME DIGESTS 
Ml 1 2 3 4 5 6 7 8 9 10 11 12 M2
Ml
M2
Gp71,ljLxg/jLtl 
React^” 6 
React^” 2 
RNAse A 
HgO 
Xho I 
BamH I 
Xba I 
EcoR I 
Bgl I 
Pst I 
Pvu II 
Rsa I
2 - - - - - - - - - - - - -
- - - - - - - - - - - - - 2
- 2 2 2 2 2 2 2 2 2 2 2  2 -
- 1 1 1 1 1 1 - - - - - - -
- 1 1 1 1 1 1 2 2 2 2 2 2 -  
- 1 1 1 1 1 1 1 1 1 1 1 1 -  
18 14 13 13 13 13 13 14 13 13 13 13 13 18
mm mam mm mm m^ mm m^ m^ mm m^
—  1 1 1 1 1 1  —  —  —  —  —  —  —
— — — — — — — l l l l l l —
KEY:
Ml = X DNA cut with Hind III
1 = Pvu II
2 = Pvu II,BamH I
3 = Pvu II,Xba I
4 = Pvu II,EcoR I
5 = Pvu II,Bgl I
6 = Pvu II,Pst I
M2 = 0X174 cut with Hae III
7 = Rsa I
8 = Rsa I,BamH I
9 = Rsa I,Xba I
10 = Rsa I,EcoR I
11 = Rsa I,Pst I
12 = Rsa I,Xho I
The numbers in the table represent the quantity of components
added in i^l.
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1 2 4 6 8 10 12M2
1 3 5 7 9 11
(See table 3.7 for key. Sizes of the XDNA, Hind III and 
0X174 DNA, Hae III marker fragments are as in figures 3.2
and 4 .12 respectively)
30
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10
5
05
01
0 10 20 30 40 50 60
Figure 3.23:
Distance from Origin (mm)
Restriction mapping gel C and the graph of distance from origin vs size of fragment used in 
determination of fragment sizes (semi-log plot)
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Southern Blots of GP71 Mapping Gels
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Figure 3.24: Southern Blots of Restriction mapping gel A probed with the mouse GPX gene.
— 1 4 5  —
Table 3.8: A summary of the fragment sizes obtained from restriction mapping of Gp71 and Southern blotting
the mapping gels
ENZYMES GEL FRAGMENT SIZES
Xba I,BamH I 
Xba I,Hind III 
Hind III,BamH I 
Bgl I 
EcoR I 
Pst I
Pst I,EcoR I 
Apa I
Apa I,BamH I 
Apa I,Xba I 
Apa I,EcoR I 
Apa I,Bgl I 
Xho I
Xho I,BamH I 
Xho I,Xba I 
Xho I,EcoR I 
Xho I,Bgl I 
Xho I,Pst I 
Pvu II
Pvu II,Bgl I
Pvu II,BamH I 
Pvu II,Xba I 
Pvu II,EcoR I 
Pvu II,Pst I 
Rsa I
Rsa I,Xba I 
Rsa I,BamH I 
Rsa I,EcoR I 
Rsa I,Pst I 
Rsa I,Xho I
A
A
A
A
A
A
B
A
B
B
B
B
B
A
B
B
B
B
B
B
A
C
A
C
C
C
C
C
A
C
c
c
c
c
c
4.23^/2.7 
5.0=^
4.23^5/2.7 
3.3/1.83^/1.2 
4. 43/0 . 59 VO. 44 
2 . 7/1. 453'V I . 35/0 , 595 
/O.64/0.47/0.43 
4.43'5/1.153'5 
4.7/1.1 
4.6/1.1/0.69 
3.8/1.4/1.1 
1.0/0.52/0.34/0.31 
3.9/1.3/1.0/0.85/0.45 
4.4/1.43'5 
4.6/1.2 
3.8/1.2/0.52 
3.2/1.2/1.2 
4.0/0.84/0.47 
2.7/1.1/0.92/0.68/0.39 
2.7/1.2/0.76/0.53/0.5
2. 3/1. 353'S/O. 833/0. 543/ 0 . 52/0. 275/0.14
2.1/1.1/0.69/0.47/0.43/0.27
1 .253/ 1 . 2/0. 863'5/o. 83/0. 54/0. 52/0. 443/ 0 . 28
/0.14
1.0/0.95/0.71/0.67/0.47/0.43/0.40/0.27
2.1/1.1/0.59/0.47/0.43/0.27/0.17
2.1/1.1/0.69/0.47/0.43/0.21
2.1/0.8/0.47/0.43/0.39/0.29/0.27/0.26
2.1/0.6/0.58/0.50/0.47/0.43/0.22/0.17
1.9/0.833/0.78/0.67/0.443/0.4/0.223/0.223
1.6/0.73/0.69/0.60/0.43/0.39/0.25/0.25
1.65/0.73/0.69/0.60/0.43/0.39/0.25
1.7/0.73/0.69/0.60/0.43/0.39/0.25
1.8/0.73/0.60/0.40/0.39/0.32/0.25
1.8/0.69/0.62/0.47/0.39/0.37/0.28/0.25
1.9/0.62/0.50/0.40/0.38/0.34/0.24
Fragments which hybridise to the mouse gene probes 2D6 and AlO 
are indicated by superscripts of 3 and 5 respectively 
(representing the 3' and 5 ’ halves of the gene)
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volume of 20ml of Hybridisation solution. The probes were 
prepared by labelling lOOng of each with 100/xCi 2^p dCTP by 
nick translation as before. Hybridisation and washing steps 
were carried out as detailed in section 2.16 and the 
stringent washing step was 2x 40 minutes at 58“C in O.lx 
SSC. The resulting autoradiographs are shown in figure 3.24 
and the fragments which hybridised to the mouse gene are 
indicated in table 3.8. This information, together with the 
mapping information from section 3.3.1, enabled a circular 
plasmid restriction enzyme map of Gp71 showing the position 
of the sequence homologous to the mouse GPX gene to be 
compiled, this is shown in figure 3.25.
3.4.3 Comparison of the Restriction Maps of the Human GPX 
gene and the Gp71 human genomic fragment
The restriction map of the.Gp71 insert is shown, in linear 
form, alongside the restriction map of human GPX in figure 
3.26. It is quite clear that there is a 1.6Kb section of the 
Gp71 map which is exactly the same as the deduced map of the 
human GPX gene. This is the same section that 
hybridises to the mouse gene. Thus the whole of the human 
GPX gene has been isolated, along with 1.3Kb of 5' flanking 
sequence and 0.3Kb of 3' flanking sequence.
3.5 DNA Sequencing of the Gp71 Subclone
The following section describes the sequencing experiments 
which were carried out in order to confirm that the subclone 
Gp71 contained the human GPX gene. Further manipulation of 
Gp71 was necessary to obtain a plasmid with the sequence of 
interest adjacent to the universal sequencing primer 
recognition site.
3.5.1 Manipulation of Subclone Gp71
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In order to obtain a clone where the sequencing primer could 
read into the GPX gene the subclone had to be cut with a 
restriction enzyme and re-ligated. As can be seen from 
figures 3.25 and 3.26, there are recognition sites for the 
restriction enzyme EcoR I at the cloning region of 
pUC19, at the end of the GPX gene, and towards the end of 
exon 1 of the GPX gene (reading in the 5'-3' direction). 
Cutting Gp71 with EcoR I excises two small fragments of 
human genomic DNA and leaves a 5Kb fragment which can be 
re-ligated to give a recombinant plasmid with the intron of 
the GPX gene adjacent to the universal sequencing primer 
recognition site. A summary of this cloning strategy is 
shown in figure 3.27.
Approximately 4/xg of Gp71 DNA were cut with EcoR I and 
electrophoresed on a 0.8% low melting point agarose gel 
(figure 3.28). The digestion was not complete, some 
covalently closed circular DNA could still be seen, but 
enough linear 5Kb fragment was obtained. The 5Kb band was 
excised from the gel and purified using the Geneclean method 
(section 2.3.7). (lO/xl of glassmilk solution was used).
The linear DNA was recovered in a final volume of 20^1 
distilled water and 3jitl of this was taken for ligation. 
Transformation of competent E.coli TBl cells (section 
2.10.1) resulted in 54 j0-gal", Amp"^  recombinant colonies, 
the results are shown in table 3.9.
A large scale plasmid DNA preparation of one clone which was 
the correct size (Gp71Eco) was performed (section 2.5.1), 
and was used for sequencing as in the following section.
3.5.2 Sequencing of the Human GPX gene using Recombinant 
Plasmid Gp71Eco
DNA Sequencing was carried out according to the methods 
detailed in section 2.18. 5jitg of the recombinant plasmid 
Gp71Eco were taken for sequencing with the universal primer. 
After 24 hours exposure to x-ray film an autoradiograph was 
obtained from which 208 bp of DNA sequence could be read,
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the autoradiograph is shown in figure 3.29. The 208bp 
sequence was converted from - strand to + strand using the 
Microgenie™ software; this is shown in figure 3.30. 
Comparison of this sequence with that of the previously 
published sequence of human GPX (again using the 
Microgenie™ software) showed that it had 100% homology with 
bases 798 to 1006 of the human GPX intron (figure 3.31). In 
view of this complete identity of intronic sequence it was 
concluded that Gp71 contains the human gene as defined by 
Ishida et al, (1987). Such conservation of non-coding 
sequence would not be expected in a polymorphic variant or a 
related member of a gene family. In view of the fact that 
Ishida et al, (1987) had published the sequence of the human 
GPX gene, and Chambers and Harrison, (1988) had commenced 
work on the regulation of the mouse GPX gene, it was decided 
that work on the DNA sequencing and further characterisation 
of the clone Gp71 would be discontinued. The clear evidence 
from restriction mapping and DNA sequencing already 
performed, that Gp71 contained the human GPX gene, meant 
that any further work along these lines would be repetition 
of published information. It was therefore decided that the 
emphasis of my subsequent work would be on the 
characterisation of a GPX-related cDNA sequence isolated 
from a human liver cDNA library, and the expression of this 
and the GPX gene in samples from normal humans and patients 
with GPX-related disorders.
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RP/
pGP71
60Kb
AmpR
LacZ
RBg
KEY:-
P= universal primer 
RP= universal reverse primer 
A= Apa I
— =human genomic DNA insert 
=GPX gene
Ba= BamH I 
Bg= Bgl I 
E = EcoR I 
H = Hind El 
Ps= Pst I 
Pv= Pvul 
R = RsaI 
X= Xba I 
Xh= Xho I
Figure 3.25: Restriction Enzyme Map of Subclone Gp71
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Figure 3.26; Comparison of the restriction maps of the human GPX gene and the Gp71 human genomic fragment
- 151 -
Xh
exoni
intron
X
exon 2pGPTI
60Kb
Amp"
lac Z
Cut witti EcoR I
B
E £
\y
Re-ligation of the5Kb fragment
exoni
intron
pGP71Eco
50Kb
Amp"X
KEY: P= Universal Primer E = EcoRI Xh=Xho I
B = BamHI X = X b a I
Figure 3.27: Cloning strategy used to produce a recombinant plasmid suitable for use in sequencing the
human GPX gene
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KEY:
m = X DNA, Hind III fragments 
A = Gp71 DNA, EcoR I cut 
(The sizes of the XDNA, Hind III fragments are 
as in figure 3.2)
Figure 3.28: A gel showing the subclone Gp71 cut with the restriction enzyme EcoR I
Table 3.9: Cloning strategy and results from the manipulation of recombinant plasmid Gp71 
DNA ENZYME NO OF 
WHITE
NO OF EFFICIENCY OF
BLUE TRANSFORMATION‘S
*no DNA 
*pUC19,long 
pUC19,long 
Gp71,30ng 
(linear, 5Kb 
fragment)
EcoR I 
EcoR I 53
300
6
4.6x10^ 
9.1x10^ 
2 . 7x10^
* = no ligase included in these controls 
■s = units in cells per ng of DNA
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m TC q
ELECTROPHORESIS 
TIMES :
1=3 hours 
1- 25 hours 
3= 2 hours 
4=15 hours
Figure 3.29: An autoradiograph of the sequencing gel from the sequencing of recombinant plasmid Gp/IEco
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5' 10 20 30 40 50
GTCGGCTCCA TGCGCGGAGA GTCTGGCTAC TCTCTCGTTT CCTTTCTGTT
60 70 80 90 100
GCTCGTAGCT GCTGAAATTC CTCTCCGCCC TTGGGATTGC GCATGGAGGG
110 120 130 140 150
*AAAATCCCG GTGACTCATA GAAAATCTCC CCTGTTTGTG GTTAGAACGT
160 170 180 190 200
TTCTCTCCTC CTCTTGACCC CGGGTTCTAG CTGCCCTTCT CTCCTGTAGG
3 '
AGAACGCC
Figure 3.30: 208bp of + strand sequence obtained from sequencing Gp7lEco
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670 680 690 700 710 72
GCCTCGGACC CCGG6GCCTG GTGGTGCTCG GCTTCCCGTG CAACCAGTTT GGGCATCAG
730 740 750 760 770 78
TGCGCCGGGC GGAGCGGGAC GGGACGGGGG CGGACGTGCA GTAGTGGCTG GGGGCGCCG
790 800 810 820 830 84
CGGTGTGGTG GTGGGTGCGT CGGCTCCATG CGCGGAGAGT CTGGCTACTC TCTCGTTTC
GT CGGCTCCATG CGCGGAGAGT CTGGCTACTC TCTCGTTTC 
1 12 22 32 4
850 860 870 880 890 90
TTTCTGTTGC TCGTAGCTGC TGAAATTCCT CTCCGCCCTT GGGATTGCGC ATGGAGGGA
TTTCTGTTGC TCGTAGCTGC TCAAATTCCT CTCCGCCCTT GGGATTGCGC ATGGAGGG*
52 62 72 82 92 10
910 920 930 940 950 96
AAATCCCGGT GACTCATAGA AAATCTCCCC TGTTTGTGGT TAGAACGTTT CTCTCCTCC
AAATCCCGGT GACTCATAGA AAATCTCCCC TGTTTGTGGT TAGAACGTTT CTCTCCTCC
112 122 132 142 152 16
970 980 990 1000 1010 102
CTTGACCCCG GGTTCTAGCT GCCCTTCTCT CCTGTAGGAG AACGCCAAGA ACGAAGAGA
CTTGACCCCG GGTTCTAGCT GCCCTTCTCT CCTGTAGGAC AACGCC
172 182 192 202
1030 1040 1050 1060 1070 108
TCTGAATTCC CTCAAGTACG TCCGGCCTGG TGGTGGGTTC GAGCCCAACT TCATGCTCT
Figure 3.31: A comparison between the human GPX gene and 208bp of Gp71 human genomic fragment
Gp71 is the lower of the two sequences. Underlined bases 
represent the coding regions of exons 1 and 2 of the human 
GPX gene. The asterisk represents a nucleotide whose 
identity could not be determined in this experiment.
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Chapter 4
Isolation and Characterisation of a Human Liver cDNA Related 
to the Glutathione Peroxidase Gene
The following results detail the experiments performed in 
order to isolate a human liver cDNA sequence with homology 
to the mouse GPX gene from the recombinant phage library in 
Xgtll (see section 2.7). Mapping and sequencing experiments 
were then undertaken to establish the relationship between 
the isolated cDNA and the human GPX gene.
After completion of this thesis it was discovered that 
GPRP was identical to the 5' half of the mouse gene. This 
invalidates the results presented in sections 4.4.4 and 
4.4.5. However, these results have not been excluded from 
this report as a full discussion has been included in 
chapter 7.
4.1 Isolation of a recombinant phage with sequence homology 
to the mouse GPX gene.
This section details the experiments performed in the 
isolation of a recombinant phage containing a human liver 
cDNA fragment with sequence homology to the mouse GPX gene, 
and determination of the approximate size of this human 
liver cDNA.
4.1.1 Preparation of DNA for use as Hybridisation Probes
The mouse DNA probes used in the following experiments were 
the 2D6 and AlO fragments of the mouse gene. These, along
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with details of their preparation for use as probes, are 
described in section 3.1.1.
4.1.2 Isolation of Recombinant Clones Hybridising to the 
Mouse GPX Gene
The human liver cDNA library in Xgtll was screened using the 
method detailed in section 2.7. 200ng of the mouse 2D6 
fragment was labelled with 150/zCi of dCTP by nick
translation (section 2.14.1). The labelled probe was added 
to 200ml of Hybridisation buffer and hybridisation was 
carried out for 5 hours in a large (24 x 24 x 10 cm) 
Tupperware box. The stringent wash used in all hybridisation 
procedures for the screening of this library was 2 x 40 
minutes at 55°C in 0.2xSSC, 0.1% SDS. One positive clone was 
identified in the first round of screening (figure 4.1), 
this was isolated by three further rounds of screening. 
Typical results from the further rounds of screening are 
shown in figure 4.2. A stock of recombinant phage clones 
which hybridised to the mouse GPX gene was prepared (section 
2.6) and stored at 4°C. As all the clones had originated 
from the same plaque in the first round of screening, only 
one of them (recombinant phage 1312) was studied further.
4.1.3 Determination of the Size of the cDNA Insert in 
Recombinant Phage 1312
DNA was made from the recombinant phage 1312 using the large 
scale method (section 2.8.2), this was a method developed 
especially for this particular recombinant as it was very 
slow growing and the conventional methods proved 
unsuccessful. From the map of Xgtll (figure 2.3) it can be 
seen that the recombinant DNA inserts can be excised using 
the restriction enzyme EcoR I. Hence a restriction enzyme 
digestion of approximately Ifig DNA using EcoR I was 
performed, along with digests using BamH I, Hind III and
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Primary Screening of the Xgt11 Human Liver
cDNA Library
Figure 4.1: Autoradiograph of the Filter from the First Round Screening of the Agtll Human Liver cDNA 
Library Showing the Positive Hybridisation Signal Produced by Recombinant Phage 1.
Further Screening to Isolate Recombinant 1312
%131
.13
%
I *
Figure 4.2: Autoradiographs of Filters from the Second, Third and Fourth Rounds of Screening of the Agtll 
Human Liver cDNA Library Showing Positive Hybridisation Signals Produced by Recombinant Phage 13, 131 and 13/-2
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KEY;
M = X Hind III marker fragments
DNAA = Uncut 1312 
B = BamH I 
C = EcoR I 
D = Hind III 
E = Pvu II
(The sizes of the marker fragments are shown in figure 3 2 .)
Figure 4.3: A Gel Showing the Restriction Fragments Produced from Cutting Recombinant Phage 1312 with
Various Enzymes
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Pvu II, the resulting fragments were electrophoresed on a 
0.8% agarose gel. Figure 4.3 shows the results obtained 
after staining the gel with ethidium bromide. The EcoR I 
digest was incomplete, the uncut phage can be seen above the 
two arms of the phage and the insert DNA is too small to be 
detected on this gel.
The other digests produced the number of fragments expected 
from the restriction map of Xgtll. In order to determine the 
size of the insert, further restriction digests were set up 
in duplicate using EcoR I, BamH I, Hind III, Kpn I, Sst I, 
and Kpn I & Sst I. These were electrophoresed on 0.6% and 2% 
agarose gels, the results can be seen in figure 4.4 along 
with a restriction map of XU^ll indicating the expected 
position of the cDNA insert. Table 4.1 shows the expected 
fragment sizes if there were no insert present and the 
fragment sizes obtained (as estimated by comparison with the 
XHind III DNA marker fragments). From this it can be seen 
that, in the Kpn I & Sst I digest, an expected fragment of 
2.13Kb was actually 3.2Kb, hence the approximate size of the 
cDNA insert was determined to be 1Kb.
4.2 Subcloning of the 1Kb cDNA Fragment from Recombinant 
Phage 1312
The 1Kb fragment from recombinant clone 1312 was excised 
using the restriction enzyme EcoR I and subcloned into pUC18 
at the EcoR I cloning site (see figure 2.1 for a restriction 
map of pUC18). As the insert to be cloned was small in size, 
the shotgun approach to cloning was taken (where the whole 
preparation of EcoR I digested 1312 was used in ligations).
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0.6%agaroGe j
KEY:
M = X Hind III marker fragments 
A = Uncut 1312 DNA 
B = EcoR I 
C = BamH I
D = Hind III 
E = Kpn I 
F = Sst I 
G = Kpn I, Sst I
(The sizes of the X^NA, Hind III fragments are 
as in figure 3.2)
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Figure 4.4: A Restriction Map of Agtll and Gels Showing the Restriction Fragments Produced in Cutting 
Recombinant Phage 1312 with Various Restriction Enzymes
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Table 4.1: A Comparison Between Expected Restriction Fragment Sizes for A9t11 and Those Obtained for the
Recombinant Phage 1312
ENZYME (S) FRAGMENT SIZES 
EXPECTED (Kbp)
FRAGMENT SIZES 
OBTAINED (Kbp)
EcoR I 
BamH I
Hind III
Kpn I
Sst I
Kpn I+Sst I
24,19,insert*
20.4+insert,11.2 
6.5, 5.5
25.5+insert,9.4 
4.4,3.9,0.6*
25.2+insert,17.1 
1.5*
2 0.7+insert,18.6
4.4
18.6,17.1,4.4,
2.1+insert,1.5*
>20,19
19,15,(partial) 
10.5,6.3,5.5
>20,9.4,4.3,3.8
>20,17
>20,18.6,4.4
18,17,4.4,3.2
* indicates fragments too small to be seen on the gel.
The fragment containing the insert in the Kpn I, Sst I digest
is underlined.
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KEY:
M = X Hind III marker fragments 
A = pUC18 EcoR I
(The sizes of the XDNA, Hind III fragments are 
as in figure 3.2)
Figure 4.5: A gel showing pUCl8 linearised with the restriction enzyme Eco RI
— 164 —
4.2.1 Preparation of the Plasmid pUC18 for Use in 
Subcloning
The plasmid pUC18 was prepared for subcloning in the same 
way as for pUC19 (section 3.2.1), using EcoR I as the 
restriction enzyme. A gel showing the linearised plasmid can 
be seen in figure 4.5.
4.2.2 Preparation of DNA from the Recombinant Phage 1312 
for Subcloning
10/Ltg of 1312 DNA (as prepared in section 4.1.3) was digested 
with the restriction enzyme EcoR I and 1/lOth of the digest 
electrophoresed on a 0.6% agarose gel in order to check that 
the DNA had been cut. Figure 4.6 shows this gel, it can be 
seen that the DNA had only partially cut but, in view of the 
fact that the 1312 DNA was in short supply and at least half 
of the preparation had been cut, it was decided to use this 
preparation. The enzyme was removed from the remaining 
digest and the DNA prepared for use in ligation in the same 
way as in section 3.2.2.
4.2.3 Subcloning Results
Ligations were carried out as detailed in section 2.10.1 and 
transformation of competent cells performed as described in 
sections 2.10.3-2.10.5. Table 4.2 shows the results obtained 
from the subcloning. 25 white colonies were picked into 5ml 
of TYN-broth with ampicillin and grown overnight, a blue 
colony was also picked for use as a control. 4ml of each of 
these cultures was used for mini plasmid preparations by the 
STET method (section 2.5.2). The final DNA preparations were 
dissolved in 30^1 of distilled water and 5/xl of each 
electrophoresed on a 0.8% agarose gel to check the sizes of 
the plasmid DNA. Figure 4.7 shows subclones 1-20 and it can 
be seen from this that there were 7 subclones 
(CPI,3,4,6,11,12,and 16) which contained extra DNA. The 
remainder of the subclones were the same size as the
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KEY:
M = X Hind III marker fragments
A = Uncut 1312 DNA
B = 1312 DNA, EcoR I cut
(The sizes of the marker fragments are shown in figure 3.2.)
Figure 4.6: A gel showing recombinant phage 1312 cut with the restriction enzyme Eco RI
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Table 4.2: Results from the subcloning of the 1Kb fragment from recombinant phage 1312 into pUCl8
DNA ENZYME RATIO NO OF NO OF EFFICIENCY OF
WHITE BLUE TRANSFORMATION^
*no DNA — — —
*pUC18,10ng - 500a Sxiof
*pUC18,10ng BamH I - 2 2x10%
pUC18,lOng BamH I 1 7 7x10%
pUC18,10ng+1312 EcoR I 1:2 15 500a 5x10%
pUC18,20ng+1312 EcoR I 1:0.5 20 500a 5x10%
* = no ligase included in these controls.
* = units in cells per /xg DNA 
a = approximate counts
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KEY:
M = X Hind III marker fragments 
1 to 2 0= Subclones number 1 to 20, number 19 is the 
/3-gal' control
(The sizes of the marker fragments are shown in figure 3.2.)
Figure 4.7: A gel showing plasmid DNA obtained from the 1312 subclones
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blue, 0-gal*, colony picked as a control (pUC18, no insert), 
as were subclones 21-25 (not shown).
4.2.4 Characterisation of subclones
DNA Dot Blots of CPI,3,4,6,11,12, and 16 were performed in 
duplicate and hybridised with the mouse probes AlO and 2D6 
in the same way as in section 3.2.4. The results (figure 
4.8) show that the AlO probe (5' half of the mouse gene) 
hybridised to subclones C P U  and CP12, and the 2D6 probe (3' 
half of the mouse gene) did not hybridise to any of the 
subclones.
At this stage the subcloning procedures were repeated 
another four times in order to try and isolate subclones 
which would hybridise to the 2D6 probe. In spite of the fact 
that over 50 further subclones were obtained, none showed 
any hybridisation to the 2D6 probe.
As the subclones C P U  and CP12 appeared to be the same size 
(figure 4.7), only C P U  was studied further. A large scale 
plasmid DNA preparation was performed (section 2.5.1) and 
the DNA digested with EcoR I in order to determine the size 
of the cDNA insert. The EcoR I digestion resulted not in the 
cutting out of the insert as expected, but in the 
linearisation of the plasmid, indicating the loss of one 
EcoR I recognition site (this was also the case for the 
subclone CP12). The plasmid was then digested with a variety 
of enzymes in order to discover if any other of the pUC18 
cloning sites remained. The results (figure 4.9) showed that 
the Xba I recognition site in the cloning site region could 
be used in conjunction with EcoR I in excising the cDNA 
insert from subclone CPU. The size of the plasmid was 
determined to be approximately 3.5Kb, the cDNA insert being
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2 # 2 #  # 
3 » » #  3 e  #
A B C D
#  #
,  4 •  t* •
Hybridised with- AlO 2D6
f
KEY:
A1 = plasmid pAlO A3 = subclone pCP5
B1 = plasmid p2D6 B3 = subclone pCP6
Cl = plasmid pUC19 C3 = subclone pCP8
D1 = X DNA D3 = subclone pCPll
A2 = subclone pCPl A4 = subclone pCP12
B2 = subclone pCP2 B4 = subclone pCP16
C2 = subclone pCP3 C4 = 0-gal* control
D2 = subclone pCP4
Figure 4.8: DNA Dot Blots of Agtll subclones hybridised against the mouse probes AlO and 2D6.
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KEY
Xba I
PstIPsM
Pvu II 
EcoR i V
Pvu I - /
pCPîl
M = X Hind III marker fragments
A = Uncut pCPll DNA
B = Pvu II F = EcoR I, BamH I
C = Pst I G = EcoR I, Sst I
D = EcoR I H = EcoR I, Kpn I
E = EcoR I, Xba I I = EcoR I, Sma I
(The sizes of the X^NA, Hind III fragments are 
as in figure 3.2)
Figure 4.9: A gel showing the DNA fragments produced by cutting the subclone CPU with various 
restriction enzymes, along with a preliminary restriction map of CPU.
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0.8Kb. The restriction fragments produced by the enzyme Pst 
I indicated that there was a recognition site for Pst I 
within the cDNA insert approximately 600bp from the Xba I 
cloning site (figure 4.9). The restriction map deduced from 
the published sequence of the human GPX cDNA (Sukenaga et 
al, 1987) shows a Pst 1 recognition site at a position 550bp 
from the 3 * end of the cDNA, so it seemed at this point that 
the cDNA insert in subclone C P U  was the 3' half of the 
human GPX cDNA.
4.3 Restriction Enzyme Mapping and Southern Blotting of 
Subclone C P U
As previously mentioned, the sequence of the human GPX cDNA 
had recently been published (Sukenaga et al, 1987) and a 
restriction map of the cDNA had been produced from this 
sequence using the Microgenie™ software on the Olivetti M24 
PC. The following section describes the restriction mapping 
experiments performed on the subclone CPU, and compares the 
restriction map obtained with the deduced restriction map of 
the human GPX cDNA.
4.3.1 Southern Blotting of Subclone C P U
In order to confirm the absence of any sequence with 
homology to the mouse probe 2D6 within the cDNA insert a 
southern blot was performed. C P U  DNA was cut with a variety 
of restriction enzymes and the fragments
electrophoresed on a 2% agarose gel for 3 hours at 100mA 
using the ERL model H5 apparatus. After staining with 
ethidium bromide the gel was photographed (figure 4.10) and 
the fragments transferred to Hybond N nylon membrane 
(Amersham) by Southern Blotting (section 2.15.1). lOOng of 
the mouse probe AlO was labelled with lOOjitCi ^^ P dCTP by 
nick translation (section 2.14.1) and used to probe the
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KEY:
Ml = X Hind III marker fragments 
M2 = 0X174 Hae III marker fragments 
A = Uncut pCPll DNA 
B = pUC19, EcoR I cut 
C = CPU, EcoR I cut 
D = CPU, EcoR I,Xba I 
E = CPU, Pst I 
F = CPU, Nar I 
G = CPU, Pvu II 
(The sizes of the marker fragments are shown in figures 3.2
and 4.12 respectively)
Figure 4.10: The Southern Blotting gel of subclone CPU
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SOUTHERN BLOTS OF SUBCLONE pCP11
SIZE OF 
DNA (Kb)
23-
4-
29-
2 -
M- 
0 9-
0’6--
5
X
-CCoc ,
X
to C5 >
HYBRIDISEDWITH:- A10 206
Xba I
PstIPstI
Pvu II 
EcoR iV
Pvu II-/
pCPîl
Hybridises to AlO
Figure 4.11: Autoradiographs of the Southern Blotting gel of CPU probed with the mouse probes 206 and 
AlO, along with a restriction map of CPU showing the sequence to which probe AlO hybridises
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filter, hybridisation and washing steps were carried out as 
detailed in section 2.16 and the stringent washing step was 
2x 45 minutes at 55°C in O.lx SSC. After developing the 
autoradiograph the probe was removed from the filter 
(section 2.15.5) and the filter probed with the mouse probe 
2D6 in the same way. The resulting autoradiographs (figure 
4.11) show that there are no fragments of the cDNA which 
hybridise to the mouse 2D6 probe under these conditions. The 
hybridisation signals at the top of the gel on the 2D6 
autoradiograph appeared to be no more than non-specific 
binding signals. The restriction enzyme Pst I cuts the cDNA 
insert at approximately 2/3rds of it's length (section 
4.2.4) and the AlO autoradiograph shows hybridisation to 
both fragments, indicating that the whole of the cDNA insert 
contains sequence homologous to the mouse AlO probe. A 
summary of this information in the form of a restriction map 
is also shown in figure 4.11.
4.3.2 Restriction Enzyme Mapping of Subclone C P U
Using the restriction map of the human GPX cDNA, and a 
restriction map of pUC19, restriction enzymes were chosen 
which had recognition sites within the GPX cDNA yet few 
sites within pUC19. Restriction enzyme digests were set up 
as shown in tables 4.3,4.5,4.7, and 4.9. The resulting DNA 
fragments were electrophoresed on 2% agarose gels, stained 
and photographed as before. The gels can be seen in figures 
4.12,4.13,4.14, and 4.15 along with the semi-log plots of 
distance from the origin vs size of the DNA marker fragments 
which were drawn for each gel. The sizes of the restriction 
fragments on each gel were estimated using the semi-log 
plots, these are shown in tables 4.4,4.6,4.8, and 4.10.
A restriction map of subclone C P U  was compiled from this 
information, this is shown in figure 4.16. It was apparent 
that the cDNA insert in C P U  had a different restriction map 
than that of the human GPX cDNA, to illustrate this
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Table 4.3: Components of restriction enzyme digests in mapping experiment A
COMPONENT
Ml
M2
pUC18
CPll,l/xg/Ml
React^” 2
T^M
React 1 
E19 
HgO 
Xba I 
Bgl I 
Pvu II 
EcoR I 
Nar I 
Rsa I
RESTRICTION ENZYME DIGESTS 
Ml 1 2 3 4 5 6 7 8  M2
- - 2 2 2 2 2 2 2 -  
- 2  2 2 2 2 2 -  - -
18 16 15 14 14 14 15 15 15 18 
- - - - - - - - 1 -
KEY:
Ml = DNA cut with Hind III M2 = 0X174 cut with Hae III
1 = pUC18 EcoR I 5 = Xba I, EcoR I
2 = Pvu II 6 = Bgl I
3 = Pvu II, Xba I 7 = Nar I
4 = Pvu II,EcoR I 8 = Rsa I
The numbers represent quantity of component added in /xl.
Table 4.4: Sizes of DNA fragments obtained from mapping experiment A 
ENZYME______________FRAGMENT SIZES (bp)
pUC18 EcoR I 
Uncut C P U  
Pvu II, Xba 
Pvu II,EcoR 
Xba I, EcoR 
Bgl I 
Nar I 
Rsa I
2,700
uncut
2,200/660/345
2,200/770/185
2,400/820
uncut
uncut
1,750/670/515/340
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Ml 1 2 3 4 5 6 7 8 M2
■ . -i - i
(See table 4.3 for key. Sizes of the XDNA, Hind III marker 
fragments are as in figure 3.2)
D
1/1
10 20 30 40 50 60 70 80
Distance Travelled (mm)
Figure 4.12: Restriction mapping gel A and the graph of distance from origin vs size of fragment used in
the determination of fragment sizes (semi-log plot)
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Table 4.5: Components of restriction digests in mapping experiment B
COMPONENT
Ml
M2
CPll,lMg/Atl
E2
React^” 2
E6
E8
E9
HgO
Sph I 
Hind III 
Nco I 
Acc I 
EcoR I 
Hae II 
Xho I 
Ava II 
Tag I 
Ssp I
RESTRICTION ENZYME DIGESTS 
Ml 1 2 3 4 5 6 7 8 9 10 11 M2
2 - -  -  -  - -  - -  - -  - -
- - - - - - - - - - - - 2
- 2 2 2 2 2 2 2 2 2 2 2 -
—  —  —  —  2 2 2 2 2  —  2 2  —
18 15 15 15 15 14 15 14 15 15 15 15 18
- - - - - - 1 1 - - - - -
mam #»» mm mm
- - - - - - - - - - - 1 -
KEY:
Ml = X DNA cut with Hind III
1 = Sph I
2 = Xho I
3 = Nco I
4 = Acc I
5 = Acc I, EcoR I
6 = Hae II
M2 = 0X174 cut with Hae III
7 = EcoR 1, Hae II
8 = Hind III
9 = Ava II
10 = Tag I
11 = Ssp I
The numbers represent guantity of component added in /xl.
Table 4.6: Sizes of restriction fragments obtained from mapping experiment B
ENZYME FRAGMENT SIZES (bp)
Sph I 
Xho I 
Nco I 
Acc I
Acc I, EcoR I 
Hae II
EcoR I, Hae II 
Hind III 
Ava II 
Tag I 
Ssp I
uncut
uncut
uncut
partial digest. 3,500 
partial digest. 3,500/2,300/485 
2,200/2,050/800/470/380/310/185 
2,050/550/380/310/235/185
3.500
partial digest. 3,500/2,400/2,100/1,600 
1,600/1,200/800/160
3.500
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(See table 4.5 for key. Sizes of the XDNA, Hind III and 
0X174 DNA, Hae III marker fragments are as in figures 3.2
and 4.12 respectively)
a
00
10 20 30 40 50 60 70 80
Distance Travelled (mm)
Figure 4.13: Restriction mapping gel B and the graph of distance from origin vs size of fragment used in
the determination of fragment sizes (semi-log plot)
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Table 4.7: Components of restriction enzyme digests in mapping experiment C
COMPONENT Ml
RESTRICTION ENZYME DIGESTS
8 10 11 12 M2
Ml
M2
CPll,l/ig//xl
E8
E9
React™ 6
_ T^M ,
React 4 
React™ 2
HgO
Xba I 
Hae II 
Tag I 
Ava II 
Pvu II 
EcoR I 
Pst I 
Apa I
- 2 2 2 2 2 2 2 2 2  
—  —  1 1  —  2 2 2 1  —
: 2 ~i 1 I - - - - -
-  -  -  2
2 2 2 -
1 —  —  —
1 2 - -
—  —  —  —  —  —  —  —  —  —  —  —  1 —
18 15 14 14 14 15 14 14 14 15 14 15 15 18
—  —  —  —  —  1 1 1 1  —  —  —  —  —
- 1 1 1 1 - - - - - - - - -
-  -  -  -  1 -
KEY:
Ml = X DNA cut with Hind III
1 = Pvu II
2 = Pvu II, EcoR I
3 = Pvu II, Xba I
4 = Pvu II, Pst I
5 = Hae II
6 = Hae II, EcoR I
M2 = 0X174 cut with Hae III
7 = Hae II, Xba I
8 = Hae II, Pst I
9 = Tag I
10 = Tag I, EcoR I
11 = Ava II
12 = Apa I
The numbers represent guantity of component added in jitl.
Table 4.8: Sizes of restriction fragments produced from mapping experiment C
ENZYMES FRAGMENT SIZES
Pvu II 2,250/750/340
Pvu H r EcoR I 2,250/750/200
Pvu H r Xba I 2,250/660/360/160
Pvu H , Pst I 2,250/530/360/180/145
Hae II 1,900/760/475/385/320/200
Hae H r EcoR I 1,900/540/395/330/260/2 00
Hae H r Xba I 1,900/7 60/385/220/200/160
Hae II, Pst I 1,900/550/385/245/200/170
Tag I 1,500/1,150/740/190
Tag Ir jEcoR I 1,500/740/650/450/180
Ava II uncut
Apa I 3,500
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(See table 4.7 for key. Sizes of the XDNA, Hind III and 
0X174 DNA, Hae III marker fragments are as in figures 3.2
and 4.12 respectively)
a
6040 5020 3010
Distance Travelled (mm)
F i g u r e  4 . 1 4 :  R e s t r i c t i o n  m a p p i n g  g e l  C  a n d  t h e  g r a p h  o f  d i s t a n c e  f r o m  o r i g i n  v s  s i z e  o f  f r a g m e n t  u s e d  i n
t h e  d e t e r m i n a t i o n  o f  f r a g m e n t  s i z e s  ( s e m i - l o g  p l o t )
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Table 4.9: Components of restriction enzyme digests in mapping experiment D
COMPONENT
Ml
M2
C P U , ljLig//xl 
React^” 2 
React^” 6
_TM
React 1
E9
HgO
Xba I 
Tag I 
Hae II 
Pvu II 
EcoR I 
Pst I 
Rsa I
RESTRICTION ENZYME DIGESTS 
Ml 1 2 3 4 5 6 7 8 9 10 11 12 M2
2 - - - - - - - - - - - - -
- - - - - - - - - - - - - 2
- 2 2 2 2 2  2 2 2 2 2 2 2 -
- - 1 1 1 - 1 1 1 2 1 - 1 -
- - - - - 2 1 1 1 - - - - -  
—  2 1 1 1 —  —  —  —  —  —  1 1 —
18 15 14 14 14 15 14 14 14 15 14 14 14 18
- 1 1 1 1 - - - - - - 1 1 -
-  - - - - - - - - - 1 1 - -
- - - - - 1 1 1 1 - - - - -
KEY:
Ml = X DNA cut with Hind III 
1 = Tag I
EcoR I 
Xba I 
Pst I
= Tag I, 
= Tag I, 
= Tag I, 
= Rsa I 
— Rsa II EcoR I
M2 = 0X174 cut with Hae III
7 = Rsa I, Xba I
8 = Rsa I, Pst I
9 = Pst I
10 = Hae II, Pvu II
11 = Tag I, Pvu II
12 = Hae II, Tag I
The numbers represent guantity of component added in /il.
T a b l e  4 . 1 0 :  S i z e s  o f  r e s t r i c t i o n  f r a g m e n t s  p r o d u c e d  f r o m  m a p p i n g  e x p e r i m e n t  D
ENZYMES FRAGMENT SIZES
Tag I 1,400/1,100/720/180
Tag I, EcoR I 1,400/720/600/430/180
Tag I, Xba I 1,400/1,100/720/180
Tag I, Pst I 1,400/720/720/335/180
Rsa I 1,750/63 0/510/330/13 0
Rsa I, EcoR I 1,750/630/510/330/13 0
Rsa I, Xba I 1,750/640/330/275/245
Rsa I, Pst I 1,750/640/280/235/215/160/13 0
Pst I 2,800/520
Hae II, Pvu II 2,2 00/380/365/350/250/2 00
Tag I, Pvu II 1,650/670/500/350/280/190/160
Hae II, Tag I 1,500/800/600/245/200/170/160
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4 f
(See table 4.9 for key. Sizes of the XDNA, Hind III and 
0X174 DNA, Hae III marker fragments are as in figures 3.2
and 4.12 respectively)
e
a
<zo
In
0
10 20
Oisfance Travelled (mm)
30 40 50 60 70
F i g u r e  4 . 1 5 :  R e s t r i c t i o n  m a p p i n g  g e l  D  a n d  t h e  g r a p h  o f  d i s t a n c e  f r o m  o r i g i n  v s  s i z e  o f  f r a g m e n t  u s e d  i n
t h e  d e t e r m i n a t i o n  o f  f r a g m e n t  s i z e s  ( s e m i - l o g  p l o t )
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RH
lacZ
rp
pCP11 
3-5 Kb 
AmpR
KEY:-
E = EcoR I 
H = Hae D 
Ps= Psf I 
Pv= Pvu n 
R = Rsa I 
T = Taq I 
)< == >(ba I 
Xh= Xho I
p=universal primer 
rp= reverse primer 
mm = cDNA insert
F i g u r e  4 . 1 6 :  R e s t r i c t i o n  e n z y m e  m a p  o f  S u b c l o n e  C P U
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cnj
E3
X
I bBi--i OMX 
VG nB9-
II nAd- 
I bex-
I Bsy.
I bex 
Id 003-
I JBN-
II bav-
I Bsy
I |6a-
II 9bh
I JBN'
II bav-
I JBN 
I Bdv 
I bBX
I bBX 
I Bsy
I isd 
I bBX
II bav.
' °4X
<
Z
Q
Ü
CL
Ü
cCO
E3
X
Ql
JD
OO
I Bsy
II nAdJ 
I Bsg
I ISd 
ve nBS-
II 9BH
VG nBg-
II B A V
I bBX-
II 9BH
VG MBS-
VG nBS
I Bsy 
I Bdv
F i g u r e  4 . 1 7 :  A  c o m p a r i s o n  b e t w e e n  t h e  r e s t r i c t i o n  e n z y m e  m a p s  o f  t h e  h u m a n  G P X  c D N A  a n d  t h e  C P U  c D N A  i n s e r t
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better figure 4.17 shows a comparison between the two maps. 
There is an Ava II and a Hae II site which are common to 
both maps, and the Pst I sites on each map are almost in the 
same position, but otherwise there is no similarity between 
the two. Also, there are a number of enzymes with 
recognition sites in the human GPX cDNA which do not cut the 
C P U  cDNA insert, namely Nar I, Sph I, Xho I, Nco I, Bgl I, 
Sst I, Kpn I, Sma I, BamH I, Xba I, Acc I, EcoR I, Hind III, 
Ssp I and Apa I. It is apparent from the restriction mapping 
therefore that subclone C P U  does not contain the human GPX 
cDNA.
4.4 Sequencing of the Subclone C P U
It was apparent from the preceding section that the subclone 
C P U  did not contain the GPX cDNA, yet it hybridised 
strongly to the mouse probe AlO. In order to determine the 
relationship between GPX and C P U  the cDNA insert was 
sequenced in the plasmid. One further subclone (CPllPst) was 
produced to enable nucleotides in the middle of the insert 
to be sequenced. To sequence the remainder of nucleotides 
which could not be sequenced from either C P U  or CPllPst 
(using the universal primer and reverse primer) 
oligonucleotides with homology to the C P U  insert were made 
for use as primers. Figure 4.18 shows a summary of the 
sequencing strategy used.
4.4.1 Preparation Of Subclone CPllPst
As can be seen from figure 4.16 there are recognition sites 
for the restriction enzyme Pst I at the cloning region of 
pUC18 (near the Xba I site) and approximately 500bp away 
from the Xba I site in the insert of CPU. 4jLtg of C P U  was 
cut with Pst I and electrophoresed on a 0.8% low melting 
point agarose gel to give two fragments of SOObp and 3,000bp
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m:: C L
CL
O
D)
0)
(Ü
L _  
4— «
co
D)
C
‘üc
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3cr
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LJ
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(N
C L
C L
to
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JD cn
O IX
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II II
F i g u r e  4 . 1 8 :  A  d i a g r a m  i l l u s t r a t i n g  t h e  s t r a t e g y  u s e d  i n  t h e  s e q u e n c i n g  o f  s u b c l o n e  C P U
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KEY:
M = X Hind III marker fragments 
C = pCPll cut with Pst I 
(The sizes of the marker fragments are shown in figure 3.2
F i g u r e  4 . 1 9 :  A  g e l  s h o w i n g  t h e  s u b c l o n e  p C P l I  c u t  w i t h  t h e  r e s t r i c t i o n  e n z y m e  P s t  I
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Table 4.11: Ligation results from the preparation of subclone CPllPst
DNA ENZYME NO OF NO OF EFFICIENCY OF
WHITE BLUE TRANSFORMATION""
*no DNA 
*pUC19,lOng 
pUC19,lOng 
CPll,30ng 
(linear, 3Kb 
fragment)
EcoR I 
Pst I
300
6
117
4.5x105 
9.0x103 
8.8x10^
* = no ligase included in these controls 
= units in cells per /xg of DNA
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(figure 4.19). The 3Kb band was excised from the gel and 
purified using the Geneclean method, with 10/zl of glassmilk 
solution (section 2.3.7). The linear DNA was recovered in a 
final volume of 20/xl distilled water and 3jnl of this was 
taken for ligation. Transformation of competent E.coli TBl 
cells (section 2.10.1) resulted in 117 jS-gal", Amp^ 
recombinant colonies, the results are shown in table 4.11.
A large scale plasmid DNA preparation of one clone (CPllPst) 
was performed (section 2.5.1) and the DNA 
cleaned by multiple ethanol precipitation steps in 
preparation for sequencing.
4.4.2 Sequencing of the pCPll cDNA Insert using the 
Universal Primer and Reverse Primer
DNA sequencing was carried out according to the methods 
detailed in section 2.18. 5jitg of the plasmids C P U  and 
CPllPst were used for each sequencing reaction, C P U  being 
sequenced using both the universal primer and the reverse 
primer while CPllPst was sequenced using only the universal 
primer. In order to read the maximum number of nucleotides, 
two gels per sequencing reaction were run; one "short" gel 
and one "long" gel (see section 2.18.8). Typical examples of 
these gels can be seen in figure 4.20. The sequencing 
reaction using C P U  and the universal primer enabled 278 
nucleotides of the sequence to be read (arrow labelled "P" 
in figure 4.18), while C P U  with the reverse primer enabled 
333 nucleotides to be read (arrow "RP" in figure 4.18). The 
latter sequence was confirmed by reading 316 nucleotides of 
the sequence in the opposite direction, using CPllPst and 
the universal primer (arrow labelled "CPllPst" in figure
4.18).
There were still one or two nucleotides whose identity was 
not completely determined due to compression artefacts in 
the sequencing gels. In order to resolve these, the
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Long" Gel 
UP RP
ATC  G A T C G
z. — ri
- L  w
^  >*>
"Short" Gel
UP RP 
A T C G A T C G
UP=universQl primer 
RP=reverse primer
____W
S
F i g u r e  4 . 2 0 :  A u t o r a d i o g r a p h s  o f  s e q u e n c i n g  g e l s  o b t a i n e d  u s i n g  p C P I I  w i t h  t h e  u n i v e r s a l  p r i m e r  a n d
r e v e r s e  p r i m e r
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sequencing reactions using C P U  with the reverse primer and 
CPllPst with the universal primer were repeated in 
duplicate, one of the duplicates being performed using the 
sequencing solutions from the Sequenase^" kit where dITP had 
been substituted for dGTP. dITP is an analogue of dGTP and 
is incorporated in the same way but affects the conformation 
of the DNA strand differently, hence it is useful in 
resolving compression artefacts caused by GC-rich regions. 
The information from these reactions, together with the 
sequences of the opposite strands, was sufficient to clarify 
the identities of the bases in question.
4.4.3 Sequencing of the C P U  cDNA Insert using Plasmid C P U  
and Internal Oligonucleotide primers
To enable the centre section of the cDNA sequence to be 
read, 17-mer oligonucleotides homologous to the newly 
determined sequence of the insert were made (section 2.13). 
In order to determine the optimum concentration of these 
oligonucleotides for use as sequencing primers, sequencing 
reactions were set up using C P U  with the universal primer 
(as control) and with three different concentrations of the 
oligonucleotide p^ ”^. The resulting autoradiograph can be 
seen in figure 4.21, it is clear from this that lOOpg of 
oligonucleotide produced the best results. (This seems 
excessive, since the recommended amount of universal primer 
is 0.5pg, but the initial measured concentration of the 
oligonucleotide may have been incorrect due to impurities 
interfering with the spectroscopic readings. Or the presence 
of impurities may have rendered some of the oligonucleotide 
molecules unable to successfully hybridise to the plasmid.) 
Hence sequencing was carried out using lOOng of p^ "^ and rp^ i" 
with plasmid CPU, resulting in 292 and 312 nucleotides of 
sequence respectively (arrows labelled p^  and rp^ in figure
4.18). As this left a section of approximately 250
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1 ;
ATCG AT
3
ATCG
PRIMER CONCENTRATION:
1= Ing 
2= lOOpg 
3= Ipg
F i g u r e  4 . 2 1 :  A u t o r a d i o g r a p h  o f  a  s e q u e n c i n g  g e l  i l l u s t r a t i n g  t h e  e f f e c t  o f  c o n c e n t r a t i o n  o f  p r i m e r  o n  t h e  
e f f i c i e n c y  o f  t h e  s e q u e n c i n g  r e a c t i o n  p e r f o r m e d  u s i n g  p C P l I
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PRIMER;-
" Long" Gel 
pTIM ppTIM  
A T C Q A T C G
-  f t
"Short" Gel
pTIM ppT IM  
A T  C G A T C G
4
F i g u r e  4 . 2 2 :  A u t o r a d i o g r a p h s  o f  s e q u e n c i n g  g e l s  o b t a i n e d  u s i n g  s y n t h e t i c  o l i g o n u c l e o t i d e s  a s  p r i m e r s
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nucleotides which had not been sequenced in both directions, 
two further 17-mer oligonucleotides were made (PI and P2, 
see section 2.13). The optimum concentration of these for 
use as primers was determined to be lOOpg as before. 
Sequencing using these oligonucleotides as primers with the 
plasmid C P U  was carried out, resulting in the determination 
of the sequence indicated by arrows "PI" and "P2" in figure 
4.18. Typical autoradiographs of the sequencing gels are 
shown in figure 4.22.
4.4.4 Sequencing Results
The sequence of the C P U  insert was compiled from the above 
information with the aid of the Microgenie software. After 
comparing the sequence with the human GPX cDNA sequence, and 
finding some homology with this (section 4.4.5), it was 
discovered that the cDNA was cloned into pUC18 in the 
opposite orientation than was expected. The sequence, in the 
correct orientation, is shown in figure 4.23. This sequence 
was compared with the mammalian database and no matches were 
found. It was also accepted by the EMBL database 
(Heidelberg) and was therefore assumed to be a novel 
sequence. The sequence has an open reading frame with an AUG 
start codon and a UGA termination codon which is 62 
nucleotides upstream from a polyadenylation signal and so 
would appear to code for a peptide. The predicted amino acid 
sequence is given underneath the sequence and the 
polyadenylation signal is underlined.
4.4.5 Comparison of the C P U  cDNA Sequence with that of the 
Human GPX cDNA sequence
The sequence of the C P U  cDNA insert was compared with the 
human GPX cDNA sequence published by Sukenaga et al, (1987) 
using the Microgenie software. Considerable homology was 
found between the two sequences, the 5' non-coding region of 
C P U  has 53% homology with the 5' non-coding region of the
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human GPX cDNA (figure 4.24), bases 328 to 564 have 82% 
homology with the coding region of exon 1 of the human gene 
(figure 4.25), and the remainder of C P U  has 39% homology 
with the 3' non-coding region of the human GPX cDNA (figure 
4.26). This relationship is illustrated in figure 4.27, and 
indicates a close relationship between the human GPX gene 
and CPU. In the light of this, and the fact that the 
sequence appears to code for a peptide, the C P U  cDNA was 
renamed Glutathione Peroxidase-Related Peptide, GPRP.
As the sequence homology between GPX and GPRP is so high it 
was anticipated that they would cross-hybridise in 
hybridisation experiments when looking at the levels of GPX 
mRNA expression in clinical samples. Hence experiments were 
needed in order to determine the extent of cross­
hybridisation and develop probes which would be specific for 
either GPRP or GPX.
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TCTAGACTAATTAAGAAACGGTTGAGTAAGACAGAGCTGGAAGATCCCCGCCTAAGCAAG 6 0 
CAGCTTCCTTCCAGACTAGTGCTACAGGAGCTAGACCAGACCCGCCCTAGGCACCTCCAG 12 0 
GCGCTTTAGCCCGGCCGCACCCTCTTCCCTGTTCCTCGATGGGGGGCGGGTAGAGGCCGG 180 
ATAAGGCGGGACCCTGAGACTTAGAGCTGGCTGCCAGCGGAAAGAAAGCGATGCCACGTG 240 
ATCTCAGCACCATCCAGTTAAAAGGAGGTGCAGGGCCCTGTGAGCGCTAGTACGGATTCC 300 
ACGTTTGAGTCCCAACATCTCCAGTATGTGTGCTGCTCGGCTCTCCGCGGCGGCACAGTC 3 60
M C A A R L S A A  A Q S  
CACCGTGTATGCCTTCTCCGCGCGCCCGCTGACGGGCGGGGAGCCTGTGAGCCTGGGCTC 42 0 
T V Y A F S A R P L T G G E P V S L G S  
CCTGCGGGGCAAGGTGCTGCTCATTGCGCCTGTCGCGTCTCTCTGAGGCACCACGATCCG 480 
L R G K V L L I E N V A S L * G T T I R  
GGACTACACCGAGATGAACGATCTGCAGAAGCGTCTGGGACTGGTGGTGCTCGGTTTCCC 540 
D Y T E M N D L Q K R L G L V  V L G F P  
GTGCAATCAGTTCGGACACCAGGTATATGGGGCGAGATGGGTGGCCTTGGGCTCTAGGCT 600 
C N Q  F G H Q V Y G A R W V A L G S R L  
CCCACGGGCGGGACACCGCTTACTTTCTCCTCTGGTACTACAGCTGGAATGCAGGCCTAT 660 
P R A G H R L L S P L V L Q L E C R P I  
CCTCGGTTATACAAGGAGGGCAACTTCCTGGTGACTCATCGGGAAACCTCTGTTTTACAG 720 
L G Y T R R A T S W  End 
TTAAAAAGTACATTCTTTCCGAAATCCTAGCACATAAATAAATGCCTTTGTCTTCCCTAG 780 
GAGAATGGCAAGAATGAAGAGATTCTGA 808
* = Selenocysteine
F i g u r e  4 . 2 3 :  T h e  n u c l e o t i d e  s e q u e n c e  o f  C P 1 1  c D N A ,  a l o n g  w i t h  t h e  p r e d i c t e d  a m i n o  a c i d  s e q u e n c e  
C P U  cDNA 1 GGTTGAGTAAGACAGAGCTGGAAGATCCCCGCCTAAGCAAG
I I I I  I I I  m i l l  I II
GPX cDNA 1 CCTCGAGGGGCCCAGCCTTGGAAGGGTAACTGGACCGCTGC
CAGCTTCCTTCC AGACTAGTGC TACAGGAGCTAGACCAGACCCGCCCTAGGCACCTCC
I I I  I I I  I I I I  I I I I  I I I I I  I n i l  I I
CGCCTGGTTGCCTGGGCCAGACCAGACATGCCTGCTGCTCCTTCCGGCTTAGG AGGAGC 
AGGCGCTTTA GCCCGGCCGCACCCTCTTCCCTGTTCCTCGATGGGGGGCGGGTAGAGGC
I I I I  I I I  i l l  M i l l  I I I  I I I  M i l l  I I I  I I  I I I I  M l  I
A CGCGTCCCGCTCGGGCGCACTCTCCAGCCTTTTCCTGGCTGAGGAG GGGCCGAGCC 
CGGATAAGGCGGGACCCTGAGACTTAGAGCTGGCTGCCAGCGGAAAGAAAGCGATGCCA
I I I I  M M M  I I  I I  I I  I I I  M M M  I M i l l
TCCGGTAGGGCGGGGGCCGGATGAGGCGGGACCTCAGGC CCGGAAAACTGCCTGTGCCA 
CGTGATCTCAGCACCATCCAGTTAAAAGGAGG TGCAGG GCCCTGTGAGCGCTA
M i l l  I I I I I  M M M M M M M I  M l  I I  M M  I I  M l
CGTGA CCCGCCGCCGGCCAGTTAAAAGGAGGCGCCTGCTGGCCTCCCCTTACAGTGCTT 
GTAC GGATTCCACGTTTGAGTC CCAACATCTCCAGT 327
I I  I I I  I I I  I I I I  M l  I I
GTTCGGGGCGCTCCGCTGGCTTCTTGGACAATTGCGCC 318
F i g u r e  4 . 2 4 :  C o m p a r i s o n  b e t w e e n  t h e  5 '  n o n - c o d i n g  r e g i o n s  o f  C P U  a n d  t h e  h u m a n  G P X  c D N A
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C P U  cDNA 
GPX cDNA
328
319
ATGTGTGCTGCTCGGCTCTCCGCGGCGGCACAGTC
M I I M M I I I I I I I M  I M M  I I I I
ATGTGTGCTGCTCGGCTAGCGGCGGCGGCGGCCCA
CACCGTGTATGCCTTCTCCGCGCGCCCGCTGACGGGCGGGGAGCCTGTGAGCCTGGGCTC
I M M M M M M M  M M M M I  I I  I I I I I I I 1 1 1 I I I I I I 1 1 I I I I I I I 1 1
GTCGGTGTATGCCTTCTCGGCGCGCCCGTTGGCCGGCGGGGAGCCTGTGAGCCTGGGCTC
CCTGCGGGGCAAGGTGCTGCTCATTGCGCCTGTCGCGTCTCTCTGAGGCACCACGATCCG
M M M M M M M I  I I  I I  I I  I I M l  M i l l  M M M M M M M I  M M
CCTGCGGGGCAAGGTACTACTTATCGAGAATGTGGCGTCCCTCTGAGGCACCACGGTCCG
GGACTACACCGAGATGAACGATCTGCAGAAGCGTCT GGGACTGGTGGTGCT
GGACTACACCCAGATGAACGAGCTGCAGCGGCGCCTCGGACCCCGGGGCCTGGTGGTGCT 
CGGTTTCCCGTGCAATCAGTTCGGACACCAG 564
M l  M M M M M I  M i l l  I I  I I  M l
CGGCTTCCCGTGCAACCAGTTTGGGCATCAG 564
F i g u r e  4 . 2 5 :  C o m p a r i s o n  b e t w e e n  b a s e s  3 2 8 - 5 6 4  o f  C P U  a n d  t h e  c o d i n g  r e g i o n  o f  e x o n  1 o f  t h e  h u m a n  G P X  g e n e .
C P U  CDNA 
GPX cDNA
565 GTATATGGGCGAGATGGGTGCCTTGG GCTCTAG GCTC
I I I  I I  M i l l  I I I I  I I I
925 GGCGCCCCTCCTACCCCGGCTGCTTGGCAGTTGCAGTGCTG
C CACGGCGGGACACCGCTTAGTTTCTCCTCTGGTACTACAGCTGGAATGCAGGCCTAT
I I I I  I I I  I I I I I I  I I I  I I I I I  I
CTGTCTCGGGGGGGTTTTCATCTATGAGGGTGTTTCCTCTAAACCTACGAGGGAGGAACA
CCTCGGTTATACAAGGAGGGCCAACTTCCTGGTGACTCATCGGGAACCTCTGTTTTGCAGT
M l  I I M M  I M l  I !  I I I  M l  I I M l
CCTTGATCTTACAGAAAATACCACCTCGAGATGGGT GCTGG TCCTGTTGATCCCAG 
TAAAAAGTACATTCTTTCCGAAATCCTAGCACATAAATAAA TGCC TTTGTCTTCCCTAG
I I I I  M l  I I M l  I M M M  M M  M M  I
TCTCTGCCAGA CCAAGGCGAGTTTC CCCAC T AATAAAGTGCCGGGTGTCAGCA 113 
GAGAATGGCAAGAATGAAGAGATTCTGA 808
F i g u r e  4 . 2 6 :  C o m p a r i s o n  b e t w e e n  b a s e s  5 6 5 - 8 0 8  o f  C P U  a n d  t h e  3 '  n o n - c o d i n g  r e g i o n  o f  t h e  h u m a n  G P X  c D N A
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F i g u r e  4 . 2 7 :  A  d i a g r a m  t o  i l l u s t r a t e  t h e  r e l a t i o n s h i p  b e t w e e n  G P R P  a n d  G P X  c D N A  s e q u e n c e s
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Chapter 5
Determination of the Suitability of the Human GPRP cDNA and 
the Human GPX gene for use as Hybridisation Probes
It had become apparent from other work in this laboratory 
(Dr David Howells, unpublished results), and from the 
comparison of the nucleotide sequence of GPRP with that of 
the human GPX gene (chapter 4), that attempts to investigate 
the expression of the human GPX gene and the extent of any 
polymorphism it may have in various clinical conditions 
would be complicated by cross-hybridisation occurring 
between these two genes. This chapter details the 
experiments performed in order to determine the extent of 
cross-hybridisation which occurs between GPRP and GPX, and 
to find a solution to this problem.
These experiments were performed before it was 
discovered that GPRP was an artefact. As GPRP is in fact a 
fragment of the mouse glutathione peroxidase gene, some of 
the following experiments were unnecessary. These results 
have not been excluded as a discussion of these, in the 
light of the new evidence, has been included in chapter 7.
5.1 Experiments Utilising the Whole of the GPRP cDNA and 
the GPX gene as Hybridisation Probes
It was decided that, in order to be able to investigate any 
polymorphisms in the human GPX gene, it would be desirable 
to have the whole of the human GPX gene for use as a 
hybridisation probe. The following experiments were 
performed in order to discover to what extent the GPX gene
— 200 —
cross-hybridised with GPRP, and also whether the specificity 
of the GPX gene as a probe could be restricted to that of 
hybridisation with the GPX gene only by altering the 
stringency of the washing conditions employed in the 
hybridisation experiments.
5.1.1 Preparation of Full Length GPX and GPRP Hybridisation 
Probes
The plasmid pCPll contains the 0.8 Kb cDNA fragment GPRP 
which can be excised using the restriction enzymes EcoR I 
and Xba I (figure 5.1). 10 /xg of pCPll were cut overnight 
with these enzymes and the resulting digest electrophoresed 
on a 0.8% low melting point agarose gel, this gel can be 
seen in figure 5.3. The 0.8 Kb bands were excised and the 
DNA purified using the Geneclean method (section 2.3.7), 
this resulted in 20/xl of DNA solution at a concentration of 
approximately 100ng//xl.
The human GPX gene was contained within the 3.3Kb genomic 
insert in the plasmid pGP71. A restriction enzyme map of the 
human GPX gene, deduced from the published nucleotide 
sequence (Ishida et al, 1987), indicated that there were 
recognition sites for the restriction enzyme Xho I in the 5' 
and 3' flanking regions of the gene. These are shown in 
figure 5.2, it can be seen that this enzyme excises 1.3 Kb 
of the 1.7 Kb human GPX gene from the plasmid pGP71. 20fig of 
pGP71 were digested with the enzyme Xho I overnight and the 
digest electrophoresed on a 1% low melting point gel, this 
gel is shown in figure 5.4. The 1.3 Kb band was excised and 
the DNA extracted from this by the cold phenol method 
(section 2.3.6), resulting in a DNA solution of 
approximately 100ng//xl.
lOOng of these isolated DNA fragments were labelled with 
lOOjLtCi of a-32p dCTP by nick translation (section 2.14.1) 
for each hybridisation experiment that was undertaken.
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lacZ
3'probe
pCP11
35Kb
AmpR
p =universal primer 
rp=reverse primer 
= cDNA inserf
KEY:- 
E = EcoR I 
H = Hoe D 
F^= Psf I 
Pv= Pvu n 
R = Rsa I 
T = Taq I 
X = Xba I 
yh= Xho I
F i g u r e  5 . 1 :  A  r e s t r i c t i o n  e n z y m e  m a p  o f  p C P l I  s h o w i n g  t h e  G P R P  i n s e r t
APv.
RPf
pGP71
60Kb
Amp” y probe
LacZ
RBg
p- 
RPx 
A = 
00= 
eq-- 
£ = 
H = 
Pi~ 
Pvz 
R: 
X = 
Xh =
txiiversal primer 
universal reverse primer 
Apa I 
BamH 1 
Bgl I 
EcoR I 
HiodB 
Pst I 
Pvu I 
Rsa I 
XbQl 
Xtvsl
- «human genomic DMA insert 
3=GPX gene
F i g u r e  5 . 2 :  A  r e s t r i c t i o n  m a p  o f  p G P 7 1  s h o w i n g  t h e  X h o  I f r a g m e n t  c o n t a i n i n g  t h e  h u m a n  G P X  g e n e
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A B C D
KEY:
M = X Hind III marker fragments 
a-d = pCPll, EcoR I and Xba I cut 
(The sizes of the marker fragments are shown in figure 3.2.)
F i g u r e  5 . 3 :  A  g e l  s h o w i n g  t h e  0 . 8  K b  G P R P  i n s e r t  e x c i s e d  f r o m  t h e  p C P l I  p l a s m i d
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IP
KEY:
M = X Hind III marker fragments
G = pGPVl, Xho I cut
(The sizes of the marker fragments are shown in figure 3.2.)
F i g u r e  5 . 4 :  A  g e l  s h o w i n g  t h e  1 . 3  K b  G P X  f r a g m e n t  e x c i s e d  f r o m  t h e  p G P 7 1  p l a s m i d
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the fragment from pGP71 is referred to as the GPX probe and 
the fragment from pCPll is referred to as the GPRP probe.
5.1.2 Use of the GPX and GPRP probes in Northern and 
Southern Blotting Experimenmts
In order to establish Southern blotting banding patterns for 
the human GPX gene, a Southern blot was performed using 
human genomic DNA isolated from whole blood (section 2.12) 
and a variety of restriction enzymes as in section 2.15.1. 
The resulting filter was hybridised against the GPX probe as 
in the standard hybridisation procedures (section 2.16). The 
washing conditions were as standard and the stringent 
washing step was with O.SxSSC at 55“C for two periods of 10 
minutes each. The autoradiograph can be seen in figure 5.5, 
from this it was apparent that there were more bands seen 
than would have been expected for a single copy gene 
(knowing the restriction enzyme map of the human GPX gene), 
table 5.1 illustrates these findings. A previous Southern 
blot hybridised with the GPRP probe had shown a similar 
banding pattern to that produced when hybridised with the 
GPX probe. These findings indicated that, under the 
hybridisation and washing conditions employed, the GPX and 
GPRP probes are not specific to themselves and cross- 
hybridise with each other. Thus it would be impossible to 
determine a Southern blotting pattern for either of these 
individually under these conditions.
To see whether this would also be the case for experiments 
involving hybridisation to RNA, a Northern blot of control 
rat and human liver total RNA was performed (section 
2.15.2). This was hybridised against the GPX probe and 
washed as above, the resulting autoradiograph can be seen in 
figure 5.6. In spite of the poor quality of the human RNA it 
can be seen that there are two bands which hybridise to the 
GPX probe. Interestingly, there is only one band hybridising 
to the rat liver RNA. These results indicate that in the
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Southern Blot of Human DNA vs Human 
GPX-1 Gene (Xho I fragment)
« C O . -  o c ^ _ _
Size in Kb
23 .36i
2.32
2 . 0 3
0.6
F i g u r e  5 . 5 :  A n  a u t o r a d i o g r a p h  o f  a  S o u t h e r n  b l o t  o f  h u m a n  D N A  d i g e s t e d  w i t h  a  v a r i e t y  o f  r e s t r i c t i o n
e n z y m e s  a f t e r  h y b r i d i s a t i o n  a g a i n s t  t h e  G P X  p r o b e
T a b l e  5 . 1 :  A  t a b l e  s h o w i n g  t h e  s i z e s  o f  t h e  D N A  b a n d s  o b t a i n e d  f r o m  t h e  S o u t h e r n  b l o t  a b o v e  c o m p a r e d  w i t h
t h e  e x p e c t e d  b a n d  s i z e s
ENZYME NUMBER OF NUMBER OF
EXPECTED BANDS BANDS OBSERVED
Apa I 3 5
Sst I 1 4
Xho I 1 2
Kpn I 1 2
Pst I 2 3
Bgl II 1 3
Bgl I 3 3
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Northern Blot of Rat and Human RNA 
vs the Human GPX Gene
Rat Human
f
F i g u r e  5 . 6 :  A n  a u t o r a d i o g r a p h  o f  a  N o r t h e r n  b l o t  o f  c o n t r o l  r a t  a n d  h u m a n  l i v e r  t o t a l  R N A  a f t e r
h y b r i d i s a t i o n  a g a i n s t  t h e  G P X  p r o b e
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human liver RNA there are two mRNA's with sequence homology 
to the GPX gene, it is postulated that one of these is the 
GPRP itiRNA and therefore any experiments performed (under 
these conditions) in order to study the expression of GPX in 
humans would be complicated by it's presence.
5.1.3 An Experiment to Determine Washing Conditions which 
will Allow Discrimination between GPX and GPRP for Future 
Hybridisation Experiments
In order to determine whether the washing conditions could 
be altered so that discrimination between GPX and GPRP could 
be effected, a DNA dot blot filter was prepared which held 
both the plasmids pGP71 and pCPll. Six copies of the filter 
were prepared so that, after hybridisation with the GPX 
probe, they could be washed under different conditions. A 
negative control of X DNA was included (to determine the 
extent of non-specific hybridisation) as was a positive 
control of human genomic DNA (to determine whether these 
conditions would be applicable for Southern blotting 
experiments) . Ijitg each of the plasmids and the X DNA and 
ISjLtg of human genomic DNA were applied to a Hybond N nylon 
filter as in the method (section 2.15.4), ISjitg of genomic 
DNA was used as this was the amount of DNA used in the 
Southern blot experiments. Prior to application onto the 
filter the samples were heated in a boiling water bath for 5 
minutes to ensure dénaturation of the DNA. Hybridisation to 
the GPX probe and the preliminary washing steps were carried 
out as before, the filters were then separated and subjected 
to two 10 minute washes under the appropriate conditions as
follows:
1. 65°C, 0.5XSSC, 0.1%SDS
2. 65°C, O.lxSSC, 0.1%SDS
3. 65°C, 0.05XSSC, 0.1%SDS
4. 60°C, 0.05XSSC, 0.1%SDS
5. 60°C, O.OlxSSC, 0.1%SDS
6. 60°C, O.lxSSC, 0.1%SDS
After rinsing with 5xSSC the filters were air dried and 
autoradiographed for 1 week, the results are shown in figure
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5.7. It can be seen that even under the most stringent 
washing conditions there is still hybridisation between the 
GPX probe and the plasmid containing the GPRP cDNA (pCPll). 
In addition to this, it is obvious that these washing 
conditions are too stringent for use in Southern blotting 
experiments as the hybridisation signal from the human 
genomic DNA was little better than that seen on the non­
specific binding control. Hence it was decided that an 
alternative to the Gp71 Xho I fragment probe would have to 
be found.
5.2 Use of DNA Derived from the 3* Non-coding Regions of 
the Human GPX and GPRP Genes as Hybridisation Probes
The results in the previous section had indicated that the 
whole of the GPX gene would not be suitable for use as a 
hybridisation probe in the experiments we wished to carry 
out. Since the 3' non-coding region of the GPX gene and 
bases 565-808 of the GPRP gene showed least homology 
(section 4.4.5) it was decided to cut out fragments from 
these sections for use as hybridisation probes.
5.2.1 Preparation of 3■ Fragments of the GPX and GPRP genes 
for Use as Hybridisation Probes
The restriction enzymes EcoR I and Pvu II were used to cut 
out a fragment of GPRP 180bp in length from plasmid pCPll 
(figure 5.1), while the restriction enzymes EcoR I and Xho I 
were used to cut out a fragment of the GPX gene 119bp in 
length from plasmid pGP71 (figure 5.2). The digests were 
electrophoresed on 3% Nusieve^” agarose gels (figures 5.8 
and 5.9) and the fragments excised and purified by phenol
- 209 -
1 2 
r -! r n
A #  # B A #  # B
C . D C  n
4
A #  .  ^  B A #  e B
C D C  D
^  - J
5 6
A #  #  B A | #  e B
D C  ^ D
J L_ J
KEY:
A = Ijiq pGPVl 
B = IjLig pCPll 
C = 1/ig X DNA
D = 18/ig Human Genomic DNA
F i g u r e  5 . 7 :  A u t o r a d i o g r a p h s  o f  t h e  D N A  d o t  b l o t  w a s h i n g  e x p e r i m e n t  u s i n g  t h e  G P X  p r o b e :  G p 7 1  X h o  I 
f r a g m e n t  ( s e e  t e x t  f o r  d e t a i l s  o f  w a s h i n g  c o n d i t i o n s  1 - 6 )
- 210 -
F i g u r e  5 . 8 :  A  g e l  s h o w i n g  a  p r e p a r i t i v e  d i g e s t  o f  a  I S O b p  f r a g m e n t  f r o m  t h e  p l a s m i d  p C P l I
119bp
F i g u r e  5 . 9 :  A  g e l  s h o w i n g  a  p r e p a r i t i v e  d i g e s t  o f  a  1 1 9 b p  f r a g m e n t  f r o m  t h e  p l a s m i d  p G P 7 1
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extraction (section 2.3.6). As these fragments were so 
small, 5' end labelling was the method chosen for labelling 
them with radioactivity. A requirement before this method 
can be used is that the DNA has it's 5' phosphate group 
removed in order to free a hydroxyl group to be 
phosphorylated by g a m m a A T P .  This was achieved by adding 
alkaline phosphatase (0.5 units per lOOng) to the completed 
restriction enzyme digest and incubating for a further 1 
hour at 37“C before electrophoresis. In this way only one 
extraction step was needed in the process of preparing DNA 
for labelling and wastage of valuable samples was avoided 
(as opposed to extracting the fragments of DNA from the gel 
first and then performing the alkaline phosphatase treatment 
which requires a further phenol extraction to remove the 
alkaline phosphatase). The DNA fragments were labelled with 
gamma-^^P ATP by 5 ' end labelling (section 2.14.2) and the 
unincorporated nucleotides removed by Nacs columns (section 
2.14.3). The probes derived from the 3' fragments of the GPX 
and GPRP genes will be referred to as 3 'GPX and 3 'GPRP 
respectively.
5.2.2 An Experiment to Determine Whether the Probes 3*GPX 
and 3'GPRP allow Discrimination Between the GPX and GPRP 
genes
The dot blot filters from section 5.1.3 were stripped of the 
GPX probe by the method described in section 2.15.5 and 
autoradiographed for 1 week to check that all the probe had 
been removed. 3 'GPX and 3'GPRP probes were prepared as above 
and each probe used in hybridisation to three of the filters 
as before. The standard preliminary washes were performed on 
the filters (section 2.16.3) and then the filters were 
separated and the following washes performed:
1. 3 'GPX probe, 2x 10 minutes at 40“C in O.lxSSC, 0.1%SDS
2. 3 'GPX probe, 2x 10 minutes at 50“C in O.lxSSC, 0.1%SDS
3. 3 'GPX probe, 2x 10 minutes at 60“C in O.lxSSC, 0.1%SDS
4. 3'GPRP probe, 2x 10 minutes at 40“C in O.lxSSC, 0.1%SDS
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5. 3*GPRP probe, 2x 10 minutes at 50°C in O.lxSSC, 0.1%SDS
6 . 3'GPRP probe, 2x 10 minutes at 60°C in O.lxSSC, 0.1%SDS 
After rinsing in 5xSSC the filters were air dried and 
autoradiographed for 3 days, the results are shown in figure 
5.10. It can be seen that the 3'GPRP did not hybridise at 
all under these conditions, this was probably due to the 
fact that it was not labelled as well as the 3 'GPX probe (a 
specific activity of approximately 2.7x10^ cpm//xg was 
determined for the 3'GPRP probe as opposed to 4.4x10* cpm/jig 
for the GPX probe). The 3 'GPX probe hybridised to both the 
pGP71 and the pCPll plasmids, indicating that even at the 
lower level of homology that exists between the 3' regions 
of the GPX and GPRP genes cross-hybridisation will still 
occur under these conditions. In addition to this there was 
no hybridisation to the human genomic DNA, therefore these 
conditions were unsuitable for use in future experiments. In 
order to discover under what conditions the 3'GPX probe 
would be specific, further stringent washes on these filters 
were carried out as follows:
1. 2x 15 minutes at 70“C in 0.05xSSC,0.1%SDS
2. 2x 15 minutes at 65“C in 0.05xSSC,0.1%SDS
3. 2x 15 minutes at 60°C in 0.05xSSC,0.1%SDS
The results from this are also shown in figure 5.10, it can 
be seen that only under the most stringent washing 
conditions does the 3'GPX probe discriminate between the two 
plasmids. Hence it was concluded that the 3' probes would be 
unsuitable for discrimination between the GPX gene and the 
GPRP gene, or mRNA's in any future experiments.
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F i g u r e  5 . 1 0 :  A u t o r a d i o g r a p h s  o f  D N A  d o t  b l o t s  h y b r i d i s e d  w i t h  t h e  3'  p r o b e s ,  l o w e r  f i l t e r s  1 - 3  r e w a s h e d
a t  h i g h e s t  s t r i n g e n c y  ( s e e  t e x t  f o r  d e t a i l s )
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5.3 Use of Synthetic Oligonucleotides as Hybridisation 
Probes to Discriminate Between the GPX and GPRP genes
As previous attempts to discriminate between the GPX and 
GPRP genes using fragments of these genes had failed, it was 
decided to look for a section of each gene which showed 
minimal homology with the other and make synthetic 
oligonucleotides corresponding to these sections. This 
section shows the origin of the oligonucleotides used and 
describes the experiments performed in order to determine 
whether they were effective for use as hybridisation probes.
5.3.1 Preparation of Synthetic Oligonucleotides for Use as 
Hybridisation Probes
The 3' non-coding region of the GPX gene was compared with 
nucleotides 565-808 of the GPRP gene using the Microgenie 
software on the Olivetti M24 computer. This comparison is 
shown in figure 5.11, the portion showing least homology 
between the two sequences is shown in bold type. The 
sequences from this portion were used for making 
oligonucleotides as described in section 2.13. These 
oligonucleotides were labelled with gamma-^^P ATP by 5' end 
labelling (section 2.14.2) and the unincorporated 
nucleotides removed by Nacs columns (section 2.14.3). The 
resulting probes will be referred to as GPX oligo and GPRP 
oligo.
5.3.2 Preparation of Filters to test the Oligonucleotide 
Probes
In order to determine whether the oligonucleotide probes 
would be suitable for probing Northern Blots, Southern blots 
and RNA dot blots examples of these filters were
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GPRP cDNA 565 GTATATGGGCGAGATGGGTGCCTTGG GCTCTAG GCTC
I I I I I  M i l l  I I I I  I I I
GPX cDNA 925 GGCGCCCCTCCTACCCCGGCTGCTTGGCAGTTGCAGTGCTG
C CACGGCGGGACACCGCTTAGTTTCTCCTCTGGTACTACAGCTGGAATGCAGGCCTAT
I I I I  I I I  I I  I I I I  I I I  I I I I I  I
CTGTCTCGGGGGGGTTTTCATCTATGAGGGTGTTTCCTCTAAACCTACGAGGGAGGAACA
CCTCGGTTATACAAGGAGGGCCAACTTCCTGGTGACTCATCGGGAACCTCTGTTTTGCAGT
I I I  I I M M  I M i  l l  I I I  M l  I I M l
CCTTGATCTTACAGAAAATACCACCTCGAGATGGGT GCTGG TCCTGTTGATCCCAG 
TAAAAAGTACATTCTTTCCGAAATCCTAGCACATAAATAAA TGCC TTTGTCTTCCCTAG
I I I I  M l  I I M l  I M M M  M M  M M  I
TCTCTGCCAGA CCAAGGCGAGTTTC CCCAC T AATAAAGTGCCGGGTGTCAGCA 113 
GAGAATGGCAAGAATGAAGAGATTCTGA 808
F i g u r e  5 . 1 1 :  A  c o m p a r i s o n  b e t w e e n  t h e  3 '  n o n - c o d i n g  r e g i o n  o f  t h e  h u m a n  G P X  g e n e  a n d  b a s e s  5 6 5 - 8 0 8  o f  t h e  
G P R P  g e n e  s h o w i n g  a  s e c t i o n  o f  2 5  n u c l e o t i d e s  w h i c h  h a s  m i n i m a l  h o m o l o g y  b e t w e e n  t h e  t w o  s e q u e n c e s
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prepared in duplicate. Northern blots were prepared using 
two samples of control rat liver RNA and three samples of 
control human liver RNA. 20/ig of each sample were 
electrophoresed on a denaturing gel and a Northern blot 
performed (section 2.15.2). As this filter was to be 
prepared in duplicate, the two sets of samples were
electrophoresed on the same gel and the filter cut in half
to ensure that exactly the same conditions were used for 
both filters.
In the preparation of Southern blots, 7 samples of control 
human genomic DNA were digested with the restriction enzyme 
BamH I and Southern blots performed (section 2.15.1). These 
filters were also prepared in duplicate, the gels being 
electrophoresed in series in order to ensure that the 
conditions were the same for both filters.
Dilutions of 20, 10, 1, 0.1, and 0.01/xg RNA were used for 
the RNA dot blots. The same control rat liver and human
liver RNA samples were used (as for the Northern blot), also
non-specific binding controls of lO/xg and 1/ig were included. 
In addition to the above filters> more DNA dot blots were 
prepared as in section 5.1.3 in order to test the 
specificity of the probes.
5.3.3 Hybridisations using the Oligonucleotide Probes.
Initially the formamide hybridisation conditions employed in 
all the other experiments were used (section 2.16.1). One of 
each of the test filters were hybridised overnight against 
either the GPX probe or the GPRP probe in a total volume of 
100ml hybridisation solution. The specific activities of the 
GPX and GPRP probes were 6.4x10* cpm//xg and 3.0x10* cpm/jLtg 
respectively. The filters were washed three times in 2xSSC,
0.1%SDS at room temperature for 10 minutes then air dried 
and autoradiographed for three days. Under these conditions 
the GPRP probe did not hybridise to any of the filters, this 
may have been due to the decreased specific activity of the 
probe.
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The GPX probe hybridised strongly to the RNA dot blots, and 
the control DNA dots showed that there was hybridisation to 
pGP71 and not pCPll - indicating that the probe is specific 
for GPX. Unfortunately the results (figure 5.12) show that 
the Northern and Southern blots were unsuccessful (despite 
the fact that there is hybridisation to the human genomic 
DNA on the DNA dot blot).
After washing the filters to remove all bound probe the 
experiment was repeated using hybridisation conditions 
tailored for oligonucleotides (section 2.16.2). The specific 
activities of the GPX and GPRP probes were 2. 5x10* cpm//zg 
and 2.6x10^ cpm//ig respectively. The filters were all washed 
for 1 hour at room temperature in 2xSSC,0.1%SDS and then the 
Northerns, Southerns and RNA dots (except the RNA dot blot 
hybridised with the GPRP probe) were washed in 6xSSC,0.1%SDS 
for 30 minutes at 50°C. The DNA test dots were split into 
three groups and washed in 6xSSC,0.1%SDS for 30 minutes at 
30°C, 40°C and 50°C. The RNA dot blot hybridised with the 
GPRP probe was washed for 30 minutes in 6xSSC,0.1%SDS at 
35“C as it seemed to be colder than the other filters after 
the first wash. After air drying the filters they were 
autoradiographed for 5 days. Figure 5.13 shows the 
autoradiographs of filters hybridised with the GPRP probe, 
all the DNA dots appeared exactly the same so only one is 
shown here. It can be seen that, in spite of the low 
specific activity of the probe, the probe has hybridised to 
the plasmid pCPll and not pGP71 and therefore is specific 
for the GPRP gene. Hybridisation can also be seen on the RNA 
dot blots, where the signal is stronger for the human liver 
RNA than for the rat liver RNA. The hybridisation to the 
Northern blots is very faint, there appears to be one band 
on each of the human liver RNA samples but nothing on the 
rat liver RNA samples. Figure 5.14 shows the autoradiographs 
of filters hybridised with the GPX probe, in this case there 
was a difference between the DNA dot filters washed at 50“C
- 219 -
NORTHERN BLOT
RAT HUMAN
RNA DOT BLOT
RAT
DNA DOT BLOT
HUMAN
# •
• •
SOUTHERN BLOT
CPU •
1
QP71
HUMAN
GENOMIC
DNA
X D N A
F i g u r e  5 . 1 3 :  A u t o r a d i o g r a p h s  o f  f i l t e r s  h y b r i d i s e d  a g a i n s t  t h e  G P R P  o l i g o p r o b e  ( s e e  t e x t  f o r  d e t a i l s )
- 220 -
r  O
A B
C D
L À
A ^
C •  . D
L
u
J
r
A ^  B
O o * e _
C #  ' D
J
KEY:
A = 1/xg pGP71 
B = Ijug pCPll 
C = 1/xg X DNA
D = 18/xg Human Genomic DNA
F i g u r e  5 . 1 4 :  A u t o r a d i o g r a p h s  o f  D N A  d o t  b l o t  f i l t e r s  h y b r i d i s e d  a g a i n s t  t h e  G P X  o l i g o p r o b e
- 221 -
and those washed at 30°C and 40°C. The hybridisation was 
specific to the GPX gene as there was no signal for the 
plasmid pCPll, but there is a strong signal from the human 
genomic DNA. This is presumably due to non-specific binding 
as the signal is greater than that for plasmid pGP71 which 
possesses a greater concentration of the GPX gene. The 
Northern, Southern and RNA dot blot filters are not shown as 
they did not have any hybridisation signals at all. Hence it 
is apparent that, while the oligonucleotide probes will 
discriminate between GPX and GPRP, their usefulness as 
probes is limited.
5.3.4 Onblots using the GPX and GPRP oligoprobes
As none of the experiments using the oligoprobes to 
hybridise to Southern blots had been successful, Onblots 
were performed. Restriction enzyme digests of control human 
genomic DNA, digested with a variety of enzymes (Apa I, Ava 
I, Bgl I, EcoR I, Kpn I, Pst I, Sst I, and Xho I) were set 
up in duplicate. The digests were electrophoresed on 
duplicate 1% agarose gels overnight at 30mA and these gels 
used for Onblots (section 2.17). The specific activities of 
the GPX and GPRP probes were 1.0x10^ cpm//xg and 8.3x10^ 
cpm/jLtg respectively. Autoradiography was carried out for 2 
weeks, figure 5.15 shows the resulting autoradiograph. It 
can be seen that the GPRP probe did not work again (probably 
due to the low specific activity of the probe) and while 
there is a signal on the gel probed with the GPX probe it is 
not sufficient to show distinct bands.
The GPX oligonucleotide probe is specific for GPX sequences,
i.e. it will not hybridise to GPRP sequences under the 
conditions employed, but it cannot be used in Northern, 
Southern or Onblots. It will, however, give sufficient 
signals in RNA dot blot experiments and therefore can be 
used in initial studies on levels of GPX mRNA in clinical 
samples.
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similarly, the GPRP oligonucleotide probe is specific for 
the GPRP sequence and can be used in RNA dot blots. As the 
nature of the putative GPRP peptide is unknown, the 
relevance of it's expression in disease states is also 
uncertain. In the light of the fact that there appear to be 
many selenoproteins which could be involved in various 
diseases, the GPRP oligonucleotide probe will also be 
employed in the proposed experiments in order to see if it 
has any relevance in these diseases.
- 223 -
Hybridised with - GPRP oligo GPX oligo
F i g u r e  5 . 1 5 :  O n b l o t s  o f  h u m a n  D N A  d i g e s t e d  w i t h  a  v a r i e t y  o f  r e s t r i c t i o n  e n z y m e s  h y b r i d i s e d  a g a i n s t  t h e
G P R P  a n d  G P X  o l i g o p r o b e s
- 224 -
Chapter 6 
Investigations on the Expression of the GPX and GPRP genes 
in Human White Blood Cells
There are many clinical conditions where altered GPX 
activity levels have been observed (chapter 1 ), yet the 
exact role of GPX in most of these diseases has not been 
ascertained. In many instances the involvement of GPX itself 
is uncertain, especially where GPX alterations have been 
extrapolated from alterations in selenium levels. The use of 
the human GPX gene as a hybridisation probe will enable 
investigation of the role of GPX in various diseases to be 
carried out at the molecular level, i.e. by relating changes 
in GPX activity levels to changes in gene expression. This 
chapter shows experiments which were carried out to 
determine the level of GPX mRNA expression in the white 
blood cells of patients with hyperlipidemia and rheumatoid 
arthritis. This work was carried out in parallel with the 
work from the previous chapter, hence the oligonucleotide 
probes (section 5.3) were not available for use in some of 
the earlier experiments. The recent discovery, that GPRP is 
identical to the mouse glutathione peroxidase gene, however, 
means that there was no requirement for the oligonucleotide 
probes in these experiments, and the results obtained using 
the GPRP oligonucleotide probe against human clinical 
samples are insignificant. The results in this section have 
not been altered as a result of the new information as a 
discussion of the relevant results has been included in 
chapter 7.
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6.1 Experiments to Investigate the Expression of GPX in 
Patients with Hyperlipidemia
It has been postulated that an alteration in GPX levels is 
involved in the aetiology of atherosclerosis (section 
1.3.2). As Patients with hyperlipidemia are considered to be 
at risk for developing cardio-vascular disorders a pilot 
study was set up to determine whether there were any 
abnormalities in the level of expression of GPX in the white 
blood cells of these patients. This section describes the 
methods used for obtaining total RNA from these patients and 
the RNA dot blots performed in this study.
6.1.1 Preparation of RNA from Whole Blood Samples
10 ml blood samples from patients with hyperlipidemia were 
taken into heparinised tubes (Dr Philip Bath, Dulwich 
Hospital, London) and frozen at -20“C within 3 hours. Total 
RNA was prepared (section 2.11.1) and the OD260 and OD280 of 
each sample were measured. A spectroscopic scan between the 
wavelengths of 220nm and 320nm was also performed for each 
sample. This was necessary in order to keep a record of the 
purity of the samples (the size of each sample was too small 
to be able to perform many re-precipitations in order to 
ensure that they were all completely pure) so that this 
information could be used at a later date in interpreting 
results. (It had been noted in preliminary experiments with 
blood samples that RNA preparations contaminated with salts 
could give rise to excessive non-specific binding.) Samples 
of RNA from the blood of control subjects (healthy males and 
females aged between 23 to 32) were prepared in the same 
way. The ratio of OD260/OD280 for the samples ranged from 2.02 
to 3.3, there did not appear to be any significant 
difference between the values of OD260/OD280 obtained for the 
patients and those of the control subjects. Similarly,
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there was no difference in the yields of RNÀ obtained for 
the two groups. Figure 6.1 shows examples of the 
spectroscopic scans obtained from the samples. It can be 
seen that, while many scans show a reasonable peak at 260nm, 
there are some where the 260nm peak is almost completely 
obscured by the absorption peak caused by salt contamination 
of the sample. Samples with particularly bad scans (such as 
that at the bottom of figure 6 .1) were excluded from these 
experiments.
6.1.2 Hybridisation Experiments Using RNA Samples from 
White Blood Cells of Patients with Hyperlipidemia
An RNA dot blot was performed (section 2.15.3) using 1/xg RNA 
samples from 7 Hyperlipidémie patients and 12 control 
subjects. A dot of l/xg yeast tRNA was included on the filter 
as a non-specific binding control. The resulting filter was 
probed with the GPX probe containing the whole of the human 
GPX gene (described in section 5.1.1). After hybridisation 
(section 2.16.1) the filter was washed as in the standard 
method (section 2.16.3), the stringent wash being two 10 
minute washes in 0.IxSSC,0.1%SDS at 65°C. The filter was 
autoradiographed for three days, the results can be seen in 
figure 6.2. There did not appear to be any difference 
between the hyperlipidémie RNA and control RNA samples.
There was a degree of non-specific binding in this 
experiment, as indicated by the hybridisation signal on the 
tRNA control.
The filter was stripped of all hybridising probe (section 
2.15.5) and re-probed with an Actin probe (kindly provided 
by Dr Janet Makowska). As actin is a "housekeeping" protein 
it is assumed that the quantities of actin mRNA will remain 
constant per fig of RNA and therefore an actin probe can be 
employed as a control to ensure that the amounts of RNA 
loaded onto the filter were the same. lOOjig of the probe 
were labelled with 100/xCi of a-^^P dCTP by nick translation
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(section 2.14.1) and hybridisation and washing carried out 
as above, except that the stringent washing step was two 
washes in 0.2xSSC,0.1%SDS at 55°C for 10 minutes. The 
results are also shown in figure 6 .2 , and indicate that 
there is no major difference in the amounts of RNA loaded 
onto each dot. The lack of hybridisation signal on the yeast 
tRNA dot indicated a lack of non-specific binding in this 
experiment.
The filter was stripped of all hybridising probe again and 
re-probed with the GPX oligonucleotide probe which had been 
made in order to combat the effects of cross-hybridisation 
between the GPX and GPRP genes (section 5.3). Hybridisation 
procedures were carried out as in section 2.16.2 and the 
filters were washed in 2xSSC,0.1%SDS at room temperature for 
60 minutes followed by 6xSSC,0.1%SDS at 35°C for 20 minutes. 
The filter was air dried and autoradiographed for 11 days, 
the results are again shown in figure 6.2. As there were no 
pCPll and pGP71 controls on this filter, it cannot be shown 
that the hybridisation signals produced are caused solely by 
hybridisation to the GPX gene, there may be some part of the 
signal attributable to the GPRP gene. However, previous 
experiments with DNA dot blots (section 5.3.3) showed that 
the GPX oligonucleotide probe is specific for the GPX gene 
under these conditions. There was no hybridisation signal 
with the yeast tRNA, indicating that there was no non­
specific binding in this experiment. There were three 
samples that showed an increased hybridisation signal; two 
hyperlipidémie RNA samples and one control RNA sample. The 
spectroscopic scans for these samples were not significantly 
different from the other samples, indicating that the 
increased signals were not likely to be due to a difference 
in sample quality (although this explanation cannot be ruled 
out so additional non-specific binding controls were 
included in further experiments). Yet it is unusual that (on 
the same filter) the experiments with the GPX gene probe and 
the Actin probe did not show a similar difference in
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hybridisation signal for these three samples. As the 
increased signal was not confined to either the control 
group or the hyperlipidémie group, and the complete GPX 
probe did not detect any differences at all, it was 
concluded that there was no significant difference in 
expression of the GPX gene in white blood cells between 
healthy individuals and patients with hyperlipidemia.
6.2 Experiments to Investigate the Expression of GPX in 
Patients with Rheumatoid Arthritis
GPX has been implicated in rheumatoid arthritis by way of 
it's role as an antioxidative defence enzyme and because one 
of the most potent in vitro inhibitors of the enzyme is the 
anti-arthritic drug, D-penicillamine (section 1.3.5). 
Indirect evidence for the involvement of GPX (and of other 
as yet unknown selenoproteins) has come from reports that 
selenium levels in the blood of patients with arthritis are 
decreased. However, some of these reports are controversial 
and remain to be confirmed (section 1.3.5). The following 
chapter details the experiments performed in order to 
investigate whether there was any difference in levels of 
expression of GPX or GPRP in the white blood cells of 
patients with rheumatoid arthritis.
After completion of this thesis it was discovered that 
the GPRP DNA was identical to the mouse GPX gene, this has 
invalidated the results obtained using the GPRP 
oligonucleotide probe. However, the results obtained using 
the GPX gene probe remain unaffected.
6.2.1 Preparation of RNA from Whole Blood Samples of 
Patients with Rheumatoid Arthritis
10 ml blood samples from 44 patients with rheumatoid 
arthritis were taken into heparinised tubes (Dr A.R.Behn, St 
Luke's Hospital, Guildford) and frozen at -20°C within 2
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hours. RNA was prepared and spectroscopic measurements made 
as before (section 6.1.1). Samples of RNA from the blood of 
control subjects (healthy males and females aged between 23 
to 32) were prepared in the same way. The ratio of OD260/OD280 
for the samples ranged from 1.4 to 2.2 (the average value 
being 1.83), there did not appear to be any significant 
difference between the yield of RNA, or the values of 
OD260/OD280/ obtained for the patients and those of the 
control subj ects. Figure 6.3 shows examples of the 
spectroscopic scans obtained from the samples, as before 
there are some scans where the absorption at 260nm is almost 
completely obscured by the absorption peak caused by salt 
contamination of the sample. Samples with particularly bad 
scans (such as that at the bottom of figure 6.3) are 
indicated in the results by an asterisk.
6.2.2 Hybridisation Experiments using RNA Samples from 
White Blood Cells of Patients with Rheumatoid Arthritis
An RNA dot blot was performed (section 2.15.3) using Ifig RNA 
samples from 16 control subjects and 24 patients with 
rheumatoid arthritis. Ifig of yeast tRNA and Ijig of an RNA 
sample which had been treated with RNAase A were included as 
controls for non-specific binding. The RNAase treated sample 
was used as it was thought that contamination of the RNA 
samples may cause spurious results with some probes (see 
results in section 6.1.2). Also included on this filter were 
Ifig dots of the pCPll and pGP71 plasmids as controls for the 
specificity of the GPX and GPRP probes. The filter was 
hybridised against the whole human GPX probe and washed as 
in section 6.1.2, the resulting autoradiograph (after 4 days 
exposure) is shown in figure 6.4. The controls of the pCPll 
and pGP71 plasmids were cut away from the rest of the filter 
and only exposed for 1 day as they were giving off such 
strong signals that they might have interfered with the rest
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of the signals on the filter. The results on this 
autoradiograph appeared to indicate that all the patient's 
samples had a greatly decreased level of GPX mRNA. There was 
no signal on the tRNA control but a weak signal appeared on 
the RNAase treated control, indicating that weak non­
specific binding was occurring. In many of the patient's 
samples the signal was no greater than that of the RNAase 
control. However, three weak signals (underlined in the 
autoradiograph) appeared where no RNA samples had been 
applied. This could only be explained by assuming that the 
dot blot apparatus was not cleaned thoroughly after it's 
last use, or the cassette in which the filter was 
autoradiographed was contaminated and meant that the 
experiment would have to be repeated.
To check that the differences in signal were not due to 
differences in the amount of RNA on the filter, the filter 
was stripped of all probe and hybridised against the actin 
probe as before. The resulting autoradiograph (also figure 
6.4) shows that the differences in signal seen in the GPX- 
hybridised filter were due to a difference in the amount of 
RNA on the filter. The fact that it was only the patient's 
samples which had decreased quantities of RNA on the filter 
could be explained by the fact that they were held in a 
separate rack during their preparation. If samples had been 
contaminated with RNAase (say by coughing over them) only 
one rack would have been contaminated, as any racks not 
being worked on were covered up.
Another RNA dot blot was prepared in triplicate, using 1/xg 
samples of RNA from the white blood cells of 19 control 
subjects and 44 patients with rheumatoid arthritis. 1/xg of 
yeast tRNA, Ijitg of an RNAase A treated sample and 1/xg of 
lambda phage DNA were included as non-specific binding 
controls (the latter was intended to control non-specific 
binding for the DNA plasmid dots) . 1/ig of the plasmids pCPll
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and pGP71 were included as controls for the specificity of 
the GPX and GPRP probes, 5/xg, 1/xg and 0.5/xg samples of human 
and rat liver RNA were also included. One of the filters was 
hybridised against the whole human GPX probe as above, the 
filter was washed using the standard washing conditions 
(section 2.16.3) with a stringent wash of 15 minutes in 
0.5xSSC,0.1%SDS at 55°C. The autoradiograph, after overnight 
exposure, is shown in figure 6.5. It can be seen from the 
signals produced by the plasmids pCPll and pGP71 that both 
the GPX and GPRP genes are hybridising to the probe in this 
experiment. As was expected for cross-species hybridisation, 
the probe hybridised to the human liver RNA to a greater 
extent than to the rat liver RNA. There is also strong non­
specific binding to the lambda phage DNA control and a weak 
signal from the RNAase control. The hybridisation signals 
produced from the control and arthritic subjects did not 
appear to be different, indicating that the levels of 
expression of GPX and GPRP mRNA were not altered in cases of 
rheumatoid arthritis.
The other two filters were hybridised against the GPX and 
GPRP oligonucleotide probes (prepared as in section 5.3), 
using the hybridisation conditions for oligonucleotides 
(section 2.16.2). The filters were washed in 2xSSC,0.1%SDS 
at room temperature for 60 minutes followed by 6xSSC,0.1%SDS 
at 30“C for 20 minutes and autoradiographed for three days. 
The results are shown in figure 6 .6 , it can be seen from the 
plasmid pCPll and pGP71 controls that the GPRP and GPX 
probes are specific for GPRP and GPX respectively. The GPX 
oligonucleotide hybridises equally to both the human and rat 
liver RNA, whereas the GPRP oligonucleotide hybridises to a 
greater extent to the human liver RNA. The tRNA and RNAase 
non-specific binding controls show no signal with either 
probe but the lambda phage DNA does hybridise to both 
probes. DNA contamination in some of the samples may explain 
the increased hybridisation signals seen, especially in the 
case of the GPX oligoprobe which has very strong binding to
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lambda phage DNA. There is no difference between the 
expression of GPX or GPRP in arthritic patients and control 
subj ects.
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Figure 6.6: Autoradiographs of dot blots of RNA from white blood cells of patients with Rheumatoid 
Arthritis and control subjects, hybridised with the GPX and GPRP oligonucleotide probes
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Chapter 7 
Discussion
In this chapter, general aspects of the experimental 
techniques and results are brought together and discussed. 
The results from chapters 4, 5 and 6 concerning the GPRP 
clone are discussed with reference to the recent discovery 
that GPRP is identical to the 5' half of the mouse 
glutathione peroxidase gene.
7•1 Methodology
In the following section various facets of the 
technology common to a number of results chapters are 
discussed.
7.1.1 Screening of Phage Libraries
The method of Benton and Davis, (1977), for screening 
phage genomic libraries is efficient and has been 
extensively used in many laboratories. However, a large 
number of clones need to be screened in order to isolate 
single copy genes. Clarke and Carbon, (1976), derived a 
formula which relates the probability of including any one 
DNA sequence in a random library of genomic recombinants 
with the number of recombinant phage as follows;
N = In(l-P)
In(l-f)
Where N = number of recombinants
P = probability of isolating the gene
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f = the fractional proportion of the genome in a 
single recombinant, i.e. fragment size (bp)
genome size (bp)
From this formula, with an average size of recombinant 
insert of 20Kb (such as that produced by random fragment 
insertion into X^h28) , 6.5 x 10^  phage need to be screened 
in order to have a 99% chance of isolating a single copy 
gene. Thus it was pleasing that, as described in chapter 3, 
when approximately 2 x 10& phage were screened (only a 
factor of three greater than the predicted number needed) 
and a recombinant which hybridised to the mouse GPX gene was 
isolated.
A similar formula applies when predicting the number of 
phage needed from a cDNA library (Maniatis et al, 1982) ;
N = In(l-P) 
ln(l-l/n)
Where N = number of recombinants
P = probability of isolating the cDNA
n = abundance of the mRNA as a fraction of the
total mRNA
As the liver expresses high levels of GPX, the abundance of 
GPX mRNA in the human liver cDNA library was expected to be 
high and therefore 2 x 10^  recombinant phage were considered 
ample when screening for the GPX cDNA and this assumption 
was not unreasonable. Later publications concerning the 
isolation of the human kidney GPX cDNA, and the rat liver 
GPX cDNA report the isolation of 24 and 140 clones by 
hybridisation with a GPX oligonucleotide and a bovine GPX 
cDNA from only 5,300 and 350,000 recombinant clones 
respectively. In the light of this it is surprising that no 
recombinant containing GPX cDNA was isolated in my study, 
and that the one clone hybridising to the mouse GPX gene 
(chapter 4), was GPRP.
The washing conditions employed in the initial stages 
of screening were not stringent, and the mouse GPX gene had
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previously been shown to hybridise to human genomic DNA (Dr 
McKenzie, this laboratory). Thus the actual screening 
procedure was not suspected to be at fault, although the 
possibility that the nick translated genomic probe may not 
hybridise very well to a cDNA by virtue of it's intronic 
regions could not be excluded. It was suggested that, as 
other colleagues were obtaining similar results from this 
cDNA library when screening for different genes, (using this 
and other methods), the \gtll library was at fault. It may 
be that during storage of the library the infectivity of the 
recombinant phage was selectively lost, i.e. that phage with 
a recombinant insert under/over a certain size were unable 
to replicate during the growth period when plated out. This 
is possible, as it is known that phage titres will decrease 
after long periods of storage at 4°C. Alternatively, the 
library may not have been as comprehensive as it should have 
been due to technical difficulties in preparation.
7.1.2 Preparation of DNA
The preparation of phage DNA from the recombinant clone 
1312, isolated from the human liver cDNA library in \gtll 
(chapter 4) was extremely difficult. The same method was 
tried as had been used successfully for recombinant \Ch28 
phage 1211 (section 2.8.1) but insufficient quantities of 
clean DNA were obtained. In retrospect, the titre of the 
phage stock used in this method was probably not high 
enough. It may be that there were insufficient phage 
particles to infect all the host cells before the culture 
ceased to grow. In the case of the \Ch28 recombinant 1211 
there were sufficient phage to enable DNA to be prepared, 
but since the ^ gtll recombinant 1312 was a slow growing 
phage (as judged by the size of the plaques produced after 
overnight incubation of overlaid plates), so very few cells 
were infected before the culture finished growing. Hence the 
number of phage present was so small that the phage DNA 
present was insufficient to survive the multi-step
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extraction procedure used in the method. The revised method, 
using the DE52 ion exchange column to remove bacterial cell 
debris and media contaminants (section 2.8.2), was chosen as 
it eliminated two precipitation steps and fewer phenol 
extractions were required, thus ensuring minimal loss of DNA 
during the preparation.
Phenol extraction also presented problems when 
isolating small quantities of DNA from agarose gels. The 
fact that the agarose is precipitated at the phenol 
interface, and that the interface is easily disturbed, meant 
that at each extraction a small amount of DNA solution was 
left behind. This was usually overcome by re-extracting the 
phenol with sterile distilled water, resulting in a larger 
volume of dilute DNA solution to be precipitated.
The Geneclean procedure (section 2.3.7) offered an 
alternative to the phenol method and was effective in the 
isolation of small quantities of DNA from agarose. However, 
the Geneclean method was sometimes suspected to result in 
impure DNA preparations. In chapter 5, when fragments of the 
human GPX gene and GPRP cDNA were isolated for use as 
hybridisation probes, the GPRP cDNA (isolated by Geneclean) 
did not nick translate as efficiently as the GPX fragment 
(isolated by the cold phenol method). Observations in other 
subcloning experiments in the laboratory have also lead to 
suspicions of the purity of DNA isolated by Geneclean, and 
colleagues in the Microbiology department at this University 
observed, on occasion, that the Geneclean method did not 
completely remove agarose from DNA preparations. In the 
light of these suspicions, and due to the absence of time in 
which to perform controlled experiments to test this theory, 
it was decided to use the phenol method for extracting DNA 
from agarose in future experiments. The Geneclean procedure, 
however, was a quick and effective method for preparing 
small quantities of plasmid DNA from subclones in order to 
check their insert size since there was no interference with 
restriction enzyme activity.
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7.1.3 Subcloning
During the course of this work many subcloning 
experiments were performed, all of which included controls. 
The results of the control experiments were occasionally 
other than would have been expected; but if they did not 
affect the overall objective of the experiment they were not 
discussed in the results section. Some of the major failures 
of subcloning experiments, in which no ligation occurred, 
were attributable to the extreme lability of T4 DNA ligase. 
The enzyme was not used if it was over two months old, but 
quite often it was found that it had ceased to function 
before this time. The problem was caused by the fact that 
the communal -20“C freezer in which it was kept was unable 
to maintain the temperature when it was being used 
constantly. The problem was solved by the use of personal T4 
DNA ligase stocks stored in non-communal freezers.
In some transfection experiments (tables 4.2, 3.1, 3.2 
and 3.3) blue E.coli colonies were seen in unligated 
controls of cut pUC plasmid DNA. This indicated that not all 
of the DNA has been cut by the restriction enzyme. Since the 
numbers of such colonies were small (except 3.1) they did 
not usually affect the results.
When alkaline phosphatase was used in the cloning 
procedure (table 3.2), control plates of the cut, 
phosphatased vector treated with ligase were included to 
check that the alkaline phosphatase had worked and that 
ligation did not take place. In this instance the number of 
blue colonies seen was small and not significantly different 
from the number seen in the absence of ligase, proving that 
the phosphatased plasmid was incapable of recircularisation.
In some experiments, when white colonies were picked 
and plasmid DNA made from the cells, DNA of a size other 
than that expected of vector + required insert was found. 
Sometimes the plasmid DNA was the same size as the original 
vector DNA, as determined by comparison with DNA from a blue
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colony (figures 3.8 and 4.7). This was probably due to the 
loss of nucleotides from the cut ends prior to vector re­
ligation due to exonuclease activity. This would disrupt the 
reading frame and hence prevent expression of the jS- 
galactosidase gene causing the formation of white colonies. 
Exonuclease activity would also explain the occasional 
isolation of plasmid DNA smaller than the original vector 
(track 3 in figure 3.8), and the loss of restriction enzyme 
sites such as that seen in recombinant plasmid CPU. In 
cases where the size of the recombinant plasmid was greater 
than that expected (tracks 1,5,6 and 16 in figure 4.7), this 
was probably due to the formation of concatamers of plasmid 
and/or insert fragments. This would have been resolved if 
the DNA was cut with restriction enzymes, as the resulting 
fragments would be the same size as those from monomers.
7.2 Isolation of the Human GPX Gene
A recombinant phage, 1211, which hybridised to the 
mouse GPX gene was isolated from a human genomic library in 
XCh28. The failure to clone the full 8.6Kb BamH I insert 
from recombinant phage 1211 into pUC19 may have been for 
technical reasons, e.g. if the two arms of the phage vector 
interfered in the recircularisation of molecules. However, 
the repeated isolation of a 1.7Kb insert, which only 
hybridised to the 5' half of the mouse GPX gene, (section
3.2) cannot be ignored. Even when a large plasmid was 
isolated, thought to contain the 8.6Kb insert, it turned out 
to be a dimer of two plasmids each containing a 1.7Kb 
insert, (figure 3.12). This means that some event was 
occurring either during ligation or within the transformed 
cells which reduced the size of the genomic insert. As all 
the 1.7Kb inserts appeared to be the same, and they all 
hybridised to the 5', but not 3', half of the mouse GPX gene 
(figure 3.11), it was proposed that the event was not a
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random one. It could be that a loop was formed and the DNA 
excised in a recombination event akin to that of 
transposition. This would require homologous sequences at 
either end of the loop, but would explain why the same size 
insert was seen on each occasion. A search for sequences 
capable of forming a loop in the human GPX gene sequence was 
made but none were found. It is likely that the sequences 
flanking the human GPX would be involved in this event and 
this has not been investigated further.
The problem was resolved by restriction mapping 
recombinant 1211 and subcloning a 3.3Kb Xho I-BamH I 
fragment which contained both halves of the gene. The 
remainder of the insert from recombinant 1211 can be 
subcloned at a later date if sequences further upstream from 
the human GPX gene are required for future experiments on 
regulation of the gene. The 3.3Kb fragment was successfully 
cloned into pUC19 to give the recombinant plasmid Gp71, 
which hybridised to both halves of the mouse GPX gene. 
Restriction enzyme mapping of this plasmid, and comparison 
of this map with one deduced for the human GPX gene (from 
the recently published sequence of Ishida et al, 1987) 
indicated that the plasmid Gp71 contained the human GPX gene 
(figure 3.26). To confirm this, sequencing of the region of 
Gp71 judged to be the intron of the gene was carried out and 
resulted 208bp of DNA sequence was obtained. This sequence 
had 100% homology with bases 798 to 1006 of the human gene 
published by Ishida et al, (1987), (figure 3.31). This 
region of the human gene represents the first 9 bases of the 
second exon and 199 bases of the intron. Complete identity 
with such a large portion of the human GPX gene intron 
proved that the plasmid Gp71 did indeed contain the human 
GPX gene, as 100% sequence homology would not be seen in 
introns of two different genes, even if they were closely 
related polymorphic alleles (Gilbert et al, 1986).
In view of the fact that, during the course of this 
particular investigation, several groups of investigators
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published sequences of the human GPX gene and cDNA (Ishida 
et al, 1987; Sukenaga et al, 1987; Mullenbach et al, 1987), 
it was decided that any experiments to further characterise 
the human gene should be discontinued. Also, regulation of 
GPX gene expression was being studied by other workers 
(Chambers and Harrison, 1988), so this line of enquiry was 
not pursued. It was decided therefore that characterisation 
of the GPX-related cDNA in C P U  which hybridised to the 
mouse GPX gene would be important and should lead to novel 
findings. The human GPX gene was excised from the plasmid 
Gp71 by cutting with the restriction enzyme Xho I, which has 
recognition sites in the 5' and 3' flanking regions of the 
gene, and was used as a hybridisation probe in the 
investigations of GPX mRNA expression and GPX polymorphisms 
by myself and colleagues.
7.3 Isolation of the GPRP DNA
After completion of this thesis it was discovered that the 
GPRP DNA was, in fact, the 5' half of the mouse glutathione 
peroxidase gene, and the recombinant plasmid C P U  was 
actually the plasmid pAlO. Comparisons between the two 
sequences and the two plasmids to illustrate this are shown 
in figures 7.1 and 7.2.
The following sections discuss the results from chapter 
4 in the light of this information and explain how this 
situation could have arisen.
7.3.1 Isolation of the Recombinant Phage 1312
Recombinant phage 1312 was isolated from a human liver cDNA 
library in ^gtll by hybridisation with the 3' half of the 
mouse GPX gene. This phage was slow growing and as a result 
preparation of large quantities of DNA was difficult (see 
discussion in section 7.1.2). This meant that insufficient 
quantities of the phage DNA were available for visualisation
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TAAGACAGAGCTGGAAGATCCCCGCCTAAGCAAGCAGCTTCCTTCCAGACTAGTGCTACAGGAGCTAGACCAGAACCCGCCC | 
TAAGACAGAGCTGGAAGATCXÎCCG(XTAAGCAAGCAGCTTCGTTCCAGACTAGTGCTAGAGGAGCTAGACCAGAAGCGGCCC
TAGGCACCTCCAGGCGCTTTA GCXXXSGCCGCAOCCTCTrcCCTGTTCCrCGATGGGGGGAGGGTAGAGGCCGGATAAGGCGG 
TAGGGACCrCCAGGCGCTTrATGCCCGGCCGCACCCTCTTœCTGTTCCTCGATGGGGGGAGGGTAGAGGCCXàGATAAGGCGG |
I
* !I
GACCCTGAGACTTAGAGCTGGCTGCCAGCCGGAAAGAAAGCGATGCCACGTGATCTCAGCACCATCCAGTTAAAAGGAGGTG ! 
GACCGTGAGACTTAGAGCTGGCTGCCAGC GGAAAGAAAGCGATGCCACGTGATCTCAGCACCATCCAGTTAAAAGGAGGTG
CAGGGCCCTGTGAGCGCTAGTACGGATTCCACGTITGAGTCCCAACATCTCCAGTATGTGTGCTGCTCGGCTCTCCGCGGCGG j 
CAGGGCGCTGTGAGCGCTAGTACGGATTCCACXSTTTGAGTCCCAACATCTCCAGTATGTGTGCTGCTCGGCTGTOCGCGGCGG .
GAGAGTGGAGGGTGTATGGGTTGTGCGGGGGGGGGCTGAGGGGGGGGGAGGGTGTGAGGGTGGGCTGCCTGGGGGGGAAGGT j 
GAGAGTGGAGGGTGTATGGGTTGTGGGGGGGGGGGGTGAGGGGGGGGGAGGCTGTGAGGGTGGGGTGGGTGGGGGGGAAGGT
GGTGGTGATTGAGAATGTGGGGTGTGTCTGAGGGAGGAGGATGGGGGAGTACAGGGAGATGAAGGATGTGGAGAAGGGTGTGG 
GGTGGTGATTGAGAATGTGGGGTGTGTGTGAGGGAGGAGGATGGGGGAGTAGAGGGAGATGAAGGATGTGGAGAAGGGTGTGG I
GAGGTGGTGGAGTGGTGGTGCTGGGTTTGGGGTGCAATGAGTTGGGACAGGAGGTATATGGGGG AGATGGTTGGGGTTGGGGT ' 
GAG TGGTGGTGGTGGGTTTGGGGTGGAATGAGTTGGGAGAGGAGGTATATGGGGGGAGATGGGT GCCJTGGGCT i
GTAGGGTGGAGGGGGGGGAGAGGGGTTAGTTTGTGGTGTGGTAGTAGAGGTGGAATGGAGGGGTATGGTGGGTTATAGAAGGA 
GTAGGGTGGAGGG GGGGAGAGGGGTTAGTTTGTGGTGTGGTAGTAGAGGTGGAATGGAGGGGTATGGTGGGTTATAGAAGGA
GGGGAAGTTGGTG TGAGTGATGGGGAAAGGTGTGTTTTGGAGTTAAAAAGTAGATTGnTGGGAAATGGTAGGAGATAAATAA 
GG GAAGTTGGTGGTGAGTGATGGGGAAAGGTGTGTTrTGGAGTTAAAAAGTAGATTGTrTGGGAAATGGTAGGAGATAAATAA
ATGGGTTTGTGTTGGGTAGGAGAATGGGAAGAA Mouse GPX bases 2 to 777
ATGGGTTTGTGTTGGGTAGGAGAATGGGAAGAA GPRP bases 15 to 781
Figure 7.1: A comparison between the GPRP and mouse GPX DNA sequences. The coding regions of the mouse GPX
gene are underlined
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Figure 7.2: Plasmids pAlO and pCPlI, illustrating the similarity between the two. The arrows and numbers
indicate the restriction sites common to both.
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of the small cDNA insert. The insert size was estimated to 
be approximately 1Kb from restriction mapping of recombinant 
1312 using enzymes which had recognition sites at either 
side of the cloning site. In retrospect, a better idea of 
the insert size and confirmation of the existence of 
seguences hybridising to both halves of the mouse GPX gene 
would have been obtained if Southern blotting experiments 
had been performed at this stage.
7.3.2 Subcloning of the cDNA from Recombinant Phage 1312
The subcloning of the insert from phage 1312 was done 
using the shotgun cloning approach, as the insert could not 
be isolated in sufficient quantities for direct cloning.
This resulted in recombinant plasmid C P U  containing an 
insert of approximately 0.8Kb. The insert could only be 
excised by using the enzymes Xba I and EcoR I in conjunction 
(as opposed to solely EcoR I) and this was thought to be as 
a result of exonuclease "nibbling" during the DNA 
preparation and subcloning procedure. After the discovery 
that GPRP was identical to the mouse genomic fragment AlO it 
was realised that the restriction sites needed to excise 
GPRP from pCPll were the same as those required to excise 
AlO from the plasmid pAlO. Hence it was concluded that the 
plasmid pCPll was, in fact, plasmid pAlO, figure 7.2 
illustrates this. This error can only be explained by 
contamination of the subcloning reaction containing 1312 DNA 
by either the plasmid pAlO or the host cell JM83 containing 
plasmid pAlO. The possibility that two tubes containing pAlO 
and 1312 DNA were mixed up has been considered but, although 
there was pAlO being used in the laboratory at that time, I 
was not performing any experiments using pAlO and do not 
believe that this was the cause. The contamination was not 
in the competent cells TBl, or in the ligation buffers and 
enzymes, as the "no DNA" control in the ligations would have 
resulted in white colonies if this were the case (table
4.2). It is possible that contamination of the DNA used in
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the ligations could have occurred via the water in which the 
DNA preparations were dissolved.
The fact that no subclones hybridising to the 3' half 
of the mouse gene were isolated, in spite of repeated 
experiments was originally thought to be due to the fact 
that the restriction enzyme EcoR I used to excise the insert 
from recombinant phage 1312 had cut the cDNA insert in half 
and only the 5* half had been subcloned (as GPX cDNA was 
expected to have an EcoR I recognition site in the middle). 
After sequencing the C P U  insert and finding that a region 
of this had 40% homology with the human GPX gene, the lack 
of hybridisation to the 3' mouse probe was put down to the 
fact that the hybridisation conditions employed in screening 
the phage library were much less stringent than those 
employed in screening recombinant plasmids.
The identity of C P U  with pAlO would indicate that the 
subcloning of the fragment from 1312 was not working at any 
stage and that only the contaminating pAlO and re­
circularised pUC19 were being seen, thus explaining why no 
clones hybridising to the 3' half of the mouse gene were 
obtained. This is likely in view of the difficulties 
experienced in preparing the 1312 DNA. Some of the larger 
plasmids seen in the subcloning were probably concatomers of 
pUC19 as discussed in section 7.1.3.
The results and methods in this thesis state that the 
plasmid with which the subcloning of the 1312 insert was 
performed was pUC18. It was originally thought that pUC19 
was used for these experiments, but the sequencing data 
showed that the multiple cloning site was in the opposite 
orientation than expected and hence it was assumed that 
pUC18 had been used in error. This confusion is easily 
explained in light of the fact that the plasmid C P U  is 
actually pAlO which is derived from pUC12.
7.3.3 Sequencing of the pCPll insert and Comparison with 
the Human GPX gene.
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The whole of the cDNA insert from C P U  was sequenced 
with universal and internal primers. It was found to contain 
an open reading frame with an AUG start codon and a UGA 
termination codon 62 nucleotides before a polyadenylation 
signal. This indicated that the cDNA could code for a poly­
peptide of approximate molecular weight 13.2 KD. The DNA 
sequence was compared with the human GPX gene using the 
Microgenie software and appreciable sequence homology 
between the two was seen. The C P U  insert was renamed 
Glutathione Peroxidase-Related Peptide (GPRP) in the light 
of this homology. No direct comparison between GPRP and the 
mouse glutathione peroxidase gene was made, as at the time 
it was believed that this was human DNA. The C P U  sequence 
was compared with the mammalian sequence database which we 
have at the university and no matches were found. The 
parameters used for this comparison should have picked up a 
match with the mouse gene if it was on the database, but at 
the time that this comparison was made it is thought that 
the mouse GPX sequence had not yet been added to the 
database. It was appreciated at the time that our database 
was not comprehensive, and it was believed that the sequence 
would be checked against the EMBL database when it was sent 
there for registration. Hence, having been accepted at the 
EMBL database, I believed that the sequence was genuinely 
unique. This belief was supported by the results discussed 
in section 7.4, where more bands than would be expected for 
a single GPX gene were seen on both Southern and Northern 
blots. Additional evidence by co-workers in this laboratory 
indicated that the GPRP gene was present in the human 
genome, as indicated by PCR of human genomic DNA using 
GPRP-specific oligonucleotide primers. However, it was 
noticed after completion of this thesis that there was a 
large degree of homology between GPRP and the mouse GPX 
gene. Direct sequence comparison between the two showed that 
GPRP was identical to the 5' half of the mouse GPX gene 
(figure 7.1). There are 7 single base differences which are
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probably due to sequencing errors and a deletion of 9 bases 
which could be caused by a small section of DNA looping out. 
However, the homology is approaching 100%, even in the 5' 
non-coding and intronic regions of the mouse gene and 
therefore it is clear that the sequences are identical. The 
original sequence comparisons in the results section have 
not been removed so that it can be seen how the error 
occurred. The PCR results indicating that GPRP was present 
in the human genome have not been successful upon repetion 
of the experiment and it is possible that the original 
finding was an artefact caused by contamination of the PCR 
reaction.
7.4 Use of the 6PX Gene and GPRP cDNA as Hybridisation 
Probes
The possibility that a novel human gene with close 
sequence homology to the human GPX gene existed lead to the 
conclusion that there would be cross-hybridisation between 
the two in any experiments designed to look at the 
difference in expression of GPX in various clinical 
conditions, i.e. the GPX probe would hybridise to any GPRP 
sequences present in the samples and vice versa.
Observations of more bands than would have been expected on 
Northern and Southern blots probed with the Xho I fragment 
of the human GPX gene confirmed this (figures 5.5 and 5.6). 
In view of the discovery that GPRP is a fragment of the 
mouse GPX gene alternative explanations have to be found for 
these results. It has recently been reported that there are 
sequences with homology to the GPX gene on chromosomes X and 
21 by McBride et al (1989), and a recent paper by Chada et 
al (1990) has also shown more bands than would normally be 
expected on Southern blots of human genomic DNA. Hence the 
extra bands seen on the Southern blot in this thesis support 
these findings. The two bands seen on the Northern blot are
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not as easily explained. It may be possible that the extra 
GPX sequences previously discussed are functional genes and 
are being expressed. It was postulated that these sequences 
are pseudogenes (as the original mapping of the GPX gene 
using GPX activity in hybrid cells resulted in only one 
location and an intronic probe will not bind to these 
sequences) but until they are completely characterised there 
is no proof that this is the case. Another explanation is 
that there are alternative polyadenylation signals in the 
GPX gene resulting in the production of different sizes of 
mRNA from the same gene. This could be possible as it has 
already been shown that the mouse GPX gene has alternative 
polyadenylation sites (although these were fairly close 
together and would not result in as large a difference in 
size of mRNA as was seen on the human Northern blot).
The experiments performed in order to try and 
distinguish between the GPRP and GPX probes were unnecessary 
in the light of the identity of GPRP with the mouse GPX gene 
and only served to illustrate the strong cross-species 
hybridisation expected from a highly conserved gene such as 
GPX.
7.5 The Expression of GPX and GPRP mRNA in Human White 
Blood Cells
In view of the central role of Glutathione Peroxidase 
in the cellular antioxidative defence system, it has been 
implicated in many diseases. Much evidence has been 
presented to suggest that GPX is involved in atherosclerosis 
and rheumatoid arthritis, but this is controversial and the 
exact role (if any) of GPX in these diseases is not 
understood (sections 1.3.2 and 1.3.5). A large part of the 
epidemiological evidence assumes that GPX is involved 
because altered selenium levels have been associated with 
the diseases. However, the presence of many other
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selenoproteins and their possible roles in the aetiology of 
disease cannot be ignored. In this study the expression of 
GPX mRNA in white blood cells of patients with rheumatoid 
arthritis and hyperlipidemia was compared with the levels of 
expression in control subjects in order to determine whether 
GPX was involved in these diseases or not. Measurement of 
mRNA levels were used since GPX protein and activity levels 
are difficult to measure reproducibly in such small samples.
Some of the samples were also examined using the GPRP 
oligonucleotide probe, but as this oligonucleotide is 
specific for the mouse GPX gene, the results obtained from 
these are insignificant. The controls of pCPll and pGP71 
plasmids on the RNA dot blot filters are also irrelevant and 
merely indicate the cross-hybridisation between the mouse 
and human GPX genes. The results seen in figure 6.6 show 
that although the GPRP probe did not bind to the human gene 
under the conditions employed, there were strong signals on 
the RNA prepared from human samples. This could be due to 
non-specific binding of the oligonucleotide to traces of 
contaminating salt or DNA in the samples. In the light of 
this, and in view of the large degree of non-specific 
binding of the GPX oligonucleotide to lambda phage DNA 
(figure 6.6), the results obtained using these 
oligonucleotides should be viewed with caution. However, the 
GPX gene probe was also used in these experiments and the 
overall conclusions remain the same.
RNA was prepared from white blood cells as blood 
samples were the easiest tissue samples to obtain. Also for 
rheumatoid arthritis there had been reports of abnormal 
granulocyte GPX levels even after selenium supplementation 
(Tarp et al, 1987). This suggested that white blood cell GPX 
and GPX mRNA levels might be used as an indicator of disease 
state. Total white blood cells were used, rather than 
separation into different cell types, as it was found that 
the procedure used to prepare pure granulocytes did not 
result in sufficient material from which to prepare RNA. 10
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ml blood samples were the maximum available and consequently 
the yield of RNA from each patient was low. This low yield 
of RNA precluded any further purification of the sample if 
it was found to be contaminated, and therefore 
representative examples of the spectroscopic scans of white 
blood cell RNA's are included in this report in order to 
illustrate the quality of the samples used.
Initial investigations of GPX mRNA levels in patients 
with rheumatoid arthritis indicated that they were 
significantly decreased compared to controls. However, this 
appeared to be due to selective degradation of the RNA 
samples, as determined by hybridisation to an actin probe. 
The experiment was repeated to confirm this, as it is 
possible that the levels of actin mRNA were selectively 
decreased since it has been reported that the cytoskeleton 
of polymorphonuclear leukocytes is affected in GPX 
deficiency (McCallister et al, 1980). These further 
experiments indicated that there was no apparent difference 
between GPX mRNA levels in patients and controls. If there 
are changes in GPX activity in white blood cells of patients 
with rheumatoid arthritis this is not due to changes at the 
transcriptional level.
The observed differences in GPX activity may therefore 
have been due to an inadequate supply of selenium for 
incorporation at the translational level, since there is 
evidence to suggest that selenium is involved in this 
disease. However, Tarp et al, (1985), reported that GPX 
activity in granulocytes remained low even after selenium 
supplementation. If this is the case the GPX activity must 
be lowered as a result of post-translational events e.g. 
enzyme inactivation, although as none of the papers 
adequately report the treatment that the patients were 
receiving, the possibility that the activity is lowered as a 
result of inhibition by anti-arthritic drugs cannot be 
excluded. In the light of this it is possible that GPX is 
not directly involved in the aetiology of this disease.
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Indeed it is strange that on the one hand lowered GPX levels 
are implicated in initiation of the disease by virtue of the 
findings that activity is lowered in patients, while there 
is clear evidence that the anti-arthritic drugs inhibit GPX 
activity. As the mechanism of inhibition of GPX by the 
gold-containing anti-arthritic drugs is via the interaction 
of gold with selenocysteine, it is possible that this 
inhibition of GPX has no relevance and that the interaction 
of gold with other selenoproteins is of more importance.
Patients with hyperlipidemia were also chosen for study 
as they are considered by clinicians to be at risk of later 
cardiac disease. It has previously been shown that treatment 
to decrease raised lipid levels can slow the rate of 
atherosclerosis (Duffield et al, 1983). The study on these 
patients was preliminary and was terminated after an initial 
set of samples had been studied since it was clear that 
there was no difference in the GPX mRNA levels in white 
blood cells from controls compared to those of patients 
(figure 6.2).
The fact that the GPX mRNA levels in hyperlipidémie 
patients were no different from controls again means that if 
GPX activity levels are altered in this disease it is not 
due to changes at the transcriptional level. It may be the 
case that GPX activity levels are unaltered in 
hyperlipidemia and that any involvement of GPX is secondary 
to the increase in lipid levels. An increase in lipid levels 
could result in increased production of hydrogen peroxide 
from the peroxisomal ^-oxidation cycle which, if not 
compensated for by an increase in catalase and GPX activity, 
would cause an increase in lipid peroxides leading to 
possible formation of atherosclerotic plaques. However, the 
levels of GPX activity in platelets should also be studied 
as platelets play a major part in the progression of the 
disease and it has been reported that platelet selenium 
levels of patients with myocardial infarction are decreased 
(Kiem et al, 1987).
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7.6 Conclusions
The human glutathione peroxidase gene has been 
isolated, along with approximately 5Kb of DNA upstream from 
the gene. Further studies on this gene and it's surrounding 
sequences were terminated in favour of studies on the GPRP 
DNA, as many other large groups had commenced work on the 
structure and regulation of the GPX gene. The identity of 
the GPRP DNA with the mouse GPX gene was not discovered 
until after completion of this thesis. The results 
concerning the experiments performed on and with the GPRP 
DNA have not been altered as a result of this discovery, as 
it was felt that a better understanding of the facts that 
led me to believe that GPRP was a human sequence would be 
achieved by this. The discussion has, however, been altered 
to incorporate the new information. The error arose as a 
result of the DNA preparations used in the subcloning of the 
recombinant phage 1312 insert being contaminated either with 
plasmid pAlO, or with the host cell JM83 containing this 
plasmid. This discovery invalidates the results concerning 
the use of GPRP as a hybridisation probe. However, the 
results obtained using the GPX gene probe are still valid 
and showed that there were no detectable differences in GPX 
mRNA levels between patients with rheumatoid arthritis or 
hyperlipidemia and control subjects.
The question of whether there is more than one 
functional GPX or GPX-related gene still remains unclear. It 
is known from results presented in this thesis, and from 
other publications, that there are other sequences in the 
human genome with homology to the GPX gene which have not 
yet been fully characterised. Further work on the human GPX 
gene is necessary to determine whether these genes are 
functional genes, or if the extra bands seen on Northern 
blots are due to different copies of mRNA being transcribed 
from the same gene.
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Appendix A 
Solutions, Media and Buffers
40% Acrylainide Stock Solution 
38g Acrylainide
2g NN*-methylenebisacrylamide
Distilled water to 100ml, store in the dark at 4“C 
Agar and Agarose
15g/l Bacto-Agar in media (for plates)
7g/l Bacto-Agar in media (for top agar)
7g/l Agarose in media (for top agarose)
lOx Alkaline Phosphatase Reaction Buffer 
(500mM Tris.HCl, ImM EDTA, pH 8.)
10ml Tris.HCl pH8 IM.
40/xl EDTA pH8 0. 5M
Distilled water to 20ml, sterilise by autoclaving.
Ampicillin Stock Solution
lOOmg/ml in distilled water
Sterilise by filtration, store at -20°C
Use at 150jLtg/ml in growth media for selection of resistant 
bacteria
Brij/DOC Solution
(1% Brij 58, 0.4% Sodium Deoxycholate in TE, pH8)
Ig Brij 58 (Sigma)
0.4g Sodium Deoxycholate
Add TE pH8 to 100ml, store at 4°C
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Chloramphenicol Stock Solution 
34mg/ml in 100% Ethanol 
Store at -20°C
Use at 170/Ltg/ml in growth media for amplification of 
plasmids
Use at 30/zg/ml in growth media for selection of resistant 
bacteria
Chloroform ; Isoamyl Alcahol 
49ml Chloroform 
1ml Pentan-2-ol
5.7M CsCl Solution for RNA Preparations 
(5.7M CsCl, lOmM EDTA, pH7.4)
96g CsCl
2ml EDTA 0.5M pH8
Add distilled water to 100ml after adjusting pH.
Add 0.2% DEPC 2 hours before autoclaving
Deionised Formamide
Add 5g Ion Exchange Resin (Analytical Grade Mixed Bed, 20-50 
mesh, AG-501-X8. Biorad) to each 100ml of Formamide. Stir at 
4“C for three hours then filter into a lightproof bottle. 
Store at -20°C.
50x Denhardt's Solution
lOg Bovine Serum Albumin
lOg Ficoll 400,000
lOg Polyvinyl pyrrolidone 40,000
Add distilled water to 11, sterilise by filtration.
Store at -20°C
(it is necessary to adjust the pH to 11 using NaOH in order 
to dissolve the components. The pH is then immediately 
returned to 8.5 using HCl)
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Denaturing Buffer for Southern Blotting 
(0.5M NaOH, 1.5M NaCl)
20g NaOH 
87.66g NaCl
Add distilled water to 11, sterilise by autoclaving.
Denaturing Buffer for Dried Gels (Onblots)
(0.5M NaOH, 0.15M NaCl)
20g NaOH 
8.77g NaCl
Add distilled water to 11, sterilise by autoclaving.
IM Dithiothretol Stock Solution
Dissolve 3.09g DTT in 20ml O.OIM Sodium acetate, pH5.2 
Sterilise by filtration, store in aliquots at -20°C
Dye Markers for Electrophoresis
DNA: 10% Bromophenol Blue in 50% Sucrose Solution 
RNA: 4% Bromophenol Blue 
4% Xylene Cyanol
lOmM EDTA in 50% glycerol
Sterilise by autoclaving.
0.5M EDTA Stock Solution
186.1g/l NagEDTA Adjust to pH8 using approx. 20g NaOH 
pellets
lOx Electrophoresis Buffer for DNA gels (”E buffer”)
(400mM Tris.acetate, 200mM Sodium acetate, lOmM EDTA, pH8.3) 
48.4g Tris.
27.2g Sodium acetate trihydrate
20ml 0.5M EDTA pH8
11.42ml Glacial Acetic Acid
Add distilled water to 11, check the pH is 8.3
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lOx Electrophoresis Buffer for RNA gels 
(400mM MOPS, lOOmM Sodium acetate, lOmM EDTA)
83.71g MOPS
33.3ml Sodium acetate 3M pH4.8 
20ml EDTA 0.5M pH8
Add distilled water to 11, add 0.2% DEPC 2 hours before 
autoclaving
Ethidium Bromide
Stock solution of 3mg/ml in TE
Use at 3jLtg/ml in gel running buffer for staining DNA and RNA 
gels
Guanidine Hydrochloride
66.85g Guanidine HCl in distilled water to 100ml 
Filter and pH to 4.5 using IM NaOH 
add;1ml 2M Potassium acetate (to 20mM)
308 mg Dithiothretol (to lOmM)
4M Guanidinium Thiocyanate Solution 
lOOg Guanidinium Thiocyanate 
Ig Sodium N-Lauroylsarcosine 
5ml IM Sodium acetate pH7 
1.4ml 0-Mercaptoethanol 
0.66ml 30% antifoam A (Sigma)
Add distilled water to 200ml, pH to 7 using IM NaOH, 
sterilise by filtration, store in the dark at room 
temperature (one month only)
Hybridisation Solution, (cloned DNA probes)
20ml 5Ox Denhardts 
250ml 20x SSC 
500ml Deionised Formamide 
200ml 50% Dextran Sulphate
10ml lOmg/ml Denatured, Sheared Salmon/Herring Sperm DNA 
18ml distilled water
0.5ml 0 2Omg/ml poly A, 2Omg/ml poly C. Store at -20°C.
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Hybridisation Solutions, (Oligonucleotide probes)
For DNA filters and onblots:
250ml 20x SSPE
5ml 20% SDS
0.5ml 2Omg/ml tRNA
10ml 1Omg/ml Denatured, Sheared Salmon/Herring Sperm DNA 
Add distilled water to 11, store at -20°C.
For RNA filters and Onblots:
333ml 20x SSC
5ml 20% SDS
40ml 5Ox Denhardts
0.5ml 2Omg/ml tRNA
10ml 1Omg/ml Denatured, Sheared Salmon/Herring Sperm DNA 
Add distilled water to 11, store at -20°C.
lOx Kinase Buffer
5ml IM Tris.HCl pH8 (500mM)
1ml IM MgClg (lOOmM)
20jLtl 0.5M EDTA pH8 (ImM)
50/xl IM DTT (50mM)
250/il 40mM Spermidine (ImM)
3.67ml distilled water, sterilise by filtration.
LB (Luria-Bertani) Medium 
lOg Tryptone 
lOg NaCl
5g Yeast Extract
Add distilled water to 11, sterilise by autoclaving.
(for LBMg-broth, add 10ml IM MgSO^ per litre medium)
NaOH/SDS solution 
(0.2M NaOH, 0.1% SDS)
40/xl ION NaOH 
20/xl 10% SDS
1.94ml distilled water. Make fresh each time.
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Neutralising Solution for Southern Blotting 
(3M NaCl, 0.5M Tris.HCl pH7.5)
12Og NaCl
500ml IM Tris.HCl pH7.5
Add distilled water to 11, sterilise by autoclaving.
Neutralising Solution for Dried Gels (Onblots)
(0.15M NaCl, 0.5M Tris.HCl pH8)
6g NaCl
500ml IM Tris.HCl pH8
Add distilled water to 11, sterilise by autoclaving.
PEG/NaCl Solution 
(20% PEG, 2.5M NaCl)
20g Polyethylene glycol 6,000 
14.6g NaCl
Add distilled water to 100ml, sterilise by filtration
Phage Buffer 
3 g KH2PO4 
7g Na2HP04 
5g NaCl 
246mg MgSOt 
lOmg CaCl2 
lOmg Gelatin
Add distilled water to 11, sterilise by autoclaving.
Phenol Preparation
100ml of redistilled phenol is melted and an equal volume of 
TE and 0.1% 8-hydroxyquinoline is added. The mixture is 
shaken to dissolve the hydroxyquinoline and ensure 
saturation of the phenol by TE. Use the lower, yellow, 
phenol layer.
Store at 4°C. Do not use if the yellow colour changes.
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Prehybridisation Solution for General Use
100ml 5Ox Denhardts
250ml 2Ox SSC
500ml Deionised Formamide
123ml Distilled water
0.5ml 2Omg/ml tRNA
0.5ml 2Omg/ml poly A
0.5ml 2Omg/ml poly C
25ml 1Omg/ml Denatured, Sheared Salmon/Herring Sperm DNA 
Store at -20°C
Proteinase K Buffer 
5.84g NaCl
10ml IM Tris.HCL pH8 
500ml 0.5M EDTA pH8
Add distilled water to 11, sterilise by autoclaving.
Solution D (Stock)
50g Guanidinium Thiocyanate 
58.6ml Sterile distilled water 
3.52ml Sterile 0.75M sodium citrate pH7 
5.28ml 10% Sarkosyl
Store in the dark at room temperature for three months only 
Solution D (Working Solution)
Add 18Oui B-Mercaptoethanol per 25ml stock solution 
Store in the dark at room temperature for one month only
40mM Spermidine
1.02g Spermidine Trihydrochloride
Add distilled water to 100ml, sterilise by filtration, store 
at -20°C.
2Ox SSC (Standard Saline Citrate)
(3M NaCl, 0.3M Sodium citrate, pH7)
175.32g NaCl 
88.23g Sodium citrate
Add distilled water to 11, sterilise by autoclaving.
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SSCP (Standard Saline Citrate, Phosphate)
7.01g NaCl (120mM)
4.41g Sodium citrate (15mM)
1.77g KH2PO4 (13mM)
2ml 0.5M EDTA pH8 (ImM)
Add distilled water to 11, adjust to pH7.2 using NaOH, 
sterilise by autoclaving.
2Ox SSPE (Standard Sodium Phosphate, EDTA)
174g NaCl 
27. 6g NaH2P04 
7.4g EDTA
Add distilled water to 11, adjust pH to 7.4 using lOM NaOH, 
sterilise by autoclaving.
STET solution
8g sucrose
5ml Triton-X-100
10ml 0.5M EDTA pH8
5ml IM Tris. pH8
Add distilled water to 100ml.
STET/lysozyme solution
Add 4mg/ml lysozyme to STET solution. Use fresh.
Sucrose Lysis Buffer 
109.5g Sucrose (0.32M)
1.21g Tris. (O.OIM)
1.02g MgCl2 (0.005M)
10ml 1% Triton x-100
Add distilled water to 11, pH7.5
Tris-HCl, IM Stock
121.Ig Tris in 800ml distilled water 
add conc. HCl to the desired pH 
(pH7.4 - 70ml, pH7.6 - 60ml, pH8 - 42ml)
Add distilled water to 11, sterilise by autoclaying.
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TE (Tris-EDTA)
(lOmM Tris.HCl, ImM EDTA)
2ml EDTA 0.5M pH8 
10ml Tris.HCl
Add distilled water to 11, sterilise by autoclaving.
Tris/Glucose/EDTA 
9g glucose 
25ml IM Tris.HCl pH8 
25ml 0.5M EDTA pH8
Add distilled water to 11, sterilise by autoclaving. 
Tris-Sucrose
25% sucrose in 0.05M Tris.HCl pH8 
lOx Tris-Borate Buffer
(0.89M Tris-borate, 0.89M Borate. 0.02M EDTA)
108g Tris.
55g Boric acid
40ml 0.5M EDTA pH8
Add distilled water to 11
TYN broth 
lOg Tryptone 
lOg Yeast Extract 
5g NaCl
Add distilled water to 11, sterilise by autoclaving. 
X-gal
(5-bromo-4-chloro-3-indoyl-B-D-galactoside)
Stock solution of 2Omg/ml in dimethylformamide.
Use in agar plates at a final concentration of 40/xg/ml
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Appendix B 
Genotype Abbreviations
Bam' An amber mutation which is suppressible by supE
and/or supF.
B1007 Deletion of the b region which damages the att
site and therefore prevents lysogénisation.
KH54 A deletion of the rex-cl region which prevents
lysogénisation.
nin 5 A deletion which removes the transcription
termination site tp2 and therefore delays early 
transcription independent of the N gene product.
SamlOO An amber mutation in the gene involved in the
lysis of the bacterial cell membrane. Suppressed by supF but
not supE. Leads to intracellular accumulation of phage.
clts857 Renders the cl gene product thermolabile.
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